| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
PTC Therapeutics, Inc.$84.85
-5.71 (-6.38%)
C 55Pipeline Score Fair Value Pharma · Commercial
Market Cap
5.71 B
EPS
-2.33
P/E Ratio
-
Value Trade
77.07 M
SEC Financials
Q1 2026Dilution Risk
Revenue
272.55 M
R&D Expenses
100.87 M
Operating CF
-59.04 M
Total Assets
2.87 B
Total Liabilities
3.05 B
Equity
-180.47 M
D/E Ratio
12,345
-5.02 %
Week
-3.22 %
1 Month
0.53 %
3 Month
-10.1 %
6 Month
73.98 %
5 Year
335.51 %
All Time
Cash Data
Cash Position
1.89 B
Monthly Burn
19.68 M
Runway
94.3 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.07 M
52 Week Range
43.18 - 87.50
% held by Insiders
3.39 %
% held by Institutions
115.73 %
Enterprise Value
4.21 B
Total Shares
82.93 M
Short %
21.98 %
Float Shares
78.79 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for PTC Therapeutics, Inc.
956Total events
1Upcoming
319Tier-1 (high impact)
2012 – 2026Coverage
Upcoming catalysts 1
Event history 955
Q3 2026
▲Trial InitiationVatiquinoneTrial
Open-label vatiquinone registration study to be initiated in Q3 2026
Friedreich's ataxiasource ↗
Jun 15, 2026
Jun 9, 2026
◆Oral PresentationPresentation
PTC Therapeutics to present at Goldman Sachs 47th Annual Global Healthcare Conference
May 20, 2026
◆Oral PresentationPresentation
PTC Therapeutics to present at RBC Capital Markets 2026 Global Healthcare Conference
May 12, 2026
◆Oral PresentationPresentation
PTC Therapeutics to present at Bank of America Securities Health Care Conference 2026
May 7, 2026
May 7, 2026
▲Interim AnalysisvotoplamTrial
Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam
Huntington's diseasesource ↗
May 7, 2026
▲FDA Feedback ReceivedVatiquinoneFDA Meeting
FDA feedback received supporting initiation of open-label vatiquinone registration study
Friedreich's ataxiasource ↗
Apr 28, 2026
▲Topline ReadoutvotoplamClinical Data
Positive topline results from 24-month interim analysis of PIVOT-HD extension study
Huntington's diseasesource ↗
Apr 28, 2026
▲Trial InitiationvotoplamTrial
Novartis initiated global Phase 3 INVEST-HD study
Huntington's diseasesource ↗
Apr 28, 2026
◆Oral PresentationvotoplamPresentation
PTC Therapeutics to host webcast to share 24-month interim analysis results from PIVOT-HD long-term extension study
Huntington's diseasesource ↗
Drug Pipeline Intelligence
C55
Pipeline Score $2.3B
Pipeline ValueFair Value
Valuation Signal16
Drugs Scored1.3x
rNPV / MCap Top 83%
Small Cap (rank 156 of 911)
Percentile RankPTC Therapeutics, Inc. carries a moderate pipeline score (55/100), with $3.5B risk-adjusted pipeline value, led by Ataluren in Cystic Fibrosis (Phase 3), across $152B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ataluren Small molecule | Cystic Fibrosis | Phase 3 | NCT00458341 | 58% | $1.8B | COMPLETED | 762 | - | - | Feb 29, 2008 | - | Mar 6, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
votoplam | Huntington's disease | Phase 3 | 2026-05-07 | Positive topline results from 24-month interim analysis of PIVOT-HD extension study Read More | PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidanc Read More | |
votoplam | Huntington's disease | Phase 3 | 2026-05-07 | Positive topline results from 24-month interim analysis of PIVOT-HD extension study Read More | PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidanc Read More | |
votoplam | Huntington's disease | Phase 3 | 2026-05-07 | Positive topline results from 24-month interim analysis of PIVOT-HD extension study Read More | PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidanc Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PTCT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PTCT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PTCT▲ +7.2%on this news
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has announced the approval of non-statutory stock options and restricted stock units as inducement grants for 18 new employees. This decision was made in accordance with the Nasdaq Listing Rule 5635(c)(4) on June 11, 2026. The stock options have an exercise price of $74.71, with a 10-year term and a vesting schedule of four years. This initiative aims to enhance the company's ability to attract and retain skilled professionals in a competitive market.
Read more →PTCTPTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
PTC Therapeutics has announced a $500 million offering of 0% Convertible Senior Notes due 2031 to refinance its 2026 convertible notes. The offering is expected to close on June 18, 2026, and the proceeds will primarily be used to repurchase existing notes. The conversion price is set at a 40% premium over the current stock price, indicating a strategic financial maneuver.
Read more →PTCTPTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes
PTC Therapeutics announced a proposed offering of $500 million in Convertible Senior Notes due 2031 to refinance its existing 2026 convertible notes. The proceeds will be used for repurchasing or repaying the 2026 notes and for share buybacks. The offering is subject to market conditions, and the terms will be finalized at pricing.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidanc
PTC Therapeutics provided a corporate update along with its financial results for Q1 2026, reporting a total revenue of $273 million, which included $226 million from product sales. The company highlighted significant growth in the Sephience launch, with first quarter revenue of $125 million, reflecting a 36% increase from the previous quarter. Positive topline results from an interim analysis of the PIVOT-HD extension study for votoplam were announced, supporting ongoing studies. However, despite these successes, PTC reported a loss of $2.8 million for the quarter and faced challenges in maintaining revenue growth.
Read more →PTCTPTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics, Inc. announced its participation in several upcoming investor conferences, including the Bank of America Securities Health Care Conference and the RBC Capital Markets Global Healthcare Conference. Executives will present at these events, which will be available via live webcast on the company's website. PTC aims to highlight its commitment to developing treatments for rare disorders.
Read more →PTCT▼ -8.1%on this newsshared move
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
PTC Therapeutics announced positive topline results from the 24-month interim analysis of the PIVOT-HD extension study, showing a dose-dependent benefit in slowing disease progression in Stage 2 Huntington's disease patients. The study demonstrated a 52% slowing at the 10 mg dose compared to a natural history cohort. The favorable safety profile was also maintained, supporting the ongoing Phase 3 INVEST-HD study initiated by Novartis.
Read more →PTCTsignificant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commerc
PTC Therapeutics announced positive topline results from the 24-month interim analysis of the PIVOT-HD extension study, indicating a dose-dependent benefit of votoplam in slowing the progression of Huntington's disease in Stage 2 patients. The study showed a 52% slowing at the 10 mg dose compared to matched historical controls. Additionally, there were no treatment-related increases in neurofilament light chain protein levels, suggesting a continued favorable safety profile. The results support the initiation of the global Phase 3 INVEST-HD study, sponsored by Novartis, to further evaluate votoplam's efficacy.
Read more →PTCTPTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
PTC Therapeutics will present results from the 24-month interim analysis of the PIVOT-HD long-term extension study for votoplam. The data supports the ongoing Phase 3 INVEST-HD study, with Novartis evaluating next steps, including potential FDA actions. The study aims to assess the safety and efficacy of votoplam in Huntington's disease patients.
Read more →PTCTPTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
PTC Therapeutics, Inc. will host a webcast on May 7, 2026, to report its first quarter financial results. The call will also provide updates on the company's business strategies and outlook. Interested parties can access the live webcast through the company's website, with a replay available for 30 days post-event.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. announced the approval of non-statutory stock options and restricted stock units for a new non-executive employee as part of their employment compensation. The awards, totaling 1,155 stock options and 925 RSUs, were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $70.42 and will vest over a four-year period. This strategy is part of PTC's efforts to entice new talent to the company.
Read more →PTCTPTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
PTC Therapeutics has appointed Jessica Chutter to its Board of Directors. Chutter, a pioneer in biotechnology investment banking, has a notable career at Morgan Stanley, where she led significant capital raising and strategic transactions. Her experience is expected to aid PTC in its growth and strategic initiatives.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has announced the approval of non-statutory stock options and restricted stock units for 18 new employees, totaling 14,550 stock options and 17,515 RSUs. These inducement grants were issued in accordance with Nasdaq Listing Rule 5635(c)(4) as part of the new hires' employment compensation. The options have an exercise price of $68.56 and a vesting schedule spanning four years, contingent upon continued employment. This initiative demonstrates PTC's commitment to attract talent and bolster its workforce.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics, Inc. announced its participation in several upcoming investor conferences, including the TD Cowen 46th Annual Health Care Conference and the Barclays Global Healthcare Conference. Executives will present on March 2, March 10, and March 11, with live webcasts available for investors. The company emphasizes its mission to develop treatments for rare disorders.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December...
PTC Therapeutics reported strong financial results for Q4 and full year 2025, with product and royalty revenue reaching $831 million, surpassing expectations. The global launch of Sephience has been successful, generating $111 million in revenue since its launch. However, the company also reported a net loss of $135 million for Q4 2025, highlighting ongoing challenges in certain product revenues.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Full-year 2025 product and royalty revenue of $831M, exceeding guidance - - Strong Sephience (sepiapterin) upta
PTC Therapeutics, Inc. reported its financial results for the fourth quarter and full year 2025, showcasing strong product and royalty revenue of $831 million, surpassing previous guidance. The company noted a significant uptake of its drug Sephience since its launch in the second half of 2025, with related revenues hitting $111 million for the full year. Despite a robust cash position of $1.95 billion, the company faced a net loss of $134.965 million in Q4 2025, and total liabilities increased significantly compared to the previous year.
Read more →PTCTPTC Therapeutics Provides Regulatory Update on Translarna™
PTC Therapeutics has withdrawn its New Drug Application resubmission for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy, following feedback from the FDA. The agency suggested that the submitted data may not meet the necessary evidence of effectiveness for approval. This decision marks a disappointing turn for the company after years of development efforts.
Read more →PTCTPTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
PTC Therapeutics, Inc. has announced a webcast conference call scheduled for February 19, 2026, to report its fourth quarter and full year 2025 financial results. The call will also provide an update on the company's business outlook. Interested parties can register for the call and access it via the company's website.
Read more →PTCTPTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2026. Matthew B. Klein, M.D., Chief...
PTC Therapeutics provided a positive update at the J.P. Morgan Annual Healthcare Conference, highlighting strong revenue growth and a promising outlook for 2026. The company reported unaudited 2025 product and royalty revenue of approximately $823 million, exceeding expectations. PTC anticipates continued growth with Sephience and plans to initiate a global Phase 3 trial for votoplam in Huntington's disease.
Read more →PTCTPTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference - Strong Sephience (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M - - Unaudited 2025 total product and royalty reven
PTC Therapeutics provided a positive update regarding its financial performance at the J.P. Morgan Annual Healthcare Conference. The company's Sephience launch has resulted in a strong quarter with unaudited Q4 revenue of $92.5 million, contributing to an estimated total product and royalty revenue of approximately $823 million for 2025. PTC anticipates continued growth in 2026 with product revenue guidance of $700-$800 million, signaling a robust financial outlook. The company's cash position is strong at roughly $1.94 billion, positioning it well for future initiatives.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ( RSUs ), each...
PTC Therapeutics, Inc. has announced the approval of 300 restricted stock units (RSUs) to a newly hired non-executive employee as an inducement for accepting the position. This decision was endorsed by the company's Compensation Committee and complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a four-year period, with portions of the shares vesting annually. This initiative reflects PTC's commitment to attract talent while adhering to industry regulations.
Read more →PTCTA PTC Therapeutics anuncia a aprovação do Sephience™ (sepiapterina) para o tratamento de crianças e adultos que vivem com fenilcetonúria (PKU) no JapãoBRAZIL - PortugueseUSA - EnglishMEXICO - Spanish
PTC Therapeutics announced the approval of Sephience (sepiapterin) by Japan's Ministry of Health for treating phenylketonuria (PKU) in patients of all ages. This marks the first approval of a PTC product in Japan and follows rapid approvals in the EU and US. Discussions on pricing will begin, with a launch expected in early 2026.
Read more →PTCTPTC Therapeutics anuncia la aprobación de Sephience™ (sepiapterina) para el tratamiento de niños y adultos con fenilcetonuria (PKU) en JapónMEXICO - SpanishUSA - EnglishBRAZIL - Portuguese
PTC Therapeutics has announced the approval of Sephience™ (sepiapterina) by Japan's Ministry of Health for treating phenylketonuria (PKU) in both children and adults. This marks a significant milestone as it is the first product approved by PTC in Japan. The company plans to negotiate pricing and expects to launch Sephience shortly after these discussions conclude in early 2026.
Read more →PTCTPTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan
PTC Therapeutics has received approval for Sephience™ (sepiapterin) from the Japanese Ministry of Health for treating phenylketonuria (PKU) in patients of all ages. This marks the first product approval for PTC in Japan. The company plans to engage in pricing discussions, with a launch expected in early 2026. Sephience is designed to reduce blood phenylalanine levels effectively.
Read more →PTCTセピエンス™（セピアプテリン）、フェニルケトン尿症（PKU）の治療薬として製造販売承認取得 PTCセラピューティクス株式会社は、本日、厚生労働省（MHLW）により、セピエンス™顆粒分包250mg、同1000mg（セピアプテリン）がフェニルケトン尿症（PKU）の治療薬として承認されたことを発表しました。幅広い年齢層および病型のPKU患者様が治療の対象となります。 PTC...
PTC Therapeutics has announced that its treatment, Sepiapterin, has been approved by Japan's Ministry of Health, Labour and Welfare for the treatment of phenylketonuria (PKU). This approval marks a significant milestone for patients with PKU in Japan, providing a new therapeutic option. The treatment is expected to improve the quality of life for patients by effectively managing their condition.
Read more →PTCT▲ +5.3%on this newsshared move
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. announced the approval of non-statutory stock options and restricted stock units for five new employees. The inducement grants, totaling 3,825 shares of stock options and 4,385 RSUs, were made in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, encouraging employee retention and long-term engagement. Each award's exercise price is set at $75.42, the closing stock price on the grant date of December 16, 2025.
Read more →PTCTPTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 44th Annual J.P. Morgan Healthcare...
PTC Therapeutics, Inc. has announced that CEO Matthew B. Klein, M.D., will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation is scheduled for 9 a.m. PST/12 p.m. EST and will be webcast live. Interested participants can access the presentation via the company's website, and it will remain available for 30 days post-event. This event highlights the company's ongoing engagement with investors and the healthcare community.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics announced the approval of inducement grants for 15 new employees, including stock options and restricted stock units. The grants were made under Nasdaq Listing Rule 5635(c)(4) to enhance employment offers. The stock options have a 10-year term and vest over four years, while the RSUs also vest over the same period. This move reflects PTC's commitment to attracting talent in the biopharmaceutical sector.
Read more →PTCTPTC Therapeutics to Host R&D Day
PTC Therapeutics will host an R&D Day on December 2, 2025, in New York City. The event will feature updates from CEO Matthew B. Klein and the R&D team on the company's small molecule splicing and inflammation platforms. A webcast of the event will be available, with a replay accessible for 30 days.
Read more →PTCT▲ +6%on this news
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
PTC Therapeutics reported a strong Q3 2025, with total revenues of $211M and a successful launch of Sephience, generating $19.6M in global revenue. The company narrowed its full-year revenue guidance to $750 - $800M, reflecting confidence in its growth. CEO Matthew B. Klein highlighted the potential of Sephience to become the standard care for PKU patients.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2025, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. announced on October 27, 2025, that it granted non-statutory stock options and restricted stock units to two new employees as part of their employment compensation. The grants, approved by the Compensation Committee, are in accordance with the Nasdaq Listing Rule 5635(c)(4), aimed at incentivizing new hires. The stock options have a 10-year term with a vesting schedule over four years, while the restricted stock units will vest annually over the same period.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results
PTC Therapeutics, Inc. announced a conference call scheduled for November 4, 2025, to discuss its third quarter financial results and provide a business update. The call will be accessible via phone and webcast, with a replay available afterward. The company emphasizes its commitment to developing treatments for rare disorders.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 28, 2025, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has approved inducement grants for 48 new employees as part of their employment compensation. On September 28, 2025, the company granted stock options and restricted stock units totaling 19,475 shares of common stock and 39,060 RSUs. These grants were made under the Nasdaq Listing Rule 5635(c)(4) and are intended to enhance the recruitment of new talent by providing competitive incentives linked to stock ownership.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Cantor Global Healthcare...
PTC Therapeutics, Inc. disclosed that its executives will participate in several upcoming investor conferences, including the Cantor Global Healthcare Conference and the Wells Fargo Healthcare Conference. The events will feature live webcasts, available on PTC's website, ensuring wide accessibility for investors. This initiative reflects PTC's commitment to transparency and engagement with its stakeholders.
Read more →PTCTPTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
PTC Therapeutics has received a Complete Response Letter from the FDA regarding its New Drug Application for vatiquinone, intended for treating Friedreich's ataxia. The FDA indicated that the evidence of efficacy was insufficient, necessitating further studies before resubmission. PTC's CEO expressed disappointment but remains optimistic about future discussions with the FDA.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2025. "We had...
PTC Therapeutics reported a strong second quarter for 2025, highlighted by the FDA and European Commission approvals of Sephience for PKU. The company initiated a global launch of Sephience and reported total revenues of $179 million. Despite a net loss of $64.8 million, PTC anticipates significant revenue growth for the full year 2025, projecting revenues between $650 million and $800 million.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - European and FDA approval of Sephience (sepiapterin) with broad labeling for PKU - - Global launch underway in Europe and U.S
PTC Therapeutics has announced significant progress with the approval of Sephience (sepiapterin) for treating phenylketonuria (PKU) by both the European and FDA authorities. The company reported a total revenue of $179 million for the second quarter of 2025. While the launch of Sephience is ongoing in Europe and the U.S., the firm is also facing financial challenges, having recorded a net loss of $64.8 million during the same period. Nonetheless, PTC's CEO expressed optimism regarding Sephience as a foundational product for future growth.
Read more →PTCTPTC Therapeutics Announces FDA Approval of Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - Broad labeling inclusive of all disease subtypes for individuals 1 month of
PTC Therapeutics has announced FDA approval for Sephience (sepiapterin), a treatment for phenylketonuria (PKU) affecting individuals aged 1 month and older. This approval includes broad labeling that caters to various subtypes of PKU, addressing a significant unmet medical need. The FDA's decision is based on data from the Phase 3 APHENITY trial, demonstrating the drug's efficacy and safety. The company is set to discuss the launch details during an upcoming conference call.
Read more →PTCTPTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has approved SEPHIENCE™ (sepiapterin) for the...
PTC Therapeutics has received FDA approval for Sephience (sepiapterin) to treat phenylketonuria (PKU) in patients aged 1 month and older. The approval includes broad labeling for sepiapterin-responsive PKU, reflecting its potential to address unmet medical needs. The decision is based on positive results from the Phase 3 APHENITY trial and long-term studies. PTC plans to quickly bring this therapy to market.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2025...
PTC Therapeutics, Inc. has announced a webcast conference call scheduled for August 7, 2025, to discuss its second quarter financial results and provide a business update. The call will offer insights into the company's operations and outlook, reinforcing its commitment to transparency with investors. Participants are encouraged to join the call early and can access a recorded version afterward. This event highlights PTC's ongoing efforts in developing treatments for rare disorders while maintaining open communication with stakeholders.
Read more →PTCTSephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Sephience™ (sepiapterin) was granted marketing authorization by the European Commission...
PTC Therapeutics, Inc. announced that Sephience (sepiapterin) received marketing authorization from the European Commission for treating phenylketonuria (PKU) in both children and adults. This approval encompasses a wide label accommodating various ages and disease severities, based on promising results from the Phase 3 APHENITY trial. The launch will start in Germany in July 2025, with further submissions and regulatory reviews ongoing in other regions. Despite the positive outcome, potential risks related to pricing, reimbursement, and regulatory success remain.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 16, 2025, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has approved inducement grants for 34 new employees, comprising stock options and restricted stock units. A total of 12,725 stock options and 27,790 RSUs were awarded, with an exercise price set at $51.87 per share. These grants were made as part of the employees' compensation following Nasdaq's inducement grant exception. The stock options vest over four years, reflecting the company's strategy to attract new talent as it continues to focus on rare disorders.
Read more →PTCT▼ -11%on this news
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Strong revenue performance of $190 million - - Positive CHMP opinion for Sephience (sepiapterin) received in April 2025, NDA r
PTC Therapeutics, Inc. reported strong financial results for the first quarter of 2025, showcasing a revenue of $190 million and a positive opinion from the CHMP for its product Sephience (sepiapterin). The company provided an update on its corporate progress, revealing a robust cash position of over $2 billion, which supports ongoing R&D and commercial activities. The anticipated NDA review for Sephience is set for July 29, 2025, as the company prepares for a global launch. CEO Matthew B. Klein expressed confidence in the company's trajectory, narrowing full-year revenue guidance.
Read more →PTCT▼ -11%on this news
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2025....
PTC Therapeutics reported strong financial results for Q1 2025, achieving $190 million in revenue and a positive opinion from the CHMP for Sephience. The company is progressing with global launch activities and anticipates a successful NDA review by the FDA. Despite a decrease in total revenue compared to the previous year, PTC maintains a robust cash position, supporting its operational and developmental plans.
Read more →PTCT▼ -18.6%on this newsshared move
PTC518 PIVOT-HD Study Achieves Primary Endpoint - Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 - - Favorable dose-dependent trends across clinical scales in Stage 2 patients at Mon
PTC Therapeutics announced that its Phase 2 PIVOT-HD study of PTC518 achieved its primary endpoint, showing a significant reduction in blood Huntingtin protein levels in Stage 2 and 3 Huntington's disease patients. The study demonstrated favorable dose-dependent trends in clinical scales for Stage 2 patients at both 12 and 24 months. Additionally, the safety profile remained positive, with no serious treatment-related adverse events reported. The company is optimistic about the potential for accelerated approval and next steps in development.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that on April 25, 2025, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has announced the approval of inducement grants of non-statutory stock options and restricted stock units to 12 new employees. These awards are part of the company's strategy to attract new talent under Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price aligned with the company’s recent stock closing price, and both options and RSUs vest over four years, contingent upon continued employment.
Read more →PTCTPTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
PTC Therapeutics received a positive opinion from the CHMP of the EMA for Sephience™ (sepiapterin), aimed at treating both children and adults with phenylketonuria (PKU). This marks a significant step towards addressing an unmet medical need in the PKU patient community, allowing for a broad label across all ages and disease severities. The company is planning to launch Sephience in key European markets following further approval by the European Commission. Simultaneously, Sephience's New Drug Application is under review by the FDA, with a target action date set for July 29, 2025.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities 2025...
PTC Therapeutics, Inc. has announced that its executives will speak at several upcoming investor conferences, including the Bank of America Securities Health Care Conference and the Goldman Sachs Global Healthcare Conference. These presentations will be webcast live and archived for 30 days, providing investors with accessible information. The company aims to engage with the investment community and provide updates on its developments during these events.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial ...
PTC Therapeutics, Inc. will host a webcast conference call on May 6, 2025, at 4:30 p.m. ET to report its first quarter 2025 financial results. The company aims to provide updates on its business and future outlook during the presentation. Interested participants can register to join the call and will have access to a replay afterward.
Read more →PTCTPTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal...
PTC Therapeutics announced that the European Commission has adopted the CHMP's negative opinion on Translarna (ataluren), leading to the non-renewal of its marketing authorization for treating nonsense mutation Duchenne muscular dystrophy in Europe. Despite this setback, the EC noted that individual EU countries may still permit its use. PTC plans to work with these countries to provide access to the drug.
Read more →PTCTPTC Therapeutics Provides Regulatory Update on Translarna (ataluren) in Europe WARREN, N.J.
PTC Therapeutics has announced that the European Commission has decided not to renew the authorization for Translarna (ataluren), a treatment for nonsense mutation Duchenne muscular dystrophy. This decision follows the Committee for Medicinal Products for Human Use's negative opinion and effectively withdraws the drug's conditional marketing authorization in the European Economic Area. However, certain EU member states may still provide access to the drug under specific articles of the EU Directive. PTC expresses disappointment but remains committed to working with individual countries to ensure continued access for patients.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced the approval of inducement grants for 35 new employees on March 24, 2025. The company granted non-statutory stock options for 12,000 shares and 28,220 restricted stock units (RSUs) as part of the employees' compensation packages. These grants were made under Nasdaq Listing Rule 5635(c)(4) to encourage employee acceptance and retention. The stock options have an exercise price of $57.03 per share and will vest over a four-year period.
Read more →PTCTPTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study ...
PTC Therapeutics, Inc. presented new data from the Phase 3 APHENITY trial at the 2025 ACMG Annual Clinical Genetics Meeting. The findings indicate that 97% of participants increased their dietary phenylalanine intake remarkably, highlighting the effectiveness of sepiapterin treatment in patients with phenylketonuria (PKU). The data support sepiapterin's potential to benefit all segments of PKU patients, particularly those with non-BH4 responsive genotypes. These results suggest a promising outlook for expanding treatment options for this rare metabolic disorder.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Full year 2024 revenue of $807 million, exceeding guidance - - All 2024 clinical and regulatory milestones were
PTC Therapeutics reported strong financial results for the full year 2024, with revenues totaling $807 million, surpassing company guidance. Key accomplishments included achieving all regulatory and clinical milestones on schedule, alongside a significant collaboration agreement with Novartis. However, the company still reported a considerable net loss of $363.3 million. The financial outlook remains cautious, with ongoing expenses and challenges in pricing and reimbursement negotiations potentially impacting future performance.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter ending December 31, 2024....
PTC Therapeutics reported a strong financial performance for Q4 2024, with revenues of $213 million, exceeding guidance for the year. The company achieved all clinical and regulatory milestones, including four NDA submissions accepted for filing. A significant licensing agreement with Novartis for the Huntington's disease program was finalized. Despite these successes, PTC experienced a net loss of $65.9 million for the quarter.
Read more →PTCTPTC Therapeutics to Participate in Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences:...
PTC Therapeutics, Inc. has announced that its executives will participate in upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Barclays 27th Annual Global Healthcare Conference. These events will feature fireside chats that will be available for live webcast. This move highlights the company's commitment to share updates and engage with the investment community.
Read more →PTCTPTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug...
PTC Therapeutics announced that the FDA has accepted for filing the New Drug Application for vatiquinone, intended for the treatment of Friedreich's ataxia in children and adults. The application has been granted Priority Review, with a target action date of August 19, 2025. Data from previous studies indicate that vatiquinone has the potential to significantly slow disease progression and is well tolerated across age groups. This application marks PTC’s fourth submission to the FDA in 2024, highlighting the company's active development pipeline.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year ...
PTC Therapeutics, Inc. has announced a conference call scheduled for February 27, 2025, to discuss its fourth quarter and full year 2024 financial results. The call aims to inform investors about the company's performance and provide an update on its business outlook. Participants are encouraged to register in advance to receive call details, and a replay will be available for later access.
Read more →PTCTPTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43 rd Annual J.P. Morgan Healthcare Conference - Unaudited 2024 total revenue of approximately $814 million, exceeding guidance - - Four appr
PTC Therapeutics provided a comprehensive update on its commercial performance and R&D activities at the J.P. Morgan Healthcare Conference. The company reported total unaudited revenue for 2024 at approximately $814 million, exceeding previous guidance. Key developments included the submission of four FDA approval applications and preparations for the global launch of sepiapterin for PKU. Despite positive outcomes, PTC faces potential challenges surrounding regulatory approvals and pricing negotiations.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ( RSUs ), each...
PTC Therapeutics, Inc. has announced the approval of 1,200 restricted stock units (RSUs) as part of its inducement grants for two new employees. These awards, approved by the Compensation Committee on January 3, 2025, are in accordance with Nasdaq Listing Rule 5635(c)(4) and are aimed at enhancing employee compensation. The RSUs will vest over a four-year period, with 25% vesting each year, contingent upon the employees' continued service with the company.
Read more →PTCTPTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief...
PTC Therapeutics provided a comprehensive update on its commercial performance and R&D pipeline during the 43rd Annual J.P. Morgan Healthcare Conference. The company reported unaudited revenues of approximately $814 million for 2024, surpassing its guidance. PTC has submitted four regulatory approval applications to the FDA and is preparing for the global launch of sepiapterin for PKU. Additionally, a collaboration agreement with Novartis for PTC518 has been finalized, enhancing PTC's financial outlook.
Read more →PTCTPTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 43rd Annual J.P. Morgan Healthcare...
PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced that its CEO, Dr. Matthew B. Klein, will present at the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 13, 2025. The presentation will be held at 11:15 a.m. PST and will be webcast live from the company's website, allowing broader access for investors and media. Following the live event, the presentation will be archived on the website for 30 days.
Read more →PTCTPTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and...
PTC Therapeutics has submitted a New Drug Application for vatiquinone to the FDA, targeting Friedreich ataxia in children and adults. This submission marks PTC's fourth application to the FDA in 2024. Positive outcomes from placebo-controlled and long-term studies support vatiquinone's efficacy and safety. The potential approval of vatiquinone could address a significant unmet need in this patient population.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has announced the approval of non-statutory stock options and restricted stock units for eight new employees. These inducement grants are part of the company's strategy to enhance its workforce under Nasdaq's inducement grant exception. The stock options have an exercise price reflecting PTC's closing stock price on the grant date and will vest over four years. This move is aimed at attracting talent by linking compensation to long-term performance and retention.
Read more →PTCT▲ +18.7%on this news
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis...
PTC Therapeutics has entered a global license and collaboration agreement with Novartis for its PTC518 Huntington's disease program. The deal includes a $1.0 billion upfront payment and potential milestone payments of up to $1.9 billion. Novartis will take over development and commercialization responsibilities after the ongoing PIVOT-HD trial. This partnership aims to enhance treatment options for Huntington's disease patients.
Read more →PTCT▲ +18.7%on this news
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program - PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in deve
PTC Therapeutics announced a global license agreement with Novartis for its PTC518 program targeting Huntington's disease. Under the agreement, PTC will receive $1 billion upfront, with potential additional payments of up to $1.9 billion based on various milestones. Novartis will take charge of the global development and commercialization efforts for PTC518, which is currently undergoing a Phase 2 clinical trial. The deal aims to accelerate the therapy's availability for patients suffering from Huntington's disease. However, the agreement's finalization is subject to customary regulatory approvals.
Read more →PTCTPTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review...
PTC Therapeutics, Inc. has announced the sale of its Rare Pediatric Disease Priority Review Voucher for $150 million, following FDA approval of its product KEBILIDI™ for treating AADC deficiency. This significant transaction provides a notable cash boost to the company, but is contingent upon standard closing conditions. Additionally, PTC faces uncertainties related to pricing and reimbursement negotiations that could impact its future commercial success.
Read more →PTCTwords, guidance , plan, anticipate, believe, estimate, expect, intend, may, target, potential, will, would, could, should, continue, and similar expressions. PTC s actual results, performance or achievements could differ
PTC Therapeutics, Inc. announced the sale of its Rare Pediatric Priority Review Voucher for $150 million, contingent upon customary closing conditions. This PRV was granted following FDA approval of KEBILIDI for treating AADC deficiency, which highlights PTC's role in addressing rare pediatric conditions. The transaction's closing is subject to the Hart-Scott Rodino Antitrust Improvements Act. The company provided a forward-looking statement regarding the potential impacts of market and regulatory conditions on future operations and financial performance.
Read more →PTCT▲ +7%on this news· ran to +21% by day 3shared move
PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of ...
PTC Therapeutics announced that its Phase 2 CardinALS trial of Utreloxastat for ALS patients did not achieve its primary endpoint of slowing disease progression. While there was a modest numerical benefit noted, the results were not statistically significant. Consequently, the company will not proceed with further development of Utreloxastat, despite its safety and tolerability. The outcome underscores ongoing challenges in effectively addressing the treatment needs of ALS patients.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 20, 2024, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced the approval of stock options and restricted stock units for ten new employees as part of their compensation package. The grants, totaling 18,815 shares and 17,995 RSUs, were approved by the company's Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and vest over four years, indicating a structured approach to employee retention and incentives. This initiative is significant as it reflects PTC's ongoing growth and commitment to attracting new talent.
Read more →PTCTPTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the...
PTC Therapeutics has received accelerated FDA approval for its gene therapy, KEBILIDI, for treating AADC deficiency, a rare genetic disorder. This gene therapy is notable for being the first to be directly administered into the brain and aims to restore dopamine production. The approval allows for use in both children and adults, with preparations for commercialization already underway. The therapy's efficacy is based on ongoing clinical trial results, although there are warnings regarding potential severe side effects and procedural complications.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2024....
PTC Therapeutics, Inc. reported strong financial results for Q3 2024, with total revenues reaching $197 million, prompting an increase in full-year guidance to between $750 and $800 million. The company has submitted multiple regulatory filings to the FDA, including for sepiapterin and vatiquinone, and is on track to meet its 2024 milestones. However, PTC also reported a net loss of $106.7 million for the quarter, highlighting ongoing financial challenges.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Strong revenue performance, supporting increase in full-year revenue guidance to $750-800 million - - Regulatory filings for s
PTC Therapeutics has provided a corporate update highlighting strong revenue growth, with updated full-year guidance increased to $750-800 million. The company's product, Translarna, generated $72 million in net revenues. PTC is currently undergoing a review process for several regulatory filings with the FDA and plans to submit an NDA for vatiquinone in December. Despite strong performance, PTC reported a net loss of $106.65 million for the third quarter of 2024, which raises concerns about its financial health.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: UBS Global...
PTC Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including the UBS Global Healthcare Conference, Jefferies London Healthcare Conference, and Citi's 2024 Global Healthcare Conference. The presentations will be accessible via live webcast, which will then be archived for 30 days. This initiative is aimed at providing investors with a comprehensive overview of the company's operations and strategic direction.
Read more →PTCTPTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New ...
PTC Therapeutics has announced the acceptance of the New Drug Application resubmission for Translarna™ (ataluren) by the FDA. This is a notable step toward providing treatment for boys and young men with nonsense mutation Duchenne muscular dystrophy (nmDMD). Clinical trials have shown significant benefits from Translarna, including improved walking distances and a delay in loss of ambulation. However, a specific FDA action date is yet to be provided since this is a resubmission after a previous complete response letter in 2016.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2024, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. announced the approval of inducement grants for nineteen new employees on October 23, 2024. The grants include stock options to purchase 13,690 shares and 20,250 restricted stock units (RSUs). These awards are part of the new hires' compensation and comply with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $42.48 per share, and both stock options and RSUs will vest over four years contingent on continued employment.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2024 financial ...
PTC Therapeutics, Inc. has announced a conference call to discuss its third quarter 2024 financial results scheduled for November 7 at 4:30 p.m. EST. The call will provide updates on the company's business and future outlook, promoting engagement with the investor community. Interested participants are encouraged to register in advance for dial-in details. A replay of the call will be available on the company’s website shortly after the event.
Read more →PTCT▲ +5.6%on this news
CHMP Maintains Negative Opinion on Translarna Reexamination - Opinion to be reviewed by European Commission - WARREN, N.J.
PTC Therapeutics, Inc. announced that the CHMP has maintained its negative opinion on the renewal of the marketing authorization for Translarna (ataluren) used to treat nonsense mutation Duchenne Muscular Dystrophy. This decision is based on specific trial results rather than the totality of evidence supporting the drug's efficacy and safety. The opinion will be reviewed by the European Commission, which is expected to make a decision in approximately 67 days. PTC remains committed to ensuring the availability of Translarna to patients while providing comprehensive evidence to the regulatory body.
Read more →PTCT▲ +5.6%on this news
CHMP Maintains Negative Opinion on Translarna™ Reexamination PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
PTC Therapeutics announced that the CHMP has upheld its negative opinion on the renewal of Translarna's marketing authorization for treating nmDMD. This decision will be reviewed by the European Commission, which is expected to make a decision in about 67 days. PTC argues that the CHMP's decision overlooks comprehensive evidence supporting the drug's efficacy and safety.
Read more →PTCTPTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has set a target regulatory action date of July 29, 2025, for the review of the...
PTC Therapeutics has announced that the FDA has established a target regulatory action date of July 29, 2025, for its New Drug Application for sepiapterin. This therapy is designed to treat phenylketonuria (PKU) in patients across all age groups and subtypes. Additionally, the results of the Phase 3 APHENITY trial have been published in The Lancet, highlighting the therapy's potential to meet significant unmet medical needs for PKU patients. However, challenges related to regulatory approval and commercialization remain a concern for the company.
Read more →PTCT▲ +16.5%on this news
PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program PTC Therapeutics, Inc. (NASDAQ: PTCT) provided today several positive updates on the vatiquinone Friedreich ataxia (FA) program. The pre-specified...
PTC Therapeutics has announced positive updates regarding vatiquinone for Friedreich ataxia, revealing statistically significant results from long-term treatment studies. The clinical data shows a meaningful reduction in disease progression over a 144-week period. The company confirmed plans to submit a New Drug Application (NDA) to the FDA by December 2024, in alignment with feedback received. Vatiquinone has demonstrated a strong safety profile and the potential to address significant unmet medical needs in FA patients, especially children and adolescents.
Read more →PTCTPTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment ...
PTC Therapeutics has received FDA acceptance for filing the New Drug Application for sepiapterin, intended for treating patients with phenylketonuria (PKU). This acceptance is seen as a crucial milestone, as clinical trial data indicate a significant reduction in phenylalanine levels among treated patients. The results also suggest that sepiapterin could allow for less restrictive diets, addressing an essential need for individuals living with PKU. The PDUFA target action date will be provided in the Day 74 Letter, as PTC continues towards regulatory approval.
Read more →PTCTFDA Grants Fast Track Designation to PTC518 Huntington's Disease Program PTC Therapeutics (NASDAQ: PTCT) announced today that the FDA has granted Fast Track designation to the PTC518 program for the treatment of...
PTC Therapeutics announced that its PTC518 program for Huntington's disease has received Fast Track designation from the FDA. This designation highlights the potential of PTC518 as a disease-modifying therapy for a condition with high unmet medical need. Recent interim data from the PIVOT-HD study showed promising results, including a significant lowering of the mutant Huntingtin protein and favorable outcomes on disease metrics. The therapy is designed to be taken orally and effectively penetrates the blood-brain barrier, aiming to address the underlying causes of Huntington's disease.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 8, 2024, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has announced the approval of non-statutory stock options and restricted stock units for nine new employees as part of their employment compensation. The inducement grants, totaling approximately 16,180 shares and 23,725 RSUs, were made under the Nasdaq inducement grant exception. The stock options come with a 10-year term and a vesting period of four years, designed to align employee interests with the company's performance.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Morgan Stanley...
PTC Therapeutics, Inc. has announced its participation in several key investor conferences, including the Morgan Stanley 22nd Annual Global Healthcare Conference and the Wells Fargo Healthcare Conference. The company will provide a company overview at each event, which will be webcast live and archived for 30 days. This initiative aims to strengthen investor relations and company visibility in the biopharmaceutical sector.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - Continued strong revenue performance - - NDAs for sepiapterin and Translarna submitted to FDA - - Positive interim data reado
PTC Therapeutics, Inc. announced a corporate update alongside the financial results for Q2 2024, revealing continued strong revenue generation. Notably, the company achieved $133.2 million in net product revenue, attributed to its expanding portfolio and patient access. PTC has submitted new drug applications for sepiapterin and Translarna to the FDA and reported positive interim results from the PIVOT-HD study. However, the company also reported a significant net loss, highlighting ongoing operational challenges.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2024. "I am...
PTC Therapeutics reported strong financial results for Q2 2024, with total revenues of $187 million. The company submitted NDAs for sepiapterin and Translarna to the FDA and achieved positive interim data from the PTC518 PIVOT-HD study. Despite a net loss of $99.2 million, PTC remains on track to meet its clinical and regulatory milestones for the year.
Read more →PTCTPTC Therapeutics Announces Sepiapterin NDA Submission to FDA PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the treatment...
PTC Therapeutics has submitted a New Drug Application (NDA) for sepiapterin to the U.S. FDA for treating phenylketonuria (PKU) in both pediatric and adult patients. The submission is based on positive results from the phase 3 APHENITY trial, which demonstrated significant reductions in phenylalanine levels. The product aims to address the unmet needs of PKU patients and enhance their quality of life through potential dietary liberalization. Regulatory submissions in Japan and Brazil are anticipated later in 2024.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2024...
PTC Therapeutics, Inc. has announced it will host a webcast conference call on August 8, 2024, to discuss its second quarter financial results. The call aims to provide insights into the company's business outlook and recent developments. Participants are encouraged to register in advance for phone access and can also view the webcast on PTC's investor relations website. A replay will be available for 30 days after the event.
Read more →PTCT▼ -11.8%on this news
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the CHMP has issued a negative opinion on the renewal of the conditional marketing...
PTC Therapeutics announced that the CHMP has issued a negative opinion regarding the renewal of Translarna's conditional marketing authorization for treating nmDMD. Despite this setback, PTC plans to request a re-examination of the opinion. The marketing authorization remains valid pending this process, and PTC expects Translarna to stay on the market through 2024.
Read more →PTCT▼ -11.8%on this news
CHMP Issues Negative Opinion on Translarna Following European Commission Request for Review - PTC to submit a request for re-examination - WARREN, N.J.
PTC Therapeutics announced that the CHMP has issued a negative opinion regarding the renewal of Translarna's conditional marketing authorization for treating nmDMD. This decision follows a previous negative opinion from the European Commission but is not final, as PTC plans to request a re-examination. Despite the negative verdict, the company remains able to market Translarna pending the outcome of these procedures until the end of 2024. The CEO expressed disappointment over the CHMP's stance, emphasizing the importance of considering evidence from the STRIDE study.
Read more →PTCT▲ +9.7%on this news
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 17, 2024, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has announced that on June 17, 2024, it approved stock options and restricted stock units (RSUs) for nine new hires as part of their compensation under Nasdaq's inducement grant exception. Specifically, the company granted non-statutory stock options to purchase a total of 1,380 shares and 6,260 RSUs. The options have an exercise price of $35.40 per share and will vest over a period of four years, contingent upon the employees' continued service. This initiative highlights PTC's efforts to boost its workforce and provide competitive compensation packages.
Read more →PTCT▼ -6.5%on this newsshared move
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease (HD) patients....
PTC Therapeutics announced interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease patients. After 12 months, the treatment demonstrated a dose-dependent reduction in mutant huntingtin protein levels and showed positive trends in clinical assessments. The FDA has lifted the partial clinical hold on the program, allowing further development of PTC518.
Read more →PTCT▼ -6.5%on this newsshared move
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients - FDA lifts PTC518 partial clinical hold based on PIVOT-HD data - - Conference ca
PTC Therapeutics reported positive interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease patients, showing a dose-dependent reduction in mutant huntingtin protein levels. At 12 months, treatment led to favorable trends in clinical assessments and was well tolerated. The FDA has lifted the partial clinical hold on PTC518, allowing further development of this potential therapy aimed at addressing an unmet need in Huntington's disease treatment. A conference call is scheduled for further discussion of these developments.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: William Blair's...
PTC Therapeutics, Inc. has announced its participation in the William Blair's 44th Annual Growth Stock Conference, scheduled for June 4. The company will present an overview aimed at potential investors, which will be available via a live webcast on their investor relations page. The webcast will also be archived for 30 days, allowing further access to the information presented.
Read more →PTCTPTC Therapeutics Announces Validation of Sepiapterin European MAA PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA. The...
PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for sepiapterin, a treatment for phenylketonuria (PKU). This validation initiates the review process in Europe, with plans for a New Drug Application (NDA) submission to the FDA by Q3 2024 and additional submissions expected in Brazil and Japan. The MAA includes promising data from the phase 3 APHENITY trial, showing substantial reductions in phenylalanine (Phe) levels among treated patients. However, challenges remain regarding market access and regulatory approvals in various regions.
Read more →PTCT▲ +21.2%on this news
PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation - European Commission decides against adoption of negative opinion - - Translarna authorization remains active in Europe
PTC Therapeutics announced that the European Commission has opted not to adopt a negative opinion regarding the conditional marketing authorization renewal for Translarna (ataluren). This decision allows Translarna to remain available for patients with nonsense mutation Duchenne muscular dystrophy in Europe while the CHMP reassesses the drug based on additional data. However, PTC has paused its 2024 revenue guidance due to the inability to forecast the drug's market impact, following the invalidation of prior Scientific Advisory Group meeting inputs.
Read more →PTCT▲ +21.2%on this news
PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of Jan....
PTC Therapeutics announced that the European Commission has opted not to adopt a negative opinion from the CHMP regarding Translarna's marketing authorization. This decision allows Translarna to remain available for patients in Europe while the CHMP re-evaluates the evidence. However, PTC has paused its revenue guidance for 2024 due to the uncertainty surrounding this authorization.
Read more →PTCTPTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™ PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™...
PTC Therapeutics has announced the FDA's acceptance of the Biologics License Application (BLA) for Upstaza, a gene therapy aimed at treating AADC deficiency. The application has been granted Priority Review with an expected decision date of November 13, 2024. Upstaza is designed to correct a genetic defect related to dopamine production and has shown positive results in clinical trials. However, the therapy's administration involves a surgical procedure, and the company faces uncertainties related to commercialization and reimbursement in the future.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: RBC Capital...
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced its participation at two upcoming investor conferences: the RBC Capital Markets 2024 Global Healthcare Conference on May 14 and the Bank of America Securities 2024 Health Care Conference on May 16. Each presentation will be webcast live and available for 30 days afterward, underscoring the company's commitment to connectivity with its investors. This engagement aims to enhance visibility and foster investor relations.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - Strong revenue performance across product portfolio - - Submitted MAA for sepiapterin and BLA for Upstaza - - On target to ach
PTC Therapeutics reported strong financial results for Q1 2024, highlighting significant revenue growth from its flagship products Translarna and Emflaza. The company has submitted a Marketing Authorization Application (MAA) for sepiapterin and a Biologics License Application (BLA) for Upstaza, marking critical steps in expanding its product portfolio. Despite the strong performance, PTC continues to face financial losses, which underscores the importance of regulatory approvals and market acceptance for its therapies as it targets several upcoming clinical milestones for the year.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2024. "We are...
PTC Therapeutics reported strong financial results for Q1 2024, with total revenues of $210 million. The company successfully submitted regulatory applications for sepiapterin and Upstaza, and remains on target for its 2024 clinical milestones. However, it also reported a net loss of $91.6 million, highlighting ongoing financial challenges.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 19, 2024, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has approved non-statutory stock options totaling 8,090 shares and 8,290 restricted stock units for six new employees as part of their compensation. This decision aligns with the Nasdaq inducement grant exception, allowing the company to enhance its workforce. The stock options have a 10-year term and vest over four years, with vesting contingent on continued employment. The awards aim to incentivize new talent to join the company.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial ...
PTC Therapeutics, Inc. has announced that it will host a conference call to discuss its financial results for the first quarter of 2024. The call is scheduled for April 25 at 4:30 p.m. ET and will provide an update on the company's business outlook. Participants are encouraged to call in 15 minutes early to avoid delays, and a replay will be available on the company's website shortly after the event.
Read more →PTCTPTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin MAA to the European Medicines Agency. The MAA submission is...
PTC Therapeutics has announced the submission of a Marketing Authorization Application (MAA) for sepiapterin to the European Medicines Agency (EMA) for treating Phenylketonuria (PKU). This submission represents a significant step towards addressing the unmet medical needs of PKU patients, supported by promising results from the phase 3 APHENITY trial. The treatment demonstrated a substantial reduction in blood phenylalanine levels, with most patients achieving control in line with guidelines. PTC plans to continue global submissions for sepiapterin in 2024, aiming for a broader market presence.
Read more →PTCTPTC Therapeutics Provides Key Regulatory Updates PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza™ (eladocagene exuparvovec), a gene therapy...
PTC Therapeutics, Inc. has announced the submission of a Biologics License Application (BLA) for Upstaza (eladocagene exuparvovec) to the U.S. FDA, targeting patients with aromatic L-amino acid decarboxylase (AADC) deficiency. This submission aligns with the company’s commitment to progressing gene therapy for a rare genetic disorder. Additionally, based on feedback from the FDA, PTC plans to resubmit a New Drug Application (NDA) for Translarna (ataluren) by mid-year, seeking approval for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The regulatory updates highlight PTC's ongoing efforts to address unmet medical needs for severe conditions affecting children.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results - 34% year-over-year growth in 2023 total revenue - - Global filings of sepiapterin remain on track with first su
PTC Therapeutics reported strong financial results for the fourth quarter and full year 2023, with a 34% increase in total revenue. The company is on track to file for global submissions of sepiapterin, targeting the treatment of PKU, with the first EU application expected by March. Additionally, PTC is preparing for a potential NDA submission for vatiquinone for Friedreich ataxia, anticipated for late 2024. Despite the positive revenue growth, the company experienced a net loss that expanded compared to the previous year.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December...
PTC Therapeutics reported a strong financial performance for 2023, with total revenue reaching $938 million, marking a 34% increase year-over-year. The company is poised for significant regulatory milestones, including the expected submission of sepiapterin for PKU treatment in March 2024 and a potential NDA for vatiquinone for Friedreich ataxia by late 2024. Despite a net loss of $155.8 million in Q4 2023, PTC's cash position improved significantly compared to the previous year.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: TD Cowen 44th...
PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced its participation in several upcoming investor conferences. The company will present a company overview at the TD Cowen 44th Annual Health Care Conference, the Leerink Partners Global Biopharma Conference 2024, and the Barclays 26th Annual Healthcare Conference. Presentations are set to occur between March 4 and March 12, 2024, and will be available via live webcasts on the company's website. This engagement highlights PTC's efforts to communicate with investors and stakeholders effectively.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Feb. 15, 2024, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced the approval of inducement grants for new employees, including stock options and restricted stock units. On February 15, 2024, the company approved 1,840 stock options and 4,275 RSUs to enhance recruitment efforts. This move complies with Nasdaq Listing Rule 5635(c)(4), reflecting PTC's strategy to attract talent while aligning with industry standards.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year ...
PTC Therapeutics, Inc. has announced a webcast conference call to discuss its financial results for the fourth quarter and full year of 2023. The call is scheduled for February 29, 2024, at 4:30 p.m. EST. Participants are encouraged to register in advance to receive dial-in details. A replay of the call will be available shortly after its conclusion and archived for 30 days.
Read more →PTCTCHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna (ataluren) Following Re-examination Procedure
PTC Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) has delivered a negative opinion regarding the renewal of conditional marketing authorization for Translarna (ataluren). This decision affects patients in Europe suffering from nonsense mutation Duchenne Muscular Dystrophy, as it could lead to the withdrawal of a therapy deemed safe and effective. The situation is particularly distressing for the patient community and healthcare professionals who advocate for the therapy's continued availability. The European Commission has 67 days to adopt this negative opinion.
Read more →PTCTCHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
PTC Therapeutics announced that the CHMP has maintained a negative opinion on the renewal of Translarna's conditional marketing authorization. This decision, which is contrary to the desires of patients and healthcare experts, could have severe implications for those suffering from nonsense mutation Duchenne Muscular Dystrophy in Europe. The European Commission has 67 days to adopt this opinion.
Read more →PTCT▲ +7.5%on this news
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 42nd Annual J.P. Morgan Healthcare...
PTC Therapeutics provided an update on its commercial progress and R&D pipeline during the 42nd Annual J.P. Morgan Healthcare Conference. The company reported a 35% increase in total revenue for 2023, reaching $946 million, and highlighted key upcoming regulatory submissions for its PKU program. Positive clinical trial results were also announced, indicating a strong outlook for 2024.
Read more →PTCT▲ +7.5%on this news
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference – Unaudited 2023 total revenue of $946 million, representing 35% year-over-year growth &
PTC Therapeutics provided an update on its commercial progress and R&D pipeline during the 42nd Annual J.P. Morgan Healthcare Conference. The company reported an impressive total revenue of $946 million for 2023, reflecting a robust 35% year-over-year growth. Looking forward, PTC expects total revenues in 2024 to range between $600 million and $850 million. However, the company noted various significant risks related to product development and the regulatory approval process that could impact future performance.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 10, 2023, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. announced the approval of non-statutory stock options and restricted stock units for two new employees, aimed at incentivizing their employment. The stock options total 3,575 shares, while the restricted stock units involve 3,035 shares. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are structured over a four-year vesting period to encourage retention and performance. The exercise price for these options has been set at $26.39 per share, reflecting the company’s stock price from December 8, 2023.
Read more →PTCTPTC Therapeutics fornece atualizações sobre atividades regulatórias do Translarna™ A PTC Therapeutics, Inc. anunciou hoje uma atualização sobre as atividades regulatórias do Translarna™ (ataluren) na Europa e nos Estados Unidos....
PTC Therapeutics, Inc. provided an update on the regulatory activities concerning its drug Translarna (ataluren) for Duchenne muscular dystrophy in Europe and the United States. The company intends to address concerns from the European Medicines Agency regarding the conditional marketing authorization renewal. In the U.S., it is preparing for discussions with the FDA to facilitate a resubmission of a new drug application. The outcomes of these regulatory processes will be critical for patient access to this therapy.
Read more →PTCTPTC Therapeutics ofrece novedades sobre las actividades regulatorias de Translarna™ PTC Therapeutics, Inc. anunció hoy novedades sobre las actividades regulatorias de Translarna™ (ataluren) en Europa y los Estados Unidos. Según lo...
PTC Therapeutics has provided updates on the regulatory activities for Translarna (ataluren) in Europe and the United States. The company has submitted a document for reevaluation to address the initial negative opinion from the European Committee for Medicinal Products for Human Use regarding the renewal of the conditional marketing authorization. In the US, PTC is engaged in discussions with the FDA to explore a potential New Drug Application for Translarna, clarifying plans for additional meetings to support this submission. PTC aims to make Translarna accessible to patients with nmDMD globally.
Read more →PTCTPTC Therapeutics Provides Updates on Translarna™ Regulatory Activities PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States. As...
PTC Therapeutics has updated on the regulatory progress of its drug Translarna (ataluren) in both Europe and the U.S. The company has submitted a briefing document for a re-examination of the CHMP's initial negative opinion regarding Translarna's conditional marketing authorization, with an opinion expected by late January 2024. In the U.S., a productive Type C meeting with the FDA has paved the way for discussions on a potential resubmission of the New Drug Application. CEO Matthew B. Klein emphasized the commitment to securing access to Translarna for patients with nmDMD worldwide.
Read more →PTCT▲ +8.1%on this news
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 1, 2023, the company approved non-statutory stock options to purchase an aggregate ...
PTC Therapeutics, Inc. announced the approval of inducement grants for 21 new employees as part of their compensation package. This includes non-statutory stock options for 14,005 shares and 19,125 restricted stock units (RSUs). The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) to incentivize acceptance of employment. The stock options have a 10-year term with a vesting schedule over four years based on continued service.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results - Third quarter 2023 total revenues of $197 million and remain on target for 2023 revenue guidance - - PTC strengthened its financial
PTC Therapeutics, Inc. reported its third quarter financial results for 2023, achieving total revenues of $197 million, on track with its year guidance. The CEO emphasized the company's strengthened financial position following recent restructuring and a partnership with Royalty Pharma. The report highlighted solid revenues from products like Translarna and Emflaza, while also noting a significant net loss attributable to shareholders. Additionally, the company outlined expectations for future growth, particularly regarding the potential $1 billion revenue opportunity from sepiapterin.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2023. "I...
PTC Therapeutics, Inc. announced its third-quarter financial results, reporting total revenues of $197 million and reaffirming its revenue guidance for 2023. The company highlighted its strengthened financial position following a strategic partnership with Royalty Pharma. However, PTC also faced challenges, including a net loss of $133 million and ongoing regulatory hurdles for its product Translarna.
Read more →PTCT▲ +15%on this news
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced an agreement with Royalty Pharma plc. to monetize up to $1.5 billion of the Evrysdi royalty...
PTC Therapeutics has entered into a royalty agreement with Royalty Pharma to monetize up to $1.5 billion from its Evrysdi royalty stream. The deal includes an upfront payment of $1 billion for approximately 67% of the royalties, with options for further sales. Proceeds will be used to eliminate existing debt and support ongoing operations, enhancing PTC's financial position.
Read more →PTCT▲ +15%on this news
PTC Therapeutics Announces Evrysdi Royalty Agreement with Royalty Pharma for Up To $1.5 Billion - PTC to receive $1B in upfront cash for approximately 67% of outstanding royalties, with option for additional $500M - - Fi
PTC Therapeutics has announced a new agreement with Royalty Pharma to monetize up to $1.5 billion from Evrysdi royalties. This entails an upfront payment of $1 billion for approximately 67% of the royalties, with additional options for later sales. The proceeds will be utilized to eliminate existing debt obligations and support future operations. The deal enhances PTC's financial situation while maintaining a stake in the royalty stream from Evrysdi, benefiting SMA patients.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 financial ...
PTC Therapeutics, Inc. has announced it will host a webcast conference call to discuss its third quarter 2023 financial results. The call is scheduled for October 26, 2023, at 4:30 p.m. ET, and will include an update on the company's business and future outlook. Participants are encouraged to join the call 15 minutes early to ensure connectivity, and a replay will be available for 30 days following the event.
Read more →PTCTPTC Announces Further Strategic Prioritization and Associated Reduction in Workforce PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio...
PTC Therapeutics announced a strategic prioritization that includes a workforce reduction affecting 25% of its employees. The company aims to focus on high-potential R&D programs while preparing to submit a re-examination request for Translarna to the CHMP. Despite the challenges, PTC remains confident in the evidence supporting Translarna's benefits.
Read more →PTCTPTC Announces Further Strategic Prioritization and Associated Reduction in Workforce - Translarna CHMP opinion re-examination request to be submitted
PTC Therapeutics announced a strategic prioritization and a significant workforce reduction affecting approximately 25% of its employees. This streamlining effort focuses on enhancing R&D programs while saving operating expenses by an estimated 20%. The company also plans to submit a re-examination request for Translarna, responding to previous negative feedback from the CHMP. Despite the challenges, PTC emphasizes its commitment to valuable assets within its portfolio.
Read more →PTCT▼ -29.8%on this news
CHMP Delivers Opinion on Translarna for Conversion to Full Authorization - Conference call to be held at 8:45 am EDT
PTC Therapeutics announced that the European Medicines Agency's CHMP issued a negative opinion regarding the full marketing authorization for Translarna, a treatment for nonsense mutation Duchenne muscular dystrophy. This decision also impacts the renewal of its existing conditional authorization. PTC expressed disappointment and plans to request a re-examination of the opinion, which is expected to be addressed by January 2024. Translarna will remain available to patients during the re-examination process.
Read more →PTCTAustralian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE™ Award for Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that an Australian patient advocacy organization is one of the two recipients of the company's...
PTC Therapeutics has awarded the 2023 STRIVE Award to the Save our Sons Duchenne Foundation in Australia, which will use the funding to develop a digital health app for young men with Duchenne Muscular Dystrophy. This app aims to assist users in managing their medical care as they transition into adulthood. Another recipient, Blue Angels from Brazil, will expand its power soccer program for individuals with disabilities.
Read more →PTCTEl programa de 2023 premios STRIVE de PTC Therapeutics financia iniciativas de apoyo a la comunidad de pacientes de Duchenne - 2023 Entre los beneficiarios se incluyen organizaciones de defensa de los pacientes en Australia y Brasil - SOUTH PLAINFIELD, Nueva Jersey, 7 de...
PTC Therapeutics announced the recipients of the STRIVE 2023 awards aimed at supporting organizations advocating for Duchenne Muscular Dystrophy. The funding will be utilized for a digital health application for patients transitioning to adulthood in Australia and for expanding a power soccer program in Brazil. This year's awards underline a commitment to addressing unmet needs within the Duchenne community. A total of 46 applications were received globally, showcasing the innovation and determination of the applicants.
Read more →PTCTPTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the two recipients of its 2023 STRIVE Awards for Duchenne Muscular Dystrophy. Through the...
PTC Therapeutics announced the recipients of its 2023 STRIVE Awards aimed at supporting the Duchenne Muscular Dystrophy community. This year, grants were awarded to organizations in Australia and Brazil, funding initiatives like a digital health app and a power soccer program. The STRIVE Awards program, which has been ongoing since 2015, aims to enhance awareness, diagnosis, and education in the Duchenne community. PTC received 46 applications from organizations globally, emphasizing the program's impact and importance in addressing patient needs.
Read more →PTCTO Programa STRIVE Awards 2023 da PTC Therapeutics Financia Iniciativas que Apoiam a Comunidade de Pacientes de Duchenne A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje os dois ganhadores do prêmio STRIVE 2023 para Duchenne Muscular Dystrophy (Distrofia Muscular...
PTC Therapeutics, Inc. has announced the winners of the 2023 STRIVE Awards, aimed at supporting Duchenne Muscular Dystrophy advocacy groups. The awards will fund initiatives in Australia and Brazil, including a digital health app and a wheelchair soccer program. This program highlights PTC's ongoing commitment to enhancing services for the Duchenne community, with a panel evaluating various innovative initiatives submitted by organizations worldwide.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Citi 2023 18th...
PTC Therapeutics, Inc. has announced its participation in multiple upcoming investor conferences, including the Citi 2023 BioPharma Conference and the Morgan Stanley Global Healthcare Conference. The company plans to present an overview of its operations and future outlook during these events. Presentations will be available via live webcast and archived for later viewing, enhancing accessibility for interested investors.
Read more →PTCTPTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from the APHENITY clinical trial and long-term extension study will be presented...
PTC Therapeutics announced the presentation of findings from the APHENITY clinical trial and its long-term extension study at the SSIEM Annual Symposium from August 29 to September 1, 2023. The trial highlights the positive results demonstrating efficacy in treating phenylketonuria (PKU) with sepiapterin. A significant aspect of the findings is the ability of patients to maintain phenylalanine control while increasing protein intake. The symposium will also feature discussions from leading experts on the advancements in PKU treatment stemming from the trial results.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2023. "I am...
PTC Therapeutics reported a strong second quarter for 2023, with total revenues of $214 million, marking a 29% increase year-over-year. The company highlighted positive results from the APHENITY and PIVOT-HD clinical trials, which bolster its growth prospects. However, it also faced a significant net loss and announced the discontinuation of certain gene therapy programs as part of a strategic shift.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results - Second-quarter 2023 total revenue of $214 million, representing 29% year-over-year growth - - Positive APHENITY and PIVOT-HD data
PTC Therapeutics reported a strong corporate update and financial results for the second quarter of 2023, highlighting a total revenue of $214 million, representing a significant growth of 29% from the previous year. The company also announced positive results from its APHENITY and PIVOT-HD clinical trials, bolstering its growth outlook. However, PTC experienced an increased net loss, which raised concerns about its financial stability amid high total liabilities.
Read more →PTCTCHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion...
PTC Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending Evrysdi® for the treatment of spinal muscular atrophy (SMA) in infants under two months old. This decision is based on interim data from the RAINBOWFISH study, which shows significant developmental improvements in treated infants. Evrysdi has been recognized for its innovative design and is already approved in numerous countries. Its availability will provide beneficial treatment options for high-risk patients.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2023...
PTC Therapeutics, Inc. has announced plans to host a webcast conference call on August 3, 2023, at 4:30 p.m. ET to discuss its second quarter financial results. The call will also include a business update and outlook for the company. Participants are advised to join the call 15 minutes early to avoid delays, and a replay will be available following the event.
Read more →PTCTPatient Living with PKU
The article discusses advancements in the management of Phenylketonuria (PKU), particularly through the introduction of sepiapterin as a novel therapeutic option. It highlights the challenges faced by PKU patients who often struggle with dietary restrictions and inadequate treatment outcomes. With a robust commercial strategy, PTC Therapeutics aims to enhance the availability of effective therapies, while also addressing patient support and education. The potential for sepiapterin to improve patient quality of life and treatment adherence is emphasized, alongside real-world data that provides insight into practitioner and patient needs in PKU management.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on July 13, 2023, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. announced the approval of non-statutory stock options and restricted stock units (RSUs) to 11 new employees on July 13, 2023. These inducement grants are part of the new hires' compensation, in accordance with NASDAQ Listing Rule 5635(c)(4). The company's Chief Financial Officer, Pierre Gravier, received a significant portion of these grants, showcasing the firm's commitment to attracting key talent. Stock options have a 10-year term with a vesting schedule of four years.
Read more →PTCTPTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO). Mr. Gravier...
PTC Therapeutics, Inc. has appointed Pierre Gravier as its new Chief Financial Officer. Gravier, who has over 17 years of experience in investment banking and healthcare, previously worked at Perella Weinberg Partners, advising companies on finance strategies. His extensive background is expected to contribute positively to PTC's future plans and patient-focused initiatives. The CEO expressed confidence in Gravier's capabilities and vision for transformational therapies.
Read more →PTCTPTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin PTC Therapeutics, Inc. (NASDAQ: PTCT), announced today that the company will provide a virtual presentation on PKU including discussion of the...
PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced a virtual presentation focused on Phenylketonuria (PKU) set for July 19, 2023. The event will feature discussions on the therapeutic landscape and the company's clinical program for sepiapterin. A key opinion leader, Dr. Ania C. Muntau, will participate, alongside senior management from PTC. Attendees will also have the opportunity to engage in a Q&A session following the presentation.
Read more →PTCTPTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the MIT-E trial of vatiquinone for the treatment of mitochondrial disease associated...
PTC Therapeutics announced that its MIT-E clinical trial for vatiquinone, aimed at treating mitochondrial disease associated seizures, did not meet its primary endpoint of reducing observable motor seizures. However, the trial showed some positive treatment effects, especially in a subgroup of children with Leigh syndrome. Despite this setback, the company plans to continue discussing results from its MOVE-FA trial and seeks to gather learnings for future developments in mitochondrial disease therapies.
Read more →PTCTPTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients - D ose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks - - Favorable tolerability profi
PTC Therapeutics has announced positive interim results from its PIVOT-HD Phase 2 clinical trial of PTC518 for Huntington's disease. The trial showed a 30% reduction in mutant Huntingtin protein levels in blood cells at a 10mg dose. Additionally, the treatment was well tolerated, with no serious adverse events reported. The study is part of a global, placebo-controlled trial structure designed to further evaluate PTC518's pharmacology and effects over a nine-month period.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 12, 2023, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. announced the approval of inducement grants of stock options and restricted stock units for 23 new employees as of June 12, 2023. The grants were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) to incentivize new hires. The stock options have an exercise price of $43.35 per share and will vest over four years, fostering employee retention. PTC continues to focus on expanding its talent pool while pursuing the development of innovative therapies for rare disorders.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Jefferies...
PTC Therapeutics, Inc. has announced its participation in upcoming investor conferences, including the Jefferies Healthcare Conference and the Goldman Sachs 44th Annual Global Healthcare Conference. The company plans to present a comprehensive overview at both events, with webcasts available for those unable to attend in person. The presentations are scheduled for June 7 and June 14, respectively. Interested parties are encouraged to connect to the company's website ahead of the scheduled presentations to ensure a timely connection.
Read more →PTCTPTC Therapeutics Announces Strategic Pipeline Prioritization - Preclinical and early research gene therapy programs discontinued - - Expected reductions of approximately 15% in residual 2023 OPEX
PTC Therapeutics has announced the discontinuation of its preclinical and early-stage research programs in gene therapy as part of a strategic pipeline prioritization. The expected outcome is a 15% reduction in operating expenses for 2023, allowing PTC to focus resources on its FDA-approved gene therapy, Upstaza, and other promising therapies. The decision will also lead to layoffs and follows the removal of CFO Emily Hill from her position. PTC's CEO emphasized the need to direct efforts towards projects with the greatest potential for patient benefit and financial return.
Read more →PTCTPTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia. The...
PTC Therapeutics reported topline results from the MOVE-FA trial of vatiquinone in Friedreich ataxia patients. While the trial did not meet its primary endpoint of change in the mFARS score, significant benefits were observed on secondary endpoints and key subscales. The treatment was well tolerated, and the company is considering discussions with regulatory authorities for a potential path to registration. The trial included 146 patients, primarily under age 18, highlighting the unmet medical need in pediatric patients.
Read more →PTCTPTC Therapeutics anuncia que o estudo clínico APHENITY atingiu o desfecho primário com sepiapterina em pacientes com Fenilcetonúria (PKU) A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o desfecho primário foi alcançado no estudo clínico APHENITY de Fase 3, direcionado para o...
PTC Therapeutics announced that the clinical trial APHENITY has successfully achieved its primary endpoint for sepiapterine in treating patients with phenylketonuria (PKU). The trial demonstrated a significant average reduction of 63% in blood phenylalanine levels in treated patients compared to a placebo. These statistically significant results support the potential of sepiapterine as a treatment option. The company plans to meet with regulatory authorities to discuss the path towards approval.
Read more →PTCTPTC Therapeutics anuncia que el ensayo APHENITY logró el criterio de valoración primario con sepiapterina en pacientes con PKU PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que se logró el criterio de valoración primario en el ensayo clínico fase 3, APHENITY, dirigido al...
PTC Therapeutics, Inc. announced that its phase 3 clinical trial, APHENITY, successfully met its primary endpoint, demonstrating a 63% reduction in blood Phe levels among patients with phenylketonuria (PKU). The study involved 98 patients and exhibited significant statistical reliability (p<0.0001). Sepiapterin was well tolerated, with minimal adverse effects noted. The company plans to discuss the results with regulatory authorities to explore potential approval pathways.
Read more →PTCT▲ +7.5%on this newsshared move
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients - Highly statistically significant and clinically meaningful results - - 63% mean blood Phe reduction in primary analys
PTC Therapeutics announced that their APHENITY trial successfully achieved its primary endpoint, demonstrating a 63% reduction in blood phenylalanine levels among patients treated with sepiapterin. This Phase 3 trial involved both adult and pediatric patients with phenylketonuria (PKU) and showed highly statistically significant results. There were no serious adverse events associated with sepiapterin, strengthening the case for its use as a viable treatment option. The company plans to discuss regulatory approval pathways following these promising results.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 24, 2023, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. announced the approval of non-statutory stock options and restricted stock units to 29 new employees as part of their employment compensation. This inducement grant was authorized by the company's Compensation Committee in compliance with NASDAQ Listing Rule 5635(c)(4). The awarded stock options will have an exercise price of $52.85 per share and will vest over four years, reflecting PTC's commitment to attracting and retaining talent.
Read more →PTCTPTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results - First-quarter 2023 total revenue of $220 million, representing 48% year-over-year growth - - Readouts from four clinical studies
PTC Therapeutics reported impressive first-quarter financial results for 2023, with total revenues of $220 million, reflecting a 48% year-over-year growth. The company anticipates sharing data from four clinical studies in the upcoming quarter, three of which are aimed at securing regulatory approval. While revenue from marketed products showed robust growth, PTC also acknowledged an increased net loss and high operating expenses during the same period.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2023 financial ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced a webcast conference call scheduled for April 27, 2023, at 4:30 p.m. ET to discuss its first quarter financial results. The call will also include updates on the company’s business outlook. Investors can access the call via the Investor section of the company’s website and a replay will be available afterward for 30 days.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 22, 2023, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has announced the approval of stock options and restricted stock units to 58 new employees as part of its recruitment strategy. This inducement is in accordance with NASDAQ Listing Rule 5635(c)(4) and aims to enhance employee compensation. The stock options have a significant term of 10 years and a structured vesting schedule over four years. This move reflects the company's commitment to attracting talent in the biopharmaceutical sector.
Read more →PTCT▼ -5.4%on this newsshared move
Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics - Chief Operating Officer Matthew Klein, M.D., M.S., F.A.C.S. to become Chief Executive Officer and join the Board of Di
Stuart Peltz, Ph.D., the founding CEO of PTC Therapeutics, announced his retirement after 25 years of leadership. Under his direction, PTC evolved from a research organization to a global biopharmaceutical leader in innovative therapies for rare diseases. Matthew Klein, M.D., formerly the Chief Operating Officer, has been appointed as the new CEO. Klein aims to continue PTC's mission of advancing science and enhancing patient care in the field of rare disorders.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Raymond James...
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced its participation in several upcoming investor conferences. The company will provide an overview at the Raymond James 44th Annual Institutional Investor Conference on March 6, the Cowen 43rd Annual Health Care Conference on March 7, and the Barclays Global Healthcare Conference on March 14. These presentations will be available for live webcast and archived for later viewing, ensuring accessibility for investors.
Read more →PTCTPTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results - 2022 total revenue of $699 million, representing 30% year-over-year growth, or $740 million and 37% growth at
PTC Therapeutics announced a corporate update alongside its financial results for 2022, showing a revenue growth of 30% year-over-year, reaching $699 million. The company reaffirmed its 2023 guidance to reach total revenues between $940 million and $1 billion, driven by growth across its marketed products. PTC also anticipates four key study readouts in the first half of 2023, three of which are registration-directed. However, despite these positive developments, PTC reported a significant net loss and increasing total liabilities, emphasizing ongoing financial challenges.
Read more →PTCTPTC Therapeutics lança o 9º programa anual de prêmios STRIVE™ para financiar iniciativas que beneficiam a comunidade de distrofia muscular de Duchenne PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje o lançamento do nono programa anual de prêmios STRIVE ™. Por meio desse programa, a PTC concede...
PTC Therapeutics has announced the launch of the 9th annual STRIVE program, aimed at providing grants to patient advocacy organizations that develop initiatives for the Duchenne Muscular Dystrophy community. The program, which encourages projects focused on innovation and adult transition, reflects PTC's long-standing commitment of 25 years to support Duchenne patients. Submissions for funding will be accepted until March 17, 2023, with winners to be announced in September. The STRIVE program has previously supported numerous initiatives across 20 countries, enhancing patient care and awareness.
Read more →PTCTPTC Therapeutics lanza el noveno programa anual de premios STRIVE™ para financiar iniciativas que beneficien a la comunidad con distrofia muscular de Duchenne PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy el lanzamiento del noveno programa anual de premios STRIVE ™. A través de este programa, PTC otorga ...
PTC Therapeutics has announced the launch of its ninth annual STRIVE program, aimed at providing grants to organizations advocating for patients with Duchenne muscular dystrophy. The 2023 program will focus on innovation and adult transition initiatives. Applications are open until March 17, 2023, with winners to be announced in September. The STRIVE program has previously supported initiatives in 20 countries, enhancing access to care and awareness of Duchenne.
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year ...
PTC Therapeutics, Inc. has announced a conference call to discuss its financial results for the fourth quarter and full year of 2022. The call is scheduled for February 21, 2023, at 4:30 p.m. ET and will be accessible via phone and webcast. A replay of the call will also be available for 30 days post-event, providing further insights into the company's performance and outlook.
Read more →PTCTPTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of 2023 EURORDIS Black Pearl Company Award for...
PTC Therapeutics, Inc. has been awarded the 2023 EURORDIS Black Pearl Company Award for Innovation, recognizing its enduring commitment to rare disease therapies over 25 years. This award highlights PTC's groundbreaking efforts in advancing the treatment landscape for rare diseases, where options are often limited. The award ceremony is scheduled for February 21 in Brussels, in conjunction with Rare Disease Day awareness activities. PTC's CEO expressed gratitude for the recognition and reaffirmed the company's dedication to patients with rare diseases.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: SVB Securities...
PTC Therapeutics, Inc. announced its participation in the SVB Securities Global Biopharma Conference on February 14, 2023. The company will provide a company overview during the event, which will also be accessible via a live webcast. This move is expected to broaden investor engagement and showcase its developments in the biopharma sector.
Read more →PTCTNICE recomenda reembolso para Translarna™ PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o National Institute for Health and Care Excellence (NICE) publicou um Documento de Avaliação ...
PTC Therapeutics, Inc. announced that the National Institute for Health and Care Excellence (NICE) has published a Final Assessment Document recommending reimbursement for Translarna (atalureno) in England and Wales. Translarna is the sole approved treatment for patients aged two or older with Duchenne muscular dystrophy caused by nonsense mutations. The NICE recommendation incorporates clinical trial data and real-world evidence that suggest Translarna can slow disease progression and improve patient outcomes. This decision is viewed as a crucial step in improving access to care for Duchenne patients.
Read more →PTCTNICE recomienda el reembolso de Translarna™ PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que el National Institute for Health and Care Excellence (NICE) ha publicado un documento de...
PTC Therapeutics, Inc. announced that the National Institute for Health and Care Excellence (NICE) has recommended the reimbursement of Translarna™ for patients with Duchenne muscular dystrophy caused by nonsense mutations. This approval is crucial as Translarna is the only treatment specifically targeting this condition and is intended for ambulatory patients aged two years and older. The recommendation is based on data from clinical trials showing the drug's potential to slow disease progression and improve outcomes for affected patients. This marks a significant milestone in expanding treatment access for the Duchenne community in England and Wales.
Read more →PTCTNICE Recommends Reimbursement for Translarna™ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Evaluation ...
PTC Therapeutics, Inc. has announced that the National Institute for Health and Care Excellence (NICE) recommended Translarna (ataluren) for use and reimbursement across the NHS in England and Wales. This recommendation is significant as Translarna is the only approved treatment for nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged 2 and older. The decision is based on robust evidence from clinical trials and real-world studies demonstrating its potential to improve patient outcomes and slow disease progression. This milestone is viewed as a critical advancement for patients diagnosed with this severe genetic disorder.
Read more →PTCTPTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the ninth annual STRIVE™ awards program. Through this program, PTC awards grants...
PTC Therapeutics has launched the ninth annual STRIVE awards program aimed at supporting initiatives for the Duchenne Muscular Dystrophy community. The program invites patient advocacy organizations to submit projects that foster innovation or help with the transition to adulthood for those living with Duchenne. Since its inception in 2015, STRIVE has funded 39 initiatives globally, addressing the needs of the Duchenne community. The application deadline for this year's awards is March 17, 2023, and recipients will be announced in September.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 5, 2023, the company approved non-statutory stock options to purchase an aggregate ...
PTC Therapeutics, Inc. announced the approval of inducement grants on January 5, 2023, under NASDAQ Listing Rule 5635(c)(4). The company issued non-statutory stock options for a total of 39,585 shares and 13,045 restricted stock units (RSUs) to 33 new employees as part of their employment compensation. The awards, which aim to enhance recruitment efforts, have a defined exercise price and vesting schedule contingent upon continued employment.
Read more →PTCT▲ +5.8%on this news· ran to +22% by day 3shared move
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference - ~$710 million unaudited 2022 total revenue, representing an impressive over 30% year-over-yea
PTC Therapeutics presented an update on its commercial progress and R&D pipeline at the J.P. Morgan Healthcare Conference. The company reported preliminary unaudited total revenue of approximately $710 million for 2022, representing over 30% growth compared to the previous year. Furthermore, PTC provided strong guidance for 2023, expecting total revenues of $940 million to $1 billion. Additionally, the company plans to report results from three registration-directed clinical trials in 2023 and initiate one more.
Read more →PTCTPTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41st Annual J.P. Morgan Healthcare...
PTC Therapeutics, Inc. announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, scheduled for January 9 at 7:30 a.m. PST/10:30 a.m. EST. The company will deliver a company overview, which will be available for live streaming on their website. The webcast will also be archived for 30 days for those unable to attend the live presentation.
Read more →PTCTAutoridade Reguladora Brasileira concede aprovação a Waylivra™ para Lipodistrofia Parcial Familiar A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que a ANVISA (Agência Nacional de Vigilância Sanitária) aprovou o Waylivra™ (volanesorsen) como ...
- Primeira aprovação regulatória global para o tratamento desta doença genética rara - SOUTH PLAINFIELD, Nova Jersey , 1º de dezembro de 2022 /PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunciou hoje que a ANVISA (Agência Nacional de Vigilância Sanitária) aprovou o
Read more →PTCTLa autoridad reguladora brasileña otorga su aprobación a Waylivra™ para tratar la lipodistrofia parcial familiar PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que la Agencia Nacional de Vigilancia Sanitaria de Brasil, ANVISA (Agência Nacional de Vigilância...
- Se trata de la primera aprobación normativa global para el tratamiento de esta rara enfermedad genética - SOUTH PLAINFIELD, Nueva Jersey , 1 de diciembre de 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunció hoy que la Agencia Nacional de Vigilancia Sanitaria
Read more →PTCTBrazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), ...
- First global regulatory approval for treatment of this rare genetic disease - SOUTH PLAINFIELD, N.J. , Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced today that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitá
Read more →PTCTUpstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec) was granted authorization by the Medicines and...
- Upstaza ™ is the first gene therapy infused directly into the brain for the treatment of AADC deficiency - - MHRA authorization follows recent European Union authorization - - AADC deficiency is a rare, fatal disorder that arrests motor development causing severe disability -
Read more →PTCTPTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding - Blackstone investment accelerates innovative product pipeline - - PTC will leverage Blackstone's network and
Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding investment accelerates innovative product pipeline - Blackstone's network and life sciences expertise to broaden business $350 million in cash at close - SOUTH PLAINFIELD, N.J., & NE
Read more →PTCTPTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results - Total quarterly revenue of $217 million, representing 57% year-over-year growth - - 2022 DMD revenue guidance and low end of tota
PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results - Total quarterly revenue of $217 million, representing 57% year-over-year growth - - 2022 DMD revenue guidance and low end of total revenue guidance increased - - Strategic financing wit
Read more →PTCT▼ -11%on this news
PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518 SOUTH PLAINFIELD, N.J., Oct. 18, 2022 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) confirmed today that enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the treatment of Huntington's disease
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2022 financial ...
SOUTH PLAINFIELD, N.J. , Oct. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will host a webcast conference call to report its third quarter 2022 financial results and provide an update on the company's business and outlook on Thu
Read more →PTCTPTC Therapeutics to Present Clinical and Real-World Evidence on Translarna™ at the Annual Congress of the World Muscle Society PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that recent clinical trial and real-world evidence on the efficacy and safety of Translarna™...
- Presentations include age of loss of ambulation and preservation of upper limb function following treatment with Translarna in patients with nonsense mutation Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J. , Oct. 11, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: P
Read more →PTCT▲ +5%on this news
PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the four recipients of its 2022 STRIVE Awards for Duchenne Muscular Dystrophy. The STRIVE...
- 2022 recipients include patient advocacy organizations from Brazil , Greece , Turkey , and the U.K. - SOUTH PLAINFIELD, N.J. , Sept. 7, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the four recipients of its 2022 STRIVE Awards for Duchenne Muscul
Read more →PTCT▲ +5%on this news
PTC 2022 Corporate Presentation September 2022 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All stateme
SCIENTIFIC PLATFORMS and RESEARCH Potential registrational studies Early - stage programs SCA - 3 MAP - Tau PTC518 HD Splicing Bio - e V atiquinone MDAS V atiquinone FA PTC857 ALS Diversified Platform Drives Strong Portfolio 38 3 Undisclosed 8 Undisclosed Gene Therapy Angelman IR
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Wells Fargo 17th ...
SOUTH PLAINFIELD, N.J. , Sept. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will present a company overview at the following conferences: Wells Fargo 17 th Annual Healthcare Conference Thursday, Sept. 8, at 1:55 p.m. EDT Morgan
Read more →PTCTPTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results - Total revenue of $166 million, representing 42% year-over-year growth - - Upstaza gene therapy granted marketing authorization b
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results - Total revenue of $166 million, representing 42% year-over-year growth - - Upstaza gene therapy granted marketing authorization by European Commission for treatment of AADC deficiency wi
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2022 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2022...
SOUTH PLAINFIELD, N.J. , July 21, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will host a webcast conference call to report its second quarter 2022 financial results and provide an update on the company's business and outlook on Th
Read more →PTCTUpstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec) was granted marketing authorization by the European...
- PTC Therapeutics to launch first gene therapy directly administered into the brain - SOUTH PLAINFIELD, N.J. , July 20, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Upstaza™ (eladocagene exuparvovec) was granted marketing authorization by the
Read more →PTCT▲ +19.9%on this news· ran to +42% by day 3
Translarna™(Ataluren)Study 041 Topline Results21stJune 2022 Forward looking statementsThis presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 199
Campbell, et al. Journal of Comparative Effectiveness Research. 2020; 9(14), 973 984. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy.2, Primary endpoint. 3, Secondary endpoint. Meta-analysis (007, 020) (N=342)Study 020 ITT
Read more →PTCT▲ +19.9%on this news· ran to +42% by day 3shared move
PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call Tuesday, June 21st at 8:00 a.m. E.T. to review topline results from Study 041 of...
SOUTH PLAINFIELD, N.J. , June 20, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) will host a conference call Tuesday, June 21 st at 8:00 a.m. E.T. to review topline results from Study 041 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular
Read more →PTCTBiotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the company's Board of Directors. Ms. Young has more than 20...
SOUTH PLAINFIELD, N.J. , June 9, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the election of Alethia Young to the company's Board of Directors. Ms. Young has more than 20 years of experience in healthcare and biotech equity research and investing.
Read more →PTCTPTC Therapeutics William Blair Growth Stock Conference Matthew Klein, M.D. Chief Operating Officer Kylie O'Keefe, SVP Global Commercial and Corporate Strategy
SCIENTIFIC PLATFORMS and RESEARCH Potential registrational studies Early - stage programs Bio - e V atiquinone MDAS V atiquinone FA PTC857 ALS Gene Therapy Angelman IRDs Cog Disorders FA PTC - AADC Diversified Platform Drives Strong Portfolio 3 Undisclosed 20 3 Undisclosed 2 Undi
Read more →PTCT▼ -6%on this newsshared move
PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the William Blair 42nd Annual Growth Stock...
SOUTH PLAINFIELD, N.J. , June 6, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the William Blair 42 nd Annual Growth Stock Conference on Thursday, June 9 at 2:20 p.m. ET The presentation will be web
Read more →PTCT▲ +5.5%on this newsshared move
Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced encouraging preliminary safety and efficacy results from its Phase 1B study of unesbulin...
- Results highlight strength of PTC Therapeutics' scientific platform in targeting difficult-to-treat rare cancer types - SOUTH PLAINFIELD, N.J. , June 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced encouraging preliminary safety and efficacy resu
Read more →PTCTFDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi®...
- Evrysdi is the first and only at-home administered treatment for patients living with SMA - - Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date - SOUTH PLAINFIELD, N.J. , May 31, 2022 /PRNewswire/ -- PTC Therapeutics, Inc
Read more →PTCTPTC Therapeutics recibe una opinión positiva del CHMP para Upstaza™ para el tratamiento de la deficiencia de AADC PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que Upstaza™ (eladocagene exuparvovec; PTC-AADC) recibió una opinión positiva del Comité de...
– Primera terapia génica administrada directamente en el cerebro – – Recomendada para la aprobación reglamentaria de la EMA – – Los resultados demostraron mejoras sostenidas en las funciones motora y cognitiva – – Teleconferencia programada para el lunes 23 de mayo a las 8:00
Read more →PTCTPTC Therapeutics recebe parecer positivo do CHMP para Upstaza™ indicada para o tratamento de deficiência de AADC A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que a Upstaza™ (eladocagene exuparvovec; PTC-AADC) recebeu parecer positivo do Comitê de...
– A primeira terapia genética administrada diretamente no cérebro – – Recomendada para receber aprovação regulatória da EMA – – Os resultados demonstraram melhorias sustentadas na função motora e cognitiva – – Teleconferência programada para segunda-feira, 23 de maio, às 8h da
Read more →PTCTPTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec; PTC-AADC) received a positive opinion from the...
– First ever gene therapy directly administered into the brain – – Recommended for regulatory approval by EMA – – Results demonstrated sustained improvements in motor and cognitive function – – Conference call scheduled for Monday, May 23 , at 8 a.m. ET – SOUTH PLAINFIELD, N.
Read more →PTCTPTC anuncia la actualización de la marca Translarna™ en Brasil para pacientes no ambulatorios con mutación sin sentido de la distrofia muscular de Duchenne PTC Therapeutics, Inc. anunció hoy que la Agencia Nacional de Vigilancia Sanitaria de Brasil, ANVISA (Agência Nacional de Vigilância Sanitária),...
SOUTH PLAINFIELD , Nueva Jersey , 18 de mayo de 2022 /PRNewswire/ -- PTC Therapeutics, Inc. anunció hoy que la Agencia Nacional de Vigilancia Sanitaria de Brasil, ANVISA (Agência Nacional de Vigilância Sanitária), aprobó actualizaciones a la marca 1 de Translarna™ (ataluren) para
Read more →PTCTPTC anuncia atualização do rótulo do Translarna™ no Brasil para pacientes não ambulatoriais com distrofia muscular de Duchenne com mutação do tipo nonsense A PTC Therapeutics, Inc. anunciou hoje que a ANVISA (Agência Nacional de Vigilância Sanitária), a agência reguladora de medicamentos no Brasil,...
SOUTH PLAINFIELD , Nova Jersey , 18 de maio de 2022 /PRNewswire/ -- A PTC Therapeutics, Inc. anunciou hoje que a ANVISA (Agência Nacional de Vigilância Sanitária), a agência reguladora de medicamentos no Brasil, aprovou atualizações no rótulo 1 do Translarna™ (atalureno) com rela
Read more →PTCTPTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results - $149 million total revenue representing impressive 26% year-over-year growth - - Initiation of PIVOT-HD Phase 2 trial of PTC518 i
PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results - $149 million total revenue representing impressive 26% year-over-year growth - - Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease - - CHMP opinion on AADC gene the
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Bank of America...
SOUTH PLAINFIELD, N.J. , April 29, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the following conferences: Bank of America Securities 2002 Healthcare Conference Tuesday, May 10 at 5:20 p.m. PT 202
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial ...
SOUTH PLAINFIELD, N.J. , April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company's business and outlook on Tu
Read more →PTCTPTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene...
- CHMP Opinion Now Expected May 2022 - SOUTH PLAINFIELD, N.J. , April 14, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced today that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficie
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 8, 2022, the company approved non-statutory stock options to purchase an...
SOUTH PLAINFIELD, N.J. , April 8, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on April 8, 2022 , the company approved non-statutory stock options to purchase an aggregate of 86,130 shares of its common stock and 33,125 restricted stock units (
Read more →PTCTPTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with...
SOUTH PLAINFIELD, N.J. , March 30, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with Huntington's disease (HD). PIVOT-HD is a global trial starting in the United State
Read more →PTCTPTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present three posters outlining data for EMFLAZA™ (deflazacort) in...
SOUTH PLAINFIELD, N.J. , March 11, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will present three posters outlining data for EMFLAZA™ (deflazacort) in Duchenne muscular dystrophy (DMD) at the Muscular Dystrophy Association (MDA) Cl
Read more →PTCT▼ -7.3%on this news
PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen Virtual 42nd...
SOUTH PLAINFIELD, N.J. , Feb. 23, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the following conferences: Cowen Virtual 42nd Annual Health Care Conference Monday, March 7 at 1:30 p.m. ET Barclays Gl
Read more →PTCTPTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results - $539 million 2021 total revenue representing impressive 41% year-over-year growth - - Continued pipeline prog
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results - $539 million 2021 total revenue representing impressive 41% year-over-year growth - - Continued pipeline progress with five registration-directed clinical trials ongo
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and year-end...
SOUTH PLAINFIELD, N.J. , Feb. 8, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will host a webcast conference call to report its fourth quarter and year-end 2021 financial results and provide an update on the company's business and o
Read more →PTCTFDA concede análise prioritária ao Evrysdi® com base nos resultados do tratamento de bebês pré-sintomáticos com atrofia muscular espinhal A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que a Agência de Administração de Alimentos e Medicamentos dos EUA (FDA) concedeu análise...
– Os resultados provisórios do estudo RAINBOWFISH mostraram que, após o tratamento com Evrysdi, bebês pré-sintomáticos com atrofia muscular espinhal alcançaram os mesmos marcos motores de bebês saudáveis – SOUTH PLAINFIELD, Nova Jersey , 26 de janeiro de 2022 /PRNewswire/ -- A P
Read more →PTCTLa FDA otorga una revisión proritaria a Evrysdi® con base en los resultados del tratamiento de lactantes presintomáticos con atrofia muscular espinal PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha otorgado una...
SOUTH PLAINFIELD , Nueva Jersey , 26 de enero de 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunció hoy que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha otorgado una revisión prioritaria de una solicitud complementaria de nuevo med
Read more →PTCTFDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental...
SOUTH PLAINFIELD, N.J. , Jan. 25, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for Evrysdi ® (risdiplam) to expand the indicat
Read more →PTCT▼ -5.3%on this news
PTC Therapeutics anuncia lançamento do 8º programa anual de premiação STRIVE™ para financiar iniciativas que beneficiam a comunidade com distrofia muscular de Duchenne A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje o lançamento do oitavo programa anual de premiação STRIVE™ para distrofia muscular de Duchenne...
– O programa de subsídios de 2022 se concentrará em iniciativas de inovação e transição para a vida adulta – – As inscrições deverão ser enviadas em 18 de março de 2022 – SOUTH PLAINFIELD, Nova Jersey , 18 de janeiro de 2022 /PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTC
Read more →PTCT▼ -5.3%on this news
PTC Therapeutics annonce le lancement du 8e programme annuel de prix STRIVE™ pour financer des initiatives au profit de la communauté de la dystrophie musculaire de Duchenne PTC Therapeutics, Inc. (NASDAQ: PTCT) a annoncé aujourd'hui le lancement du huitième programme annuel de prix STRIVE™ pour la dystrophie musculaire...
- Le programme de subventions 2022 se concentrera sur les initiatives d' innovation et de transition vers l'âge adulte - Les candidatures doivent être envoyées au plus tard le 18 mars 2022. SOUTH PLAINFIELD, New Jersey , 18 janvier 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (N
Read more →PTCT▼ -5.3%on this news
PTC Therapeutics anuncia los premios STRIVE™ para financiar iniciativas de distrofia muscular de Duchenne PTC Therapeutics, Inc. (NASDAQ: PTCT) ha anunciado hoy el lanzamiento del octavo programa anual de premios STRIVE™ para la distrofia muscular de...
-PTC Therapeutics anuncia el lanzamiento del octavo programa anual de premios STRIVE™ para financiar iniciativas en beneficio de la comunidad de la distrofia muscular de Duchenne – El programa de subvenciones de 2022 se centrará en iniciativas de innovación y transición a la eda
Read more →PTCT▼ -5.3%on this news
PTC Therapeutics gibt den Start des 8. jährlichen STRIVE™-Preisprogramms zur Finanzierung von Initiativen zugunsten der Duchenne-Muskeldystrophie-Gemeinschaft bekannt PTC Therapeutics, Inc. (NASDAQ: PTCT) gab heute den Start des 8. jährlichen STRIVE™-Auszeichnungsprogramms für Duchenne-Muskeldystrophie (Duchenne)...
- Das Zuschussprogramm für 2022 konzentriert sich auf Initiativen für Innovation und den Übergang ins Erwachsenenalter - Einsendeschluss ist der 18. März 2022 SOUTH PLAINFIELD, New Jersey , 18. Januar 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) gab heute den Sta
Read more →PTCT▼ -5.3%on this news
PTC Therapeutics anuncia el lanzamiento del octavo programa anual de premios STRIVE™ para financiar iniciativas que beneficien a la comunidad de la distrofia muscular de Duchenne PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy el lanzamiento del octavo programa anual de premios STRIVE™ para la distrofia muscular de Duchenne...
– El programa de subvenciones para 2022 se enfocará en iniciativas de innovación y transición a la edad adulta . – El periodo de postulaciones cierra el 18 de marzo de 2022. SOUTH PLAINFIELD, Nueva Jersey , 18 de enero de 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTC
Read more →PTCT▼ -5.3%on this news
PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the eighth annual STRIVE™ awards program for Duchenne muscular dystrophy...
SOUTH PLAINFIELD, N.J. , Jan. 18, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the launch of the eighth annual STRIVE ™ awards program for Duchenne muscular dystrophy (Duchenne). Through this program, PTC provides grants to patient advocacy organiza
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 7, 2022, the company approved non-statutory stock options to purchase an aggregate ...
SOUTH PLAINFIELD, N.J. , Jan. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on Jan. 7, 2022 , the company approved non-statutory stock options to purchase an aggregate of 18,255 shares of its common stock and 10,675 restricted stock units ("
Read more →PTCTPTC Therapeutics annonce le lancement du 2022 Global Talent Pipeline Program PTC Therapeutics, Inc. (NASDAQ: PTCT) a annoncé aujourd'hui le lancement du 2022 Talent Pipeline Program de l'entreprise, une initiative mondiale...
– Bourse d'un an offrant diverses expériences professionnels dans les secteurs d'activité de PTC – SOUTH PLAINFIELD, New Jersey , 13 janvier 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) a annoncé aujourd'hui le lancement du 2022 Talent Pipeline Program de l'entrep
Read more →PTCTPTC Therapeutics anuncia lançamento do programa Global Talent Pipeline de 2022 A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje o lançamento do programa Global Talent Pipeline de 2022 da empresa, uma iniciativa global com...
– O programa de bolsa de um ano oferece diversas experiências de trabalho em todas as áreas de negócios da PTC – SOUTH PLAINFIELD, Nova Jersey , 13 de janeiro de 2022 /PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunciou hoje o lançamento do programa Global Talent Pi
Read more →PTCTPTC Therapeutics anuncia el lanzamiento del 2022 Global Talent Pipeline Program PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy el lanzamiento del 2022 Talent Pipeline Program de la compañía, una iniciativa global de un año...
– La afiliación de un año proporciona experiencias laborales diversas en las áreas de negocios de PTC – SOUTH PLAINFIELD, N.J. , 13 de enero de 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunció hoy el lanzamiento del 2022 Talent Pipeline Program de la compañía,
Read more →PTCTPTC Therapeutics gibt Start des weltweiten Talent Pipeline-Programms 2022 bekannt PTC Therapeutics, Inc. (NASDAQ: PTCT) hat heute den Start des Talent Pipeline-Programms 2022 des Unternehmens bekannt gegeben, einer einjährigen,...
– Das einjährige Stipendium bietet vielfältige Arbeitserfahrung in den Geschäftsbereichen von PTC – SOUTH PLAINFIELD, New Jersey , 13. Januar 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) hat heute den Start des Talent Pipeline-Programms 2022 des Unternehmens bekan
Read more →PTCTPTC Therapeutics anuncia el lanzamiento de su Programa de reserva de talento global 2022 PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy el lanzamiento del Programa de reserva de talento 2022 de la empresa, una iniciativa global de un...
- Beca de un año ofrece diversas experiencias laborales en todas las áreas comerciales de PTC - SOUTH PLAINFIELD, Nueva Jersey , 13 de enero de 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunció hoy el lanzamiento del Programa de reserva de talento 2022 de la em
Read more →PTCTPTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the company's 2022 Talent Pipeline Program, a one-year, global initiative...
SOUTH PLAINFIELD, N.J. , Jan. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the launch of the company's 2022 Talent Pipeline Program, a one-year, global initiative designed to provide recent college graduates with high-quality, real-world opportu
Read more →PTCT▲ +5.1%on this newsshared move
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40 th Annual J.P. Morgan Healthcare Conference - $536 million unaudited 2021 total revenue representing impressive 41% year-over-year growth
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference - $536 million unaudited 2021 total revenue representing impressive 41% year-over-year growth - - $700 - 750 million 2022 total revenue guidance - - Res
Read more →PTCT▼ -5.9%on this newsshared move
Waylivra™ recebe precificação na categoria de medicamentos inovadores para tratar a Síndrome de Quilomicronemia Familiar no Brasil A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o Waylivra™ (volanesorsen) obteve a classificação de Categoria 1 da Câmara de Regulação do...
– solicitação adicional enviada à ANVISA para uma nova indicação para tratar a Lipodistrofia Parcial Familiar – SOUTH PLAINFIELD, Nova Jersey , 5 de janeiro de 2022 /PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunciou hoje que o Waylivra™ (volanesorsen) obteve a cla
Read more →PTCTWaylivra™ recibe asignación de precios en la categoría de fármaco innovador para tratar el síndrome de quilomicronemia familiar en Brasil PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que Waylivra™ (volanesorsen) recibió con éxito la clasificación de Categoría 1 de la Câmara de...
– Se presentó una solicitud adicional a ANVISA de una nueva indicación para tratar la lipodistrofia parcial familiar – SOUTH PLAINFIELD, Nueva Jersey , 4 de enero de 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunció hoy que Waylivra™ (volanesorsen) recibió con
Read more →PTCTWaylivra™ Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Waylivra™ (volanesorsen) has successfully received Category 1 classification from Câmara...
SOUTH PLAINFIELD, N.J. , Jan. 4, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Waylivra™ (volanesorsen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED (Drug Market Regulation Chambe
Read more →PTCT▲ +6.9%on this newsshared move
PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 40th Annual J.P. Morgan Virtual...
SOUTH PLAINFIELD, N.J. , Jan. 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the 40 th Annual J.P. Morgan Virtual Healthcare Conference on Monday, Jan. 10 , at 7:30 a.m. EST . The presentation wil
Read more →PTCTDatos publicados por Molecular Therapy demuestran efectos sostenidos de la terapia génica PTC-AADC para la deficiencia de AADC PTC Therapeutics anunció hoy la publicación de resultados que demuestran que los efectos favorables y sostenidos de su terapia génica PTC-AADC...
Uno de los conjuntos de datos más extensos que demuestra la eficacia sostenida de una terapia génica mediada por AAV SOUTH PLAINFIELD, Nueva Jersey , 23 de diciembre de 2021 /PRNewswire/ -- PTC Therapeutics anunció hoy la publicación de resultados que demuestran que los efectos
Read more →PTCTDados publicados pela Molecular Therapy demonstram efeitos sustentados da terapia genética PTC-AADC para deficiência AADC A PTC Therapeutics anunciou hoje a publicação de resultados que mostram que os efeitos favoráveis e sustentados de sua terapia genética PTC-AADC...
SOUTH PLAINFIELD , Nova Jersey , 23 de dezembro de 2021 /PRNewswire/ -- A PTC Therapeutics anunciou hoje a publicação de resultados que mostram que os efeitos favoráveis e sustentados de sua terapia genética PTC-AADC persistiram por até nove anos em pacientes com deficiência de d
Read more →PTCTModificadores de splicing administrados por via oral que diminuem sistemicamente a proteína da doença de Huntington são descobertos por meio da inovadora plataforma de splicing da PTC Therapeutics A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje a publicação da Nature Communications caracterizando o novo mecanismo de splicing induzido por...
SOUTH PLAINFIELD , Nova Jersey , 20 de dezembro de 2021 /PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunciou hoje a publicação da Nature Communications caracterizando o novo mecanismo de splicing induzido por compostos identificados pelo programa da doença de Hunting
Read more →PTCTModificadores de empalme orales que reducen de manera sistemática la proteína de la enfermedad de Huntington descubierta a través de la innovadora plataforma de empalme de PTC Therapeutics PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy la publicación en Nature Communications que caracteriza el nuevo mecanismo de empalme inducido por...
SOUTH PLAINFIELD , Nueva Jersey , 20 de diciembre de 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunció hoy la publicación en Nature Communications que caracteriza el nuevo mecanismo de empalme inducido por compuestos identificados en el programa de la enfermedad
Read more →PTCTOral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the Nature Communications publication characterizing the novel splicing mechanism induced by...
SOUTH PLAINFIELD, N.J. , Dec. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the Nature Communications publication characterizing the novel splicing mechanism induced by compounds identified from the Huntington Disease (HD) program. These splicing
Read more →PTCTEvrysdi® recebe dois prêmios de prestígio por inovação excepcional na descoberta de medicamentos A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o Evrysdi® (risdiplam) recebeu vários prêmios que a reconhecem como uma das terapias mais...
SOUTH PLAINFIELD , Nova Jersey , 7 de dezembro de 2021 /PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunciou hoje que o Evrysdi ® (risdiplam) recebeu vários prêmios que a reconhecem como uma das terapias mais inovadoras de 2021 e por seu impacto que pode salvar vidas.
Read more →PTCTEvrysdi® es reconocida con dos prestigiosos premios por innovación sobresaliente en el descubrimiento de fármacos PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que Evrysdi® (risdiplam) recibió múltiples premios que la reconocen como una de las terapias más...
SOUTH PLAINFIELD , Nueva Jersey , 7 de diciembre de 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunció hoy que Evrysdi ® (risdiplam) recibió múltiples premios que la reconocen como una de las terapias más innovadoras de 2021 y por su impacto en materia de salvar
Read more →PTCTEvrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi® (risdiplam) has received multiple awards that recognize it as one of the most...
SOUTH PLAINFIELD, N.J. , Dec. 6, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Evrysdi ® (risdiplam) has received multiple awards that recognize it as one of the most innovative therapies of 2021 and for its life-saving impact. The British Pharm
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 29, 2021, the company approved non-statutory stock options to purchase an...
SOUTH PLAINFIELD, N.J. , Dec. 2, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on Nov. 29, 2021 , the company approved non-statutory stock options to purchase an aggregate of 83,750 shares of its common stock and 21,550 restricted stock units ("
Read more →PTCTPTC 2021 Corporate Deck Updated
GAAP R&D and SG&A expense for the full year 2021 is anticipated to be between $815 and $835 million. 2021 Potential Milestones to Generate Value 51 PTC857 Data PTC518 Data Evrysdi CHMP Opinion PTC518 Phase 2 Study Initiation Unesbulin LMS and DIPG Data PTC923 PKU P3 Trial Emvodod
Read more →PTCTPTC Therapeutics to Participate at Upcoming Virtual Investor Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx...
SOUTH PLAINFIELD, N.J. , Nov. 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET . The presentation will be webca
Read more →PTCTPTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results - Total quarterly revenue of $139 million; 17% increase over third quarter 2020 - - Raises 2021 DMD franchise revenue guidance
PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results - Total quarterly revenue of $139 million; 17% increase over third quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $400-$420M from $370-$390M - - Continues to advance
Read more →PTCTPTC Therapeutics to Participate at Upcoming Virtual Investor Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Credit Suisse 30th Annual Healthcare...
SOUTH PLAINFIELD, N.J. , Oct. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, Nov. 9 at 8:00 a.m. ET . The presentation will be webc
Read more →PTCTPTC anuncia la ampliación de la indicación en la etiqueta de Translarna™ para incluir a pacientes ambulatorios a partir de los 2 años de edad en Brasil PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que la Agencia Nacional de Vigilancia Sanitaria de Brasil (ANVISA) aprobó la ampliación de la...
SOUTH PLAINFIELD , Nueva Jersey , 25 de octubre de 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunció hoy que la Agencia Nacional de Vigilancia Sanitaria de Brasil (ANVISA) aprobó la ampliación de la indicación de Translarna™ (ataluren) para incluir a niños ambul
Read more →PTCTPTC anuncia ampliação do Translarna™ para incluir pacientes ambulatoriais com até dois anos de idade no Brasil A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que a ANVISA (Agência Nacional de Vigilância Sanitária) aprovou a ampliação da indicação do...
SOUTH PLAINFIELD, New Jersey , 25 de outubro de 2021 /PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunciou hoje que a ANVISA (Agência Nacional de Vigilância Sanitária) aprovou a ampliação da indicação do Translarna™ (atalureno) para incluir crianças ambulatoriais de d
Read more →PTCTPTC Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian National Health Surveillance Agency, ANVISA (Agência Nacional de Vigilância...
SOUTH PLAINFIELD, N.J. , Oct. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Brazilian National Health Surveillance Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved the expansion of the indication of Translarna™ (at
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2021 financial ...
SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will host a webcast conference call to report its third quarter 2021 financial results and provide an update on the company's business and outlook on Thu
Read more →PTCTPTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing...
SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. today at 4 p.m. ET . "We are committed to being an
Read more →PTCTTegsedi® recebe precificação inovadora de categoria de medicamento no Brasil A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o Tegsedi® (Inotersen) obteve a classificação de Categoria 1 da Câmara de Regulação do...
SOUTH PLAINFIELD , Nova Jersey , 11 de outubro de 2021 /PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunciou hoje que o Tegsedi ® (Inotersen) obteve a classificação de Categoria 1 da Câmara de Regulação do Mercado de Medicamentos (CMED) no Brasil. A classificação de C
Read more →PTCTTegsedi® recibe precio por su categoría de fármacos innovadores en Brasil PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que Tegsedi® (inotersen) ha recibido con éxito la clasificación de Categoría 1 de la Câmara de...
SOUTH PLAINFIELD , Nueva Jersey , 11 de octubre de 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunció hoy que Tegsedi ® (inotersen) ha recibido con éxito la clasificación de Categoría 1 de la Câmara de Regulação do Mercado de Medicamentos - CMED (Cámara de Regula
Read more →PTCTTegsedi® Receives Innovative Drug Category Pricing in Brazil PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tegsedi® (inotersen) has successfully received Category 1 classification from Câmara de...
SOUTH PLAINFIELD, N.J. , Oct. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Tegsedi ® (inotersen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED (Drug Market Regulation Chamber)
Read more →PTCTLos resultados muestran mejoras duraderas y holísticas en niños con deficiencia de AADC que fueron tratados con terapia génica PTC-AADC PTC Therapeutics, Inc. (NASDAQ: PTCT) presentó hoy un nuevo análisis de los resultados de cinco años que muestra su nueva terapia génica, PTC-AADC,...
SOUTH PLAINFIELD , Nueva Jersey , 30 de septiembre de 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) presentó hoy un nuevo análisis de los resultados de cinco años que muestra su nueva terapia génica, PTC-AADC, que produce mejoras profundas en niños con deficiencia d
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 22, 2021, the company approved non-statutory stock options to purchase an...
SOUTH PLAINFIELD, N.J. , Sept. 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on Sept. 22, 2021, the company approved non-statutory stock options to purchase an aggregate of 51,400 shares of its common stock and 18,790 restricted stock units
Read more →PTCTOs resultados mostram melhorias duradouras e holísticas em crianças com deficiência AADC tratadas com terapia genética PTC-AADC A PTC Therapeutics, Inc. (NASDAQ: PTCT) apresentou hoje uma nova análise de resultados de cinco anos que mostram sua nova terapia genética, a...
– Análise dos resultados de cinco anos apresentados na 50 ª reunião anual da sociedade de neurologia infantil – SOUTH PLAINFIELD, Nova Jersey , 29 de setembro de 2021 /PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT ) apresentou hoje uma nova análise de resultados de cinco
Read more →PTCTResults Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented a new analysis of five-year results that shows its novel gene therapy, PTC-AADC, leads to...
SOUTH PLAINFIELD, N.J. , Sept. 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today presented a new analysis of five-year results that shows its novel gene therapy, PTC-AADC, leads to profound improvements in children with aromatic L-Amino acid decarboxylase ( AA
Read more →PTCT▼ -9.9%on this news
PTC518 Huntington's Disease Program Update
What is the Exposure? What is the Level of HTT Reduction? Demonstrate Clinical Benefit PTC518 Phase 2 Study Design Phase 2 study objectives 25 Demonstrate safety, tolerability and pharmacology of PTC518 and HTT mRNA and protein reduction in HD patients Demonstrate PTC518 effect o
Read more →PTCTOs dados do STRIDE mostram que o Translarna™ retarda a perda de ambulação por mais de cinco anos em meninos com Distrofia Muscular de Duchenne causada por mutações nonsense PTC Therapeutics, Inc. (NASDAQ: PTCT) apresentou hoje resultados reais do registro de pacientes STRIDE demonstrando que o tratamento com Translarna™...
SOUTH PLAINFIELD, N.J. , 21 de setembro de 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) apresentou hoje resultados reais do registro de pacientes STRIDE demonstrando que o tratamento com Translarna™ (ataluren) retarda a perda de ambulação por mais de cinco anos em
Read more →PTCTLos datos de STRIDE muestran que Translarna™ retrasa la pérdida de ambulación por más de cinco años en niños con distrofia muscular de Duchenne por mutación sin sentido PTC Therapeutics, Inc. (NASDAQ: PTCT) presentó hoy resultados reales del registro de pacientes STRIDE que demuestra que el tratamiento con...
SOUTH PLAINFIELD , Nueva Jersey , 21 de septiembre de 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) presentó hoy resultados reales del registro de pacientes STRIDE que demuestra que el tratamiento con Translarna™ (ataluren) retrasa la pérdida de la ambulación por má
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study....
SOUTH PLAINFIELD, N.J. , Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study. The new results include HTT mRNA and protein lowering, as well as PTC518 exp
Read more →PTCTSTRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented real-world results from the STRIDE patient registry demonstrating that treatment with...
SOUTH PLAINFIELD, N.J. , Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today presented real-world results from the STRIDE patient registry demonstrating that treatment with Translarna ™ (ataluren) delays loss of ambulation by more than five years in boys w
Read more →PTCTPTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program. The...
SOUTH PLAINFIELD, N.J. , Sept. 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the three recipients who will receive funding through the company's STRIVE Awards program. The global STRIVE Awards program provides grants to non-profit organizations se
Read more →PTCT▲ +5.2%on this news
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Morgan Stanley...
SOUTH PLAINFIELD, N.J. , Aug. 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the following conferences: Morgan Stanley Virtual 19 th Annual Global Healthcare Conference Friday, September 10 th at
Read more →PTCTPTC Therapeutics anuncia aprovação do Waylivra™ no Brasil como primeiro tratamento para Síndrome da Quilomicronemia Familiar A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que a Agência Nacional de Vigilância Sanitária (ANVISA) aprovou o Waylivra™ (volanesorsen) como ...
SOUTH PLAINFIELD , Nova Jersey , 24 de agosto de 2021 /PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunciou hoje que a Agência Nacional de Vigilância Sanitária (ANVISA) aprovou o Waylivra™ (volanesorsen) como o primeiro tratamento para a Síndrome da Quilomicronemia Fa
Read more →PTCTPTC Therapeutics anuncia la aprobación de Waylivra™ en Brasil como primer tratamiento para el síndrome de quilomicronemia familiar PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que la agencia reguladora de la salud del Brasil, ANVISA (Agencia Nacional de Vigilancia...
SOUTH STRINGFIELD, Nueva Jersey , 24 de agosto de 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) anunció hoy que la agencia reguladora de la salud del Brasil, ANVISA (Agencia Nacional de Vigilancia Sanitaria), aprobó Waylivra™ (volanesorsen) como el primer tratamient
Read more →PTCTPTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), ...
SOUTH PLAINFIELD, N.J. , Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen) as the first treatment for familial
Read more →PTCTTargeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, Gene Therapy in the Putamen for Curing AADC Deficiency and...
SOUTH PLAINFIELD, N.J. , Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the publication of a manuscript, "Gene Therapy in the Putamen for Curing AADC Deficiency and Parkinson's Disease," in the European Molecular Biology Organization Journal.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Aug. 17, 2021, it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Aug. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on Aug. 17, 2021, it approved non-statutory stock options to purchase an aggregate of 51,670 shares of its common stock and 19,755 restricted stock units ("RSUs"), e
Read more →PTCTPTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results - Total quarterly net revenue of $117 million; 55% increase over second quarter 2020 - - Raises 2021 DMD franchise revenue gu
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results - Total quarterly net revenue of $117 million; 55% increase over second quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $370-$390M from $355-$375M - - Progress across
Read more →PTCTSignificant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the FIREFISH pivotal study were published in the New England...
SOUTH PLAINFIELD, N.J. , July 28, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that results from Part 2 of the FIREFISH pivotal study were published in the New England Journal of Medicine. This trial showed that symptomatic Type 1 spinal muscular at
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021...
SOUTH PLAINFIELD, N.J. , July 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its second quarter 2021 financial results and provide an update on the company's business and outlook on Th
Read more →PTCTResults Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit...
SOUTH PLAINFIELD, N.J. , June 24, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit of EMFLAZA ® (deflazacort) over prednisone for the treatment of Duchenne mus
Read more →PTCTEvrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Japan by the Japanese Ministry of Health, Labor and...
SOUTH PLAINFIELD, N.J. , June 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Evrysdi™ (risdiplam) was approved in Japan by the Japanese Ministry of Health, Labor and Welfare for the treatment of spinal muscular atrophy (SMA). The approval has
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , June 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of 118,350 shares of its common stock and 30,835 restricted stock units ("RSUs"), e
Read more →PTCTPre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in RAINBOWFISH PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic...
SOUTH PLAINFIELD, N.J. , June 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic infants with spinal muscular atrophy (SMA) treated with Evrysdi were able to
Read more →PTCTHealth and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L. Smith to the Company's Board of Directors. Ms. Smith has previously...
SOUTH PLAINFIELD, N.J. , June 9, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the election of Mary L. Smith to the Company's Board of Directors. Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health
Read more →PTCTPTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC)...
SOUTH PLAINFIELD, N.J. , May 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of pati
Read more →PTCTPTC Therapeutics to Participate at Upcoming Virtual Investor Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conference: William Blair 41st ...
SOUTH PLAINFIELD, N.J. , May 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the following conference: William Blair 41 st Annual Growth Stock Conference Wednesday, June 2 nd at 3:40 p.m. ET The
Read more →PTCTNew Data Shows Devastating Impact of AADC Deficiency on Caregivers PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from the first study on the impact of caring for a child with the ultra-rare genetic...
SOUTH PLAINFIELD, N.J. , May 17, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced data from the first study on the impact of caring for a child with the ultra-rare genetic disorder, aromatic L-Amino acid decarboxylase deficiency (AADC-d). Results show t
Read more →PTCTPTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results - PTC518 demonstrated dose-dependent reduction of HTT mRNA in preliminary results from Phase 1 healthy volunteer trial - - Tot
PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results - PTC518 demonstrated dose-dependent reduction of HTT mRNA in preliminary results from Phase 1 healthy volunteer trial - - Total net revenue of $118 million; 73% increase over first q
Read more →PTCTPTC Therapeutics to Participate at Upcoming Virtual Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: BofA Securities...
SOUTH PLAINFIELD, N.J. , April 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the following conferences: BofA Securities 2021 Virtual Health Care Conference Tuesday, May 11 th at 8:45 a.m. ET 20
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2021 financial ...
SOUTH PLAINFIELD, N.J. , April 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its first quarter 2021 financial results and provide an update on the company's business and outlook on Tu
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , April 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate of 75,085 shares of its common stock and 33,740 restricted stock units ("RSUs"),
Read more →PTCTPTC518 Huntington's Disease Deep Dive April 15th, 2021 Forward Looking Statements: This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All sta
Director, Biology PTC518 Huntington Deep Dive Splicing Platform and Huntington's Disease Stuart Peltz, CEO PTC518 Phase 1 Study Matthew Klein, CDO The Phase 1 Trial is a 4-Part Study 56 Phase 1 trial in healthy volunteers is ongoing Multiple ascending dose - Up to 5 cohorts of 8
Read more →PTCTContinued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1...
SOUTH PLAINFIELD, N.J. , April 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular atrophy (SMA) treated with Evrysdi™ (risdiplam) obtained inc
Read more →PTCTPTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United States for individuals who...
SOUTH PLAINFIELD, N.J. , April 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today introduced a new no-charge, patient-initiated testing program in the United States for individuals who have symptoms consistent with, or a diagnosis of, cerebral palsy (CP) with n
Read more →PTCTPTC Therapeutics Received Gallup's Don Clifton Strengths-Based Culture Award PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 Don Clifton Strengths-Based Culture Award from...
SOUTH PLAINFIELD, N.J. , April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that it has been named a winner of the 2021 "Don Clifton Strengths-Based Culture Award" from Gallup. The award recognizes organizations with strong workplace cultures tha
Read more →PTCTPTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday,...
SOUTH PLAINFIELD, N.J. , April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T. The Huntington Disease Deep Dive will provide an o
Read more →PTCTPTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™...
SOUTH PLAINFIELD, N.J. , April 1, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi ™ (risdiplam) in the European Union under its License and Collaboration Agreeme
Read more →PTCTPTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the European Commission (EC) has granted marketing authorization to Evrysdi™ (risdiplam)...
SOUTH PLAINFIELD, N.J. , March 30, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the European Commission (EC) has granted marketing authorization to Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy (SMA) in patients 2 months and
Read more →PTCTResults from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi™ (risdiplam) in children and...
SOUTH PLAINFIELD, N.J. , March 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi™ (risdiplam) in children and adults with Type 2 or Type 3 spinal muscular atrophy (SMA) at the 2021 Mus
Read more →PTCTPTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from a real-world study of patients with Duchenne muscular dystrophy (DMD) and Becker...
SOUTH PLAINFIELD, N.J. , March 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced results from a real-world study of patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) who switched from prednisone to EMFLAZA ® (deflaza
Read more →PTCTSpinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine The Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics, Inc. (NASDAQ: PTCT) have entered into a new collaboration focused on regenerative...
NEW YORK and SOUTH PLAINFIELD, N.J. , March 9, 2021 /PRNewswire/ -- The Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics, Inc. (NASDAQ: PTCT ) have entered into a new collaboration focused on regenerative medicine to further advance scientific research in SMA and oth
Read more →PTCTCHMP Adopts Positive Opinion for Evrysdi™ for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) ...
SOUTH PLAINFIELD, N.J. , Feb. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrysdi™ (risdiplam) for the treatment of
Read more →PTCTPTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the fourth quarter and full year ending December 31, 2020 and provided a...
SOUTH PLAINFIELD, N.J. , Feb. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced financial results for the fourth quarter and full year ending December 31, 2020 and provided a corporate update. "Despite the challenges of the pandemic, PTC has been ab
Read more →PTCTPTC Therapeutics, Inc. Summary Consolidated Balance Sheets (in thousands, except share data)
PTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update - $333 million 2020 total net product revenue representing 14% year-over-year growth - - Advancing multiple registration-directed clinical trials - - PTC518 healthy vol
Read more →PTCTPositive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH study...
SOUTH PLAINFIELD, N.J. , Feb. 24, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH study evaluating Evrysdi™ (risdiplam) in infants with symptomatic type 1 spinal muscular
Read more →PTCTPTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19 PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the second stage of the FITE19 clinical trial to assess PTC299 in COVID-19...
SOUTH PLAINFIELD, N.J. , Feb. 17, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced the initiation of the second stage of the FITE19 clinical trial to assess PTC299 in COVID-19 patients. PTC299 is an oral investigational drug with a novel dual mechanism
Read more →PTCTPTC Therapeutics to Participate at Upcoming Virtual Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Raymond James...
SOUTH PLAINFIELD, N.J. , Feb. 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the following conferences: Raymond James 42 nd Annual Institutional Investors Conference Tuesday, March 2 nd at 7:30 a
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year-end...
SOUTH PLAINFIELD, N.J. , Feb. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its fourth quarter and year-end 2020 financial results and provide an update on the company's business and
Read more →PTCTPTC Therapeutics to Host Call to Review Results from its Study of Translarna (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
PTC Therapeutics to Host Call to Review Results from its Study of Translarna (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy SOUTH PLAINFIELD, N.J., Feb. 4, 2021 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call today at 5:30 p.m. E.T
Read more →PTCTPTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh annual STRIVE Awards program for Duchenne muscular dystrophy. The...
SOUTH PLAINFIELD, N.J. , Jan. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the launch of the seventh annual STRIVE Awards program for Duchenne muscular dystrophy. The Awards provide a grant to patient advocacy organizations around the world who
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Jan. 13, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of 13,465 shares of its common stock and 4,665 restricted stock units ("RSUs"), e
Read more →PTCTPTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39 th Annual J.P. Morgan Healthcare Conference - ~$333 million preliminary unaudited 2020 total net product revenue representing 14% year-over-y
PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference - ~$333 million preliminary unaudited 2020 total net product revenue representing 14% year-over-year growth - - Huntington splicing program healthy voluntee
Read more →PTCTPTC Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 39th Annual J.P. Morgan Healthcare...
SOUTH PLAINFIELD, N.J. , Jan. 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11 th at 7:30 a.m. EST . The presentation will be we
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2020 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Dec. 18, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on December 15, 2020 it approved non-statutory stock options to purchase an aggregate of 12,500 shares of its common stock and 4,360 restricted stock units ("RSUs"),
Read more →PTCTPTC Therapeutics to Host Translarna™ Deep Dive Webinar PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing Translarna on Tuesday, December 15 at 12:00 noon ET. The ...
SOUTH PLAINFIELD, N.J. , Dec. 9, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) will host a webinar in its deep dive series discussing Translarna on Tuesday, December 15 at 12:00 noon ET . The Translarna Deep Dive will provide an overview of results from the clinica
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 2, 2020 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Dec. 4, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on December 2, 2020 it approved non-statutory stock options to purchase an aggregate of 41,955 shares of its common stock and 20,735 restricted stock units ("RSUs"),
Read more →PTCTPTC Announces Translarna™ Approval in Russia for the Treatment of Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval in the Russian Federation for...
SOUTH PLAINFIELD, N.J. , Dec. 4, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Translarna™ (ataluren) has been granted marketing approval in the Russian Federation for nonsense mutation Duchenne muscular dystrophy (nmDMD). It is estimated that 1
Read more →PTCTPTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone...
SOUTH PLAINFIELD, N.J. , Nov. 30, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in children and young adults with Friedreich ataxia (FA). FA is a genet
Read more →PTCTPTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3rd Annual HealthCONx...
SOUTH PLAINFIELD, N.J. , Nov. 19, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1 st at 11:45 a.m. ET . The presentation will be w
Read more →PTCTPTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted PTC596 both...
SOUTH PLAINFIELD, N.J. , Nov. 18, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted PTC596 both Orphan Drug Designation and Fast Track designation for the potential treatment o
Read more →PTCTPTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. PTC518 was ...
SOUTH PLAINFIELD, N.J. , Nov. 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. PTC518 was identified from PTC's splicing platform and is being developed for the tre
Read more →PTCTPTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare Diseases PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of data on two rare diseases, providing new insights on the burden of Aromatic ...
SOUTH PLAINFIELD, N.J. , Nov. 16, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the presentation of data on two rare diseases, providing new insights on the burden of Aromatic L-Amino acid Decarboxylase deficiency (AADC-d) and Duchenne muscular dystr
Read more →PTCTPTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update - Evrysdi TM makes rapid progress with multiple international approvals and strong U.S. launch - - Total net revenue of $118.4
PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update - EvrysdiTM makes rapid progress with multiple international approvals and strong U.S. launch - - Total net revenue of $118.4 million, 66% YoY increase; Total net product revenue of $8
Read more →PTCTPTC Therapeutics to Participate at Upcoming Virtual Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Credit Suisse...
SOUTH PLAINFIELD, N.J. , Oct. 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the following conferences: Credit Suisse 29 th Annual Virtual Healthcare Conference Wednesday, November 11 th at 9:30
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 23, 2020 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Oct. 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on October 23, 2020 it approved non-statutory stock options to purchase an aggregate of 18,610 shares of its common stock and 6,860 restricted stock units ("RSUs"),
Read more →PTCTPTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in Massachusetts PTC Therapeutics, Inc. (NASDAQ: PTCT) and the AADC Family Network today announced that Oct. 23, 2020, has been officially designated as the first...
SOUTH PLAINFIELD, N.J. , Oct. 22, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) and the AADC Family Network today announced that Oct. 23, 2020 , has been officially designated as the first Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Awareness Day in the St
Read more →PTCTEvrysdi™ (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Brazil by the National Health Surveillance Agency...
SOUTH PLAINFIELD, N.J. , Oct. 21, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Evrysdi™ (risdiplam) was approved in Brazil by the National Health Surveillance Agency (ANVISA) for the treatment of spinal muscular atrophy (SMA). The approval was
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2020 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2020 financial ...
SOUTH PLAINFIELD, N.J. , Oct. 15, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its third quarter 2020 financial results and provide an update on the company's business and outlook on Thu
Read more →PTCTTwo-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that two-year data from Part 1 of the FIREFISH study demonstrated that infants on Evrysdi™...
SOUTH PLAINFIELD, N.J. , Sept. 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that two-year data from Part 1 of the FIREFISH study demonstrated that infants on Evrysdi™ (risdiplam) continued to improve and achieve motor milestones. Evrysdi™ was ap
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 21, 2020 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Sept. 25, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on September 21, 2020 it approved non-statutory stock options to purchase an aggregate of 75,670 shares of its common stock and 12,845 restricted stock units ("RSUs
Read more →PTCTPTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Jefferies Virtual Gene Therapy/Editing...
SOUTH PLAINFIELD, N.J. , Sept. 24, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 1 st at 9:00 a.m. ET . The presentation will b
Read more →PTCTPTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new program that provides genetic testing and counseling for people who may have a...
SOUTH PLAINFIELD, N.J. , Sept. 9, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today introduced a new program that provides genetic testing and counseling for people who may have a neurotransmitter disorder, such as aromatic L-amino acid decarboxylase (AADC) defici
Read more →PTCTPTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the winners of its sixth annual STRIVE Awards grant program for Duchenne muscular dystrophy....
SOUTH PLAINFIELD, N.J. , Sept. 8, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the winners of its sixth annual STRIVE Awards grant program for Duchenne muscular dystrophy. This year's winning initiatives, spanning across four continents, include an
Read more →PTCTPTC Therapeutics to Present at the Cantor Virtual Global Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Cantor Virtual Global Healthcare...
SOUTH PLAINFIELD, N.J. , Sept. 3, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the Cantor Virtual Global Healthcare Conference on Thursday, September 17 th at 9:20 a.m. ET . The presentation will b
Read more →PTCTPTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi™ (risdiplam) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company achieved a $20 million milestone payment from Roche under its License and...
SOUTH PLAINFIELD, N.J. , Aug. 26, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company achieved a $20 million milestone payment from Roche under its License and Collaboration Agreement. The milestone payment was triggered by the first comme
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on August 18, 2020 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Aug. 21, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on August 18, 2020 it approved non-statutory stock options to purchase an aggregate of 49,165 shares of its common stock and 14,175 restricted stock units ("RSUs"),
Read more →PTCTPTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the acceptance of the Marketing Authorization Application (MAA) by the European Medicines...
SOUTH PLAINFIELD, N.J. , Aug. 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the acceptance of the Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for Evrysdi™ (risdiplam) for the treatment of spinal muscular atrop
Read more →PTCTPTC Therapeutics Announces FDA Approval of Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam), the first...
SOUTH PLAINFIELD, N.J. , Aug. 7, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in a
Read more →PTCTPTC Therapeutics' Mary Frances Harmon Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its Senior Vice President of Corporate and Patient Relations, Mary Frances Harmon,...
SOUTH PLAINFIELD, N.J. , Aug. 6, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is proud to announce that its Senior Vice President of Corporate and Patient Relations, Mary Frances Harmon , has been named to PharmaVOICE magazine's annual list of the most inspiring pe
Read more →PTCTPTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2020....
SOUTH PLAINFIELD, N.J. , Aug. 5, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the second quarter ending June 30, 2020 . "We are pleased with the progress in our pipeline and the strong commercia
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2020...
SOUTH PLAINFIELD, N.J. , July 22, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its second quarter 2020 financial results and provide an update on the company's business and outlook on We
Read more →PTCTPTC Therapeutics to Host Deep Dive Webinar on Splicing Platform PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host the second webinar in its deep dive series discussing its therapeutic...
SOUTH PLAINFIELD, N.J. , July 21, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that it will host the second webinar in its deep dive series discussing its therapeutic platforms and programs on Friday, July 24 at 10:00 am ET . The splicing platform
Read more →PTCTPTC Therapeutics Announces Agreement to Monetize a Portion of the Risdiplam Royalty Stream for $650 Million PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced an agreement to monetize a portion of the risdiplam royalty stream for $650 million from...
SOUTH PLAINFIELD, N.J. , July 20, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced an agreement to monetize a portion of the risdiplam royalty stream for $650 million from Royalty Pharma plc. The capital from the collaboration will enable PTC to further
Read more →PTCTPTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the first subject in the Phase 1 clinical trial evaluating PTC857 in healthy volunteers...
SOUTH PLAINFIELD, N.J. , July 8, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the first subject in the Phase 1 clinical trial evaluating PTC857 in healthy volunteers has been dosed. PTC857, discovered through PTC's Bio-e platform, is an investi
Read more →PTCTPTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
"We are excited to see that the CHMP adopted the positive opinion for this label modification allowing patients who become non-ambulatory to continue to use Translarna," said Stuart W. Peltz , Ph.D., Chief Executive Officer of PTC Therapeutics. "All nonsense mutation Duchenne pat
Read more →PTCTPTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19 PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the U.S. Food and Drug Administration has authorized the initiation of a Phase 2/3 trial...
SOUTH PLAINFIELD, N.J. , June 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced that the U.S. Food and Drug Administration has authorized the initiation of a Phase 2/3 trial to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 10, 2020 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , June 12, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on June 10, 2020 it approved non-statutory stock options to purchase an aggregate of 54,675 shares of its common stock and 3,940 restricted stock units ("RSUs"), eac
Read more →PTCTPTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 1 of the SUNFISH trial in children and adults with type 2 or 3 spinal...
SOUTH PLAINFIELD, N.J. , June 12, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced two-year data from Part 1 of the SUNFISH trial in children and adults with type 2 or 3 spinal muscular atrophy (SMA) and new preliminary 12-month data from JEWELFISH. The
Read more →PTCTPTC Therapeutics Launches New Talent Pipeline Program to Help Students who Graduated During the 2020 COVID-19 Pandemic PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the Talent Pipeline Program (TPP), a one-year global internship program aimed at...
SOUTH PLAINFIELD, N.J. , June 10, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the launch of the Talent Pipeline Program (TPP), a one-year global internship program aimed at providing recent graduates real-world experience in the biopharmaceutical i
Read more →PTCTPTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has successfully completed the acquisition of Censa Pharmaceuticals, Inc., a...
SOUTH PLAINFIELD, N.J. , June 1, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that it has successfully completed the acquisition of Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clin
Read more →PTCTPTC Therapeutics to Host First Deep Dive Webinar on Bio-e Platform PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will hold a series of virtual deep dive webinars discussing its therapeutic platforms...
SOUTH PLAINFIELD, N.J. , May 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that it will hold a series of virtual deep dive webinars discussing its therapeutic platforms and programs. The first webinar in the series will discuss its Bio-e platform
Read more →PTCTPTC Therapeutics, Inc. to Hold Virtual 2020 Annual Meeting of Stockholders PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and...
SOUTH PLAINFIELD, N.J. , May 27, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and
Read more →PTCTPTC Therapeutics to Present at the Jefferies Virtual Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference...
SOUTH PLAINFIELD, N.J. , May 26, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 nd at 1:00 p.m. ET . The presentation will be webcast li
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 11, 2020 it approved non-statutory stock options to purchase an aggregate of 50,025 ...
SOUTH PLAINFIELD, N.J. , May 15, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on May 11, 2020 it approved non-statutory stock options to purchase an aggregate of 50,025 shares of its common stock and 4,470 restricted stock units ("RSUs"), each
Read more →PTCTPTC Therapeutics to Acquire Censa Pharmaceuticals - Acquisition diversifies and strengthens PTC Therapeutics' rare disorders portfolio - - Compelling Phase 3 ready asset to potentially address unmet need in PKU
PTC Therapeutics to Acquire Censa Pharmaceuticals - Acquisition diversifies and strengthens PTC Therapeutics' rare disorders portfolio - - Compelling Phase 3 ready asset to potentially address unmet need in PKU - SOUTH PLAINFIELD, N.J., May 6, 2020 - PTC Therapeutics, Inc. (
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present in a virtual format at the following conferences: 2020 BofA...
SOUTH PLAINFIELD, N.J. , May 5, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present in a virtual format at the following conferences: 2020 BofA Securities Health Care Conference Tuesday, May 12 th at 3:40 p.m. ET 2020 RBC Cap
Read more →PTCTPTC Therapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2020....
SOUTH PLAINFIELD, N.J. , April 30, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the first quarter ending March 31, 2020 . "PTC continued to execute on our strategic priorities including the deve
Read more →PTCTConfirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive results from part 2 of the pivotal FIREFISH study evaluating risdiplam in infants with ...
SOUTH PLAINFIELD, N.J. , April 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced positive results from part 2 of the pivotal FIREFISH study evaluating risdiplam in infants with type 1 spinal muscular atrophy (SMA). The global study met its primary en
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 17, 2020 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , April 22, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on April 17, 2020 it approved non-statutory stock options to purchase an aggregate of 151,850 shares of its common stock and 6,260 restricted stock units ("RSUs"),
Read more →PTCTPTC Therapeutics Announces New Leadership Appointments PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointments of Matthew Klein, M.D., to Chief Development Officer and Eric Pauwels to Chief ...
SOUTH PLAINFIELD, N.J. , April 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the appointments of Matthew Klein , M.D., to Chief Development Officer and Eric Pauwels to Chief Business Officer. Dr. Klein will be responsible for the development of o
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss First Quarter 2020 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2020 financial ...
SOUTH PLAINFIELD, N.J. , April 16, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its first quarter 2020 financial results and provide an update on the company's business and outlook on Th
Read more →PTCTPTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee...
SOUTH PLAINFIELD, N.J. , April 7, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of risdipla
Read more →PTCTPTC Therapeutics Announces Management Change PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Marcio Souza, Chief Operating Officer, has resigned and will be leaving the company by...
SOUTH PLAINFIELD, N.J. , March 16, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Marcio Souza , Chief Operating Officer, has resigned and will be leaving the company by April 25 th , 2020. "We are grateful to Marcio for the significant contribu
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 6, 2020 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , March 11, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on March 6, 2020 it approved non-statutory stock options to purchase an aggregate of 103,750 shares of its common stock to 35 new employees. The awards were made pu
Read more →PTCTPTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update
PTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update SOUTH PLAINFIELD, N.J. March 2, 2020 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present at the following conferences: Cowen 40th Annual Health Care...
SOUTH PLAINFIELD, N.J. , Feb. 25, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present at the following conferences: Cowen 40 th Annual Health Care Conference Wednesday, March 4 th at 10:40 a.m. ET Barclays Global Healthcare C
Read more →PTCTPTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the sixth annual STRIVE grant awards program for Duchenne muscular dystrophy. The ...
SOUTH PLAINFIELD, N.J. , Feb. 18, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the launch of the sixth annual STRIVE grant awards program for Duchenne muscular dystrophy. The STRIVE Awards provide a grant to patient advocacy organizations to develop
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year-end...
SOUTH PLAINFIELD, N.J. , Feb. 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its fourth quarter and year-end 2019 financial results and provide an update on the company's business and
Read more →PTCTSUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that positive 1 year clinical data from Part 2 of the pivotal SUNFISH study evaluating...
SOUTH PLAINFIELD, N.J. , Feb. 6, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that positive 1 year clinical data from Part 2 of the pivotal SUNFISH study evaluating risdiplam in people aged 2-25 years with nonambulatory type 2 and type 3 spinal musc
Read more →PTCTPTC Therapeutics Announces First Publication of Real-World Data Showing Translarna™ (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced real-world data showing that boys with nonsense mutation Duchenne muscular dystrophy treated...
SOUTH PLAINFIELD, N.J. , Feb. 3, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced real-world data showing that boys with nonsense mutation Duchenne muscular dystrophy treated with Translarna™ (ataluren) and standard of care (SoC), preserved the ability
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 29, 2020 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Feb. 3, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on January 29, 2020 it approved non-statutory stock options to purchase an aggregate of 182,150 shares of its common stock to 57 new employees. The awards were made p
Read more →PTCTPTC Therapeutics to Host A Conference Call to Review Part 2 of the SUNFISH Clinical Trial Data at the SMA Europe Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will host a conference call on Thursday, February 6, 2020, at 8:00 am ET...
SOUTH PLAINFIELD, N.J. , Feb. 3, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will host a conference call on Thursday, February 6, 2020 , at 8:00 am ET highlighting data on risdiplam in type 2/3 spinal muscular atrophy patients from
Read more →PTCTRisdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive topline results from part 2 of FIREFISH demonstrating that the study met its primary...
SOUTH PLAINFIELD, N.J. , Jan. 23, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced positive topline results from part 2 of FIREFISH demonstrating that the study met its primary endpoint of proportion of infants who are sitting without support after 12 m
Read more →PTCTPTC 2020 JP Morgan Healthcare Conference Stuart W. Peltz, Ph.D., CEO Forwar lookingstatement Th i s pr e s en tat i o n co n ta i ns for w ar d - lo o k in g s ta tem en t s wi t h in the m ean i ng o f T he P r i va te
2020 JP Morgan Healthcare Conference Stuart W. Peltz, Ph.D., CEO lookingstatement Th i s pr e s en tat i o n co n ta i ns for w ar d - lo o k in g s ta tem en t s wi t h in the m ean i ng o f T he P r i va te S e c u r i ti e s Li ti g a ti o n R efor m Ac t o f 1995 . Al l s t
Read more →PTCTPTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference - PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020 - - 3 clinical trials from PTC's
PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference - PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020 - - 3 clinical trials from PTC's new redox platform to begin in 2020 - - ~ $306 million p
Read more →PTCTPTC Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 38th Annual J.P. Morgan Healthcare...
SOUTH PLAINFIELD, N.J. , Jan. 6, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15 th at 8:30 a.m. PST . The presentation will be
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 9, 2019 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Dec. 13, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on December 9, 2019 it approved non-statutory stock options to purchase an aggregate of 59,150 shares of its common stock to 17 new employees. The awards were made p
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 25, 2019 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Nov. 29, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on November 25, 2019 it approved non-statutory stock options to purchase an aggregate of 144,550 shares of its common stock to 36 new employees. The awards were made
Read more →PTCTPTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the United States Food and Drug Administration (FDA) has granted priority review for the...
"The FDA's acceptance of the NDA is an important step towards making risdiplam available to SMA patients in the U.S.," said Stuart W. Peltz , Ph.D., Chief Executive Officer of PTC Therapeutics. "We are proud that risdiplam, the first oral small molecule targeting splicing, was pr
Read more →PTCTPTC Therapeutics to Present at the Evercore ISI 2nd Annual HealthCONx Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will participate in a panel discussion titled, Gene Therapy with Base Business ...
SOUTH PLAINFIELD, N.J. , Nov. 19, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will participate in a panel discussion titled, "Gene Therapy with Base Business – Extracting Value," at the 2 nd Annual Evercore ISI HealthCONx Conference
Read more →PTCTPTC Therapeutics Launches A No-Cost Testing Program to Drive AADC Deficiency Patient Identification PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of a no-cost testing program for aromatic L-amino acid decarboxylase (AADC)...
SOUTH PLAINFIELD, N.J. , Nov. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the launch of a no-cost testing program for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic condition. Children with AADC deficiency fail to thrive
Read more →PTCTRisdiplam (RG7916) Pivotal SUNFISH Study Demonstrates Statistically Significant Improvement for Patients with Type 2/3 Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive results from part 2 of SUNFISH demonstrating that the study met its primary endpoint...
SOUTH PLAINFIELD, N.J. , Nov. 11, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced positive results from part 2 of SUNFISH demonstrating that the study met its primary endpoint of change from baseline after 1 year of treatment with risdiplam compared to
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 25, 2019 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Oct. 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on October 25, 2019 it approved non-statutory stock options to purchase an aggregate of 339,875 shares of its common stock to 27 new employees. The awards were made
Read more →PTCTPTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30,...
SOUTH PLAINFIELD, N.J. , Oct. 29, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the third quarter ending September 30, 2019 . "We are following through on our commitment to build an innovative, d
Read more →PTCTPTC Therapeutics Announces Results from Long-Term AADC Deficiency Gene Therapy Treatment Demonstrating Sustained Improvements PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced new results from its investigational gene therapy, PTC-AADC, in patients living with aromatic...
SOUTH PLAINFIELD, N.J. , Oct. 24, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced new results from its investigational gene therapy, PTC-AADC, in patients living with aromatic L-amino acid decarboxylase (AADC) deficiency. The data demonstrated clinical
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 18, 2019 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Oct. 23, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on October 18, 2019 it approved non-statutory stock options to purchase an aggregate of 144,150 shares of its common stock to 29 new employees. The awards were made
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2019 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2019 financial ...
SOUTH PLAINFIELD, N.J. , Oct. 15, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its third quarter 2019 financial results and provide an update on the company's business and outlook on Tue
Read more →PTCTPTC Therapeutics Establishes Strategic Collaboration with Aldevron to Support GMP Plasmid Manufacturing PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a collaboration with Aldevron, LLC to secure GMP manufacturing capacity for PTC's gene therapy...
SOUTH PLAINFIELD, N.J. , Oct. 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a collaboration with Aldevron, LLC to secure GMP manufacturing capacity for PTC's gene therapy portfolio, including the Friedreich ataxia and Angelman syndrome programs in
Read more →PTCTPTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna™ (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that data from STRIDE,* the first international registry for patients with Duchenne muscular...
SOUTH PLAINFIELD, N.J. , Oct. 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that data from STRIDE,* the first international registry for patients with Duchenne muscular dystrophy due to a nonsense mutation receiving Translarnaä (ataluren), demonst
Read more →PTCTRisdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data demonstrating the ongoing benefit of risdiplam (RG7916) for the treatment of all types of...
SOUTH PLAINFIELD, N.J. , Oct. 2, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced data demonstrating the ongoing benefit of risdiplam (RG7916) for the treatment of all types of spinal muscular atrophy (SMA) at the 24th International Annual Congress of t
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cantor Global...
SOUTH PLAINFIELD, N.J. , Sept. 27, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the following conferences: Cantor Global Healthcare Conference Friday, October 4 th at 10:40 a.m. ET Chardan Genetic M
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 18, 2019 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Sept. 20, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on September 18, 2019 it approved non-statutory stock options to purchase an aggregate of 211,500 shares of its common stock to 48 new employees. The awards were ma
Read more →PTCTPTC Therapeutics Announces Pricing of Private Offering of Convertible Senior Notes PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it has priced its private offering of $250.0 million aggregate principal amount of its...
SOUTH PLAINFIELD, N.J. , Sept. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) announced today that it has priced its private offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"). The Notes will be sold only
Read more →PTCTPTC Therapeutics Announces Pricing of Public Offering of Common Stock
PTC Therapeutics Announces Pricing of Public Offering of SOUTH PLAINFIELD, N.J., Sept. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 2,475,248 shares of its common stock at a public offering price of $40.40 p
Read more →PTCTPTC Therapeutics Announces Proposed Private Offering of Convertible Senior Notes PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing an offering of $250.0 million aggregate principal amount of its...
SOUTH PLAINFIELD, N.J. , Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) announced today that it is commencing an offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"), subject to market conditions and o
Read more →PTCTPTC Therapeutics Announces Proposed Public Offering of Common Stock PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of $100.0 million of shares of its common stock. PTC...
SOUTH PLAINFIELD, N.J. , Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) announced today that it is commencing a public offering of $100.0 million of shares of its common stock. PTC intends to grant the underwriter an option for a period of 30 days to purcha
Read more →PTCTPTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award Winners PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2019 global STRIVE Awards program, designed to support...
SOUTH PLAINFIELD, N.J. , Sept. 6, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is pleased to announce the recipients of the Company's 2019 global STRIVE Awards program, designed to support non-profit organizations serving the Duchenne muscular dystrophy community.
Read more →PTCTPTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2019....
SOUTH PLAINFIELD, N.J. , Aug. 6, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the second quarter ending June 30, 2019 . "Over the second quarter we've made important progress towards our strateg
Read more →PTCTPTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has signed a long-term lease agreement with Bristol-Myers Squibb Company (NYSE: BMY). Under...
SOUTH PLAINFIELD, N.J. , Aug. 5, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced it has signed a long-term lease agreement with Bristol-Myers Squibb Company (NYSE: BMY ). Under the lease agreement, PTC will gain access to approximately 185,000 square f
Read more →PTCTPTC Therapeutics Expands Presence in New Jersey by Securing
PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility - Facility will support gene therapy production and continued development of pipeline of investigational medicines - - PTC to gain access to highly-qualified specialists in biologic
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on July 26, 2019 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , July 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on July 26, 2019 it approved non-statutory stock options to purchase an aggregate of 208,100 shares of its common stock to 72 new employees. The awards were made pur
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2019 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2019...
SOUTH PLAINFIELD, N.J. , July 23, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its second quarter 2019 financial results and provide an update on the company's business and outlook on Tu
Read more →PTCTPTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therapeutics today announced a strategic collaboration to develop novel gene therapies in rare...
SOUTH PLAINFIELD, N.J. and BOSTON , July 1, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) and Odylia Therapeutics today announced a strategic collaboration to develop novel gene therapies in rare inherited retinal diseases (IRDs) utilizing the Anc80 vector system de
Read more →PTCTPTC Provides Update on Translarna™ (ataluren) Application for Label Expansion PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
SOUTH PLAINFIELD, N.J. , June 28, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has completed their review of a proposed indication extension of Tra
Read more →PTCTPTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug...
SOUTH PLAINFIELD, N.J. , June 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Emflaza® (deflazacort) to expand its labeling to inclu
Read more →PTCTPTC Therapeutics Promotes Emily Hill to Chief Financial Officer PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Emily Hill to Chief Financial Officer. Ms. Hill joined PTC Therapeutics in...
SOUTH PLAINFIELD, N.J. , June 3, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the promotion of Emily Hill to Chief Financial Officer. Ms. Hill joined PTC Therapeutics in November 2013 and was most recently Senior Vice President and Head of Investor
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 20, 2019 it approved non-statutory stock options to purchase an aggregate of 76,250 ...
SOUTH PLAINFIELD, N.J. , May 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on May 20, 2019 it approved non-statutory stock options to purchase an aggregate of 76,250 shares of its common stock to 15 new employees. The awards were made pursua
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Jefferies Healthcare Conference on...
SOUTH PLAINFIELD, N.J. , May 30, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, June 6th at 4:00 p.m. ET . The presentation will be webcast live on the
Read more →PTCTPTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical...
SOUTH PLAINFIELD, N.J. , May 20, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This year's funding will ac
Read more →PTCTPTC Therapeutics and MRI Interventions Announce Strategic Investment PTC Therapeutics, Inc. (NASDAQ: PTCT) and MRI Interventions, Inc. (OTCQB: MRIC) today announced a strategic equity investment, with PTC purchasing $4....
SOUTH PLAINFIELD, N.J. and IRVINE, Calif. , May 9, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) and MRI Interventions, Inc. (OTCQB: MRIC ) today announced a strategic equity investment, with PTC purchasing $4.0 million in shares of MRI common stock. PTC and MRI hav
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Bank of America...
SOUTH PLAINFIELD, N.J. , May 8, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the following conferences: Bank of America Merrill Lynch Healthcare Conference Tuesday, May 14 th at 1:40 p.m. PT RBC Cap
Read more →PTCTData from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced clinical data from the studies of FIREFISH and SUNFISH demonstrating the benefit of risdiplam...
SOUTH PLAINFIELD, N.J. , May 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced clinical data from the studies of FIREFISH and SUNFISH demonstrating the benefit of risdiplam (RG7916) for the treatment of Type 1, 2 and 3 spinal muscular atrophy (SMA). P
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 23, 2019 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , May 3, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on April 23, 2019 it approved non-statutory stock options to purchase an aggregate of 210,900 shares of its common stock to 27 new employees. The awards were made purs
Read more →PTCTPTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2019....
SOUTH PLAINFIELD, N.J. , May 2, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the first quarter ending March 31, 2019 . "We believe we are making great strides towards our vision of having many m
Read more →PTCTTranslarna™ (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval from the Brazilian National...
SOUTH PLAINFIELD, N.J. , April 29, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Translarna ™ (ataluren) has been granted marketing approval from the Brazilian National Health Surveillance Agency (ANVISA) under rare diseases procedure, for the t
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss First Quarter 2019 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2019 financial ...
SOUTH PLAINFIELD, N.J. , April 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its first quarter 2019 financial results and provide an update on the company's business and outlook on Th
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company...
SOUTH PLAINFIELD, N.J. , March 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the following conferences: Cowen and Company 39 th Annual Health Care Conference Monday, March 11 th at 11:20 a.m. ET B
Read more →PTCTPTC to Expand Product Portfolio in Latin America with WAYLIVRA™ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive...
SOUTH PLAINFIELD, N.J. , March 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive opinion for WAYLIVRA™ by the Committee for Medicinal Products for Human Use
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 25, 2019 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , March 1, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on February 25, 2019 it approved non-statutory stock options to purchase an aggregate of 125,000 shares of its common stock to 20 new employees. The awards were made
Read more →PTCTPTC Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides a Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending...
SOUTH PLAINFIELD, N.J. , Feb. 28, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2018 . "We are proud to be in the strong position of having a
Read more →PTCTPTC Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides a Corporate Update
PTC Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides a Corporate Update SOUTH PLAINFIELD, N.J., - February 28, 2019 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quart
Read more →PTCTPTC Therapeutics Announces Partial Exercise of Underwriter's Option to Purchase Additional Shares PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the sole underwriter of its previously announced public offering of 6,720,000 shares of...
SOUTH PLAINFIELD, N.J. , Feb. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) announced today that the sole underwriter of its previously announced public offering of 6,720,000 shares of its common stock, which closed on January 25, 2019 , has partially exercised
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2018 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end...
SOUTH PLAINFIELD, N.J. , Feb. 14, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2018 financial results and provide an update on the company's business and
Read more →PTCTPTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the fifth annual STRIVE grant award program for Duchenne Muscular Dystrophy. The...
SOUTH PLAINFIELD, N.J. , Feb. 13, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the launch of the fifth annual STRIVE grant award program for Duchenne Muscular Dystrophy. The STRIVE Awards provide funds to patient advocacy organizations around the wo
Read more →PTCTPTC Therapeutics Launches New Program to Support Research Projects in Rare, Genetic Disorders PTC Therapeutics, Inc. (NASDAQ: PTCT) today launched PRIORITY, an annual funding program for innovative research. In its inaugural year, PRIORITY...
SOUTH PLAINFIELD, N.J. , Jan. 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today launched PRIORITY, an annual funding program for innovative research. In its inaugural year, PRIORITY will fund programs designed to improve Duchenne screening in infants and suppo
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 22, 2019 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Jan. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on January 22, 2019 it approved non-statutory stock options to purchase an aggregate of 170,050 shares of its common stock to 24 new employees. The awards were made
Read more →PTCTPTC Therapeutics Announces Pricing of Public Offering of Common Stock PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 6,720,000 shares of its common stock at a public offering...
SOUTH PLAINFIELD, N.J. , Jan. 23, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) announced today the pricing of a public offering of 6,720,000 shares of its common stock at a public offering price of $30.20 per share, before underwriting discounts. All of the shares
Read more →PTCTPTC Therapeutics Announces Proposed Public Offering of Common Stock PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of $200 million of shares of its common stock. All of...
SOUTH PLAINFIELD, N.J. , Jan. 22, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) announced today that it is commencing a public offering of $200 million of shares of its common stock. All of the shares in the offering are to be sold by PTC. PTC intends to grant the u
Read more →PTCTPTC Therapeutics Provides Corporate Update and Outlines 5-year Strategic Plan at 2019 J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a corporate update, which will be detailed as part of the company's presentation at the 37th...
SOUTH PLAINFIELD, N.J. , Jan. 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today provided a corporate update, which will be detailed as part of the company's presentation at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8 th at 5:00 p.m.
Read more →PTCTPTC Therapeutics Announces Executive Team Updates Focused on Accelerating Pipeline and Bringing Gene Therapy Manufacturing In-house PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Dr. Mark Pykett to Chief Scientific Officer and Dr. Neil Almstead to Chief...
SOUTH PLAINFIELD, N.J. , Jan. 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the promotion of Dr. Mark Pykett to Chief Scientific Officer and Dr. Neil Almstead to Chief Technical Operations Officer. "Achievement of our long-term strategy requires
Read more →PTCTto PTC's Current Report on Form 8-K filed on
PTC Therapeutics Provides Corporate Update and Outlines 5-year Strategic Plan at 2019 J.P. Morgan Healthcare Conference - Multiple products to be launched by 2023 potentially generating ~$1.5 billion revenue annually- - Plan to submit BLA in 2H 2019 for AADC gene therapy program
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the J.P. Morgan Healthcare Conference on...
SOUTH PLAINFIELD, N.J. , Jan. 2, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the J.P. Morgan Healthcare Conference on Tuesday, January 8 th at 5 p.m. PST . The presentation will be webcast live on t
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 17, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Dec. 20, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on December 17, 2018 it approved non-statutory stock options to purchase an aggregate of 24,500 shares of its common stock to 5 new employees. The awards were made p
Read more →PTCTPTC Therapeutics Deepens Financial and Commercial Expertise of Board with Two New Appointments PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Emma Reeve and Stephanie Okey to the Company's Board of Directors. Ms. Reeve ...
SOUTH PLAINFIELD, N.J. , Dec. 18, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the appointment of Emma Reeve and Stephanie Okey to the Company's Board of Directors. Ms. Reeve currently serves as the Chief Financial Officer of Constellation Pharmaceu
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 4, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Dec. 7, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on December 4 , 2018 it approved non-statutory stock options to purchase an aggregate of 48,750 shares of its common stock to 10 new employees. The awards were made p
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 13, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Nov. 16, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on November 13 , 2018 it approved non-statutory stock options to purchase an aggregate of 75,200 shares of its common stock to 19 new employees. The awards were made
Read more →PTCTPTC Therapeutics Reports Third Quarter 2018 Financial Results and Provides a Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30,...
SOUTH PLAINFIELD, N.J. , Nov. 5, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the third quarter ending September 30, 2018 . "We have been aggressively pursuing our vision to build a leading, ful
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Credit Suisse 27th Annual Healthcare...
SOUTH PLAINFIELD, N.J. , Oct. 30, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, November 13 th at 10:55 a.m. MST . The presentation w
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 17, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Oct. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on October 17 , 2018 it approved non-statutory stock options to purchase an aggregate of 68,700 shares of its common stock to 13 new employees. The awards were made
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2018 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2018 financial ...
SOUTH PLAINFIELD, N.J. , Oct. 22, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its third quarter 2018 financial results and provide an update on the company's business and outlook on Mon
Read more →PTCTPTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced preliminary data from the first international drug registry for Duchenne patients receiving...
SOUTH PLAINFIELD, N.J. , Oct. 6, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced preliminary data from the first international drug registry for Duchenne patients receiving Translarna ™ (ataluren), underscoring the long-term clinical benefit of Transla
Read more →PTCTRisdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced interim clinical data from the Part 1, open-label studies of FIREFISH and SUNFISH demonstrating ...
SOUTH PLAINFIELD, N.J. , Oct. 3, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced interim clinical data from the Part 1, open-label studies of FIREFISH and SUNFISH demonstrating the benefit of risdiplam (RG7916) for the treatment of Type 1, 2 and 3 spin
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 25, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Sept. 28, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on September 25, 2018 it approved non-statutory stock options to purchase an aggregate of 122,200 shares of its common stock to 33 new employees. The awards were ma
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Chardan Genetic Medicines Conference on...
SOUTH PLAINFIELD, N.J. , Sept. 25, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at Chardan Genetic Medicines Conference on Tuesday, October 9 th at 2:00 p.m. EST . The presentation will be webcast live
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Jefferies Gene Therapy Summit on Thursday,...
SOUTH PLAINFIELD, N.J. , Sept. 13, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at Jefferies Gene Therapy Summit on Thursday, September 27 th at 1:30 p.m. EST . The presentation will be webcast live on
Read more →PTCTPTC Therapeutics Announces Winners of Global Duchenne Muscular Dystrophy Patient Group STRIVE Awards in Recognition of World Duchenne Awareness Day PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2018 global STRIVE Awards (Strategies to Realize...
SOUTH PLAINFIELD, N.J. , Sept. 7, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is pleased to announce the recipients of the Company's 2018 global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organiz
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on August 22, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Aug. 24, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on August 22 , 2018 it approved non-statutory stock options to purchase an aggregate of 381,500 shares of its common stock to 15 new employees. The awards were made
Read more →PTCTPTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics
PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics SOUTH PLAINFIELD, N.J., August 23, 2018 - PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that it has successfully completed the acquisition of Agilis Biotherapeutics, Inc., a private biotechnol
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on August 6, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Aug. 10, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on August 6 , 2018 it approved non-statutory stock options to purchase an aggregate of 170,200 shares of its common stock to 27 new employees. The awards were made p
Read more →PTCTPTC Therapeutics Reports Second Quarter 2018 Financial Results and Provides a Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2018....
SOUTH PLAINFIELD, N.J. , Aug. 7, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the second quarter ending June 30, 2018 . "We have made significant progress towards delivering on our strategic pla
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2018 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2018...
SOUTH PLAINFIELD, N.J. , July 26, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its second quarter 2018 financial results and provide an update on the company's business and outlook on Tu
Read more →PTCTPTC Therapeutics Announces Publication of Data Demonstrating the Clinical Differentiated Benefit of Deflazacort PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of data in Muscle & Nerve comparing the efficacy and safety of deflazacort and...
SOUTH PLAINFIELD, N.J. , July 24, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the publication of data in Muscle & Nerve comparing the efficacy and safety of deflazacort and prednisone/prednisolone from the placebo arm of the ACT DMD study. The resu
Read more →PTCTPTC Therapeutics to Acquire Agilis Biotherapeutics - Expands and diversifies current pipeline with four gene therapy programs - BLA submission in AADC deficiency expected in 2019
PTC Therapeutics to Acquire Agilis Biotherapeutics - Expands and diversifies current pipeline with four gene therapy programs - BLA submission in AADC deficiency expected in 2019 SOUTH PLAINFIELD, N.J., July 19, 2018 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that i
Read more →PTCTPTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two Years with Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the presentation of data from the Translarna (ataluren) Phase II Study 030 demonstrating that...
SOUTH PLAINFIELD, N.J. , July 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the presentation of data from the Translarna (ataluren) Phase II Study 030 demonstrating that the safety and pharmacokinetic profile of Translarna in children from two to
Read more →PTCTUpdated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of updated interim clinical data from Part 1 of the FIREFISH study...
SOUTH PLAINFIELD, N.J. , June 16, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the presentation of updated interim clinical data from Part 1 of the FIREFISH study investigating risdiplam (RG7916) in babies with Type 1 Spinal Muscular Atrophy (SMA),
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 7, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , June 8, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on June 7 , 2018 it approved non-statutory stock options to purchase an aggregate of 134,450 shares of its common stock to 18 new employees and a restricted stock uni
Read more →PTCTCHMP Adopts Positive Opinion for the Expansion of the Translarna™ (ataluren) Label to Include Patients as Young as 2 Years of Age PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
SOUTH PLAINFIELD, N.J. , June 1, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of expanding the indication of Translarna™ (
Read more →PTCTPTC Therapeutics Reports First Quarter 2018 Financial Results and Provides a Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2018....
SOUTH PLAINFIELD, N.J. , May 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the first quarter ending March 31, 2018 . "Over the past twenty years it has been our mission to bring clinically dif
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss First Quarter 2018 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2018 financial ...
SOUTH PLAINFIELD, N.J. , May 1, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its first quarter 2018 financial results and provide an update on the company's business and outlook on Wedne
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Bank of America Merrill Lynch 2018 Health...
SOUTH PLAINFIELD, N.J. , April 30, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the Bank of America Merrill Lynch 2018 Health Care Conference, on Tuesday, May 15th at 2:20 p.m. PT The presentation wi
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 24, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , April 27, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on April 24 , 2018 it approved non-statutory stock options to purchase an aggregate of 172,150 shares of its common stock to 25 new employees and a restricted stock
Read more →PTCTPreliminary Clinical Data from FIREFISH Trial in Type 1 SMA Patients Presented at the American Academy of Neurology Annual Meeting PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of preliminary data from Part 1, the dose finding portion, of the ongoing...
SOUTH PLAINFIELD, N.J. , April. 24, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the presentation of preliminary data from Part 1, the dose finding portion, of the ongoing FIREFISH clinical trial. The open-label trial is evaluating RG7916, an oral s
Read more →PTCTPTC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the underwriters of its previously announced public offering of 4,000,000 shares of its...
SOUTH PLAINFIELD, N.J. , April 12, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) announced today that the underwriters of its previously announced public offering of 4,000,000 shares of its common stock, which closed on April 3, 2018 , have exercised in full their o
Read more →PTCTPTC Therapeutics Announces R&D Day to Review Multiple Orphan Disorder Programs PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it will hold its R&D Day on Tuesday, April 17, 2018 from 12:00 p.m. to 5:00 p.m. ET in New York...
SOUTH PLAINFIELD, N.J. , April 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced that it will hold its R&D Day on Tuesday, April 17, 2018 from 12:00 p.m. to 5:00 p.m. ET in New York City . Members of PTC's senior management and research teams will provide a
Read more →PTCTPTC Therapeutics Announces Proposed Public Offering of Common Stock PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of 4,000,000 shares of its common stock. All of the...
SOUTH PLAINFIELD, N.J. , March 27, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) announced today that it is commencing a public offering of 4,000,000 shares of its common stock. All of the shares in the offering are to be sold by PTC. PTC intends to grant the underw
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 13, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , March 19, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on March 13 , 2018 it approved non-statutory stock options to purchase an aggregate of 25,200 shares of its common stock to six new employees. The awards were made
Read more →PTCTPTC Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ended...
SOUTH PLAINFIELD, N.J. , March 6, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2017 . "Our mission for the past 20 years has been to develop a
Read more →PTCTPTC Therapeutics To Participate At Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company...
SOUTH PLAINFIELD, N.J. , March 1, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the following conferences: The presentations will be webcast live on the Events and Presentations page under the investo
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 26, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Feb. 28, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on February 26 , 2018 it approved non-statutory stock options to purchase an aggregate of 96,750 shares of its common stock to sixteen new employees. The awards were
Read more →PTCTPTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA's Office of New Drugs PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA's...
SOUTH PLAINFIELD, N.J. , Feb. 20, 2018 / PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA's prior position and denied PTC's appeal of the Complete Response Letter in
Read more →PTCTPTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA's Office of New Drugs
PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA's Office of New Drugs SOUTH PLAINFIELD, N.J., FEBRUARY 20, 2018 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of New Drugs of the U.S. Food and Drug Administration has rei
Read more →PTCTPTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) is delighted to announce the launch of the fourth annual STRIVE (Strategies to Realize Innovation, Vision and...
SOUTH PLAINFIELD, N.J. , Feb. 13, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is delighted to announce the launch of the fourth annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne Muscular Dystrophy (DMD). The
Read more →PTCTPTC Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2018 RBC Capital Markets...
SOUTH PLAINFIELD, N.J. , Feb. 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will present a company overview at the upcoming 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22nd at 2:35 pm ET . The pres
Read more →PTCTPreliminary Data from FIREFISH trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of early interim data from Part 1, the dose-finding portion of the FIREFISH...
SOUTH PLAINFIELD, N.J. , Jan. 27, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the presentation of early interim data from Part 1, the dose-finding portion of the FIREFISH study. FIREFISH is a two-part seamless, open-label, multi-center study to inv
Read more →PTCTPTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks a
Preliminary Data from FIREFISH trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy SOUTH PLAINFIELD, N.J., Jan. 27, 2018 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of early interim data from Part
Read more →PTCTjpmpresentation2018
jpmpresentation2018
Read more →PTCTPTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities
PTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities - Preliminary 2017 unaudited total revenues of approximately $195M, a 135% increase vs. 2016 - - Full-year 2018 net product revenue guidance of $260M to $295M - - Survival data from FIREFISH stud
Read more →PTCTPTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a corporate update, which will be detailed as part of the company's presentation at the 36th...
SOUTH PLAINFIELD, N.J. , Jan. 8, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today provided a corporate update, which will be detailed as part of the company's presentation at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th at 2:30 pm
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 3, 2018 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Jan. 5, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on January 3 , 2018 it approved non-statutory stock options to purchase an aggregate of 33,200 shares of its common stock to seven new employees. The awards were made
Read more →PTCTPTC Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 36th Annual JP Morgan...
SOUTH PLAINFIELD, N.J. , Jan. 3, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will present a company overview at the upcoming 36 th Annual JP Morgan Healthcare Conference on Wednesday, January 10 th at 2:30 pm PT . The presentation
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 11, 2017 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Dec. 15, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on December 11 , 2017 it approved non-statutory stock options to purchase an aggregate of 10,000 shares of its common stock to two new employees. The awards were mad
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 15, 2017 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Nov. 20, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on November 15 , 2017 it approved non-statutory stock options to purchase an aggregate of 61,500 shares of its common stock to eight new employees. The awards were m
Read more →PTCTPTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update - Total third quarter revenue of $41.9M representing 82% growth over 3Q2016 - - Increasing 2017 revenue guidance to $160-$185M - SOUTH PLAINFIELD, N.J., - Nov. 2, 2017 - PTC Therapeutic
Read more →PTCTPTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30,...
SOUTH PLAINFIELD, N.J. , Nov. 2, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the third quarter ending September 30, 2017 . "Our performance this quarter combined with our commercial, financial
Read more →PTCTPTC Therapeutics Receives Complete Response Letter for Ataluren's NDA
PTC Therapeutics Receives Complete Response Letter for Ataluren's NDA SOUTH PLAINFIELD, N.J., October 25, 2017 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of Drug Evaluation I of the U.S. Food and Drug Administration (FDA) has issued a complete respon
Read more →PTCTPTC Therapeutics Receives Complete Response Letter for Ataluren's NDA PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of Drug Evaluation I of the U.S. Food and Drug Administration (FDA) has issued...
SOUTH PLAINFIELD, N.J. , Oct. 25, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Office of Drug Evaluation I of the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) of the
Read more →PTCTPTC Therapeutics to Present at the Credit Suisse 26th Annual Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming Credit Suisse 26th Annual...
SOUTH PLAINFIELD, N.J. , Oct. 24, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will present a company overview at the upcoming Credit Suisse 26th Annual Healthcare Conference on Tuesday, November 7 at 1:35 pm MT . The presentation
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 23, 2017 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Oct. 23, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on October 23 , 2017 it approved non-statutory stock options to purchase an aggregate of 31,000 shares of its common stock to eight new employees. The awards were ma
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter financial...
SOUTH PLAINFIELD, N.J. , Oct. 19, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company's business and outlook on Thursday
Read more →PTCTSpinal Muscular Atrophy Program Advances into Pivotal Study in SMA Patients PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA...
SOUTH PLAINFIELD, N.J. , Oct. 12, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) transitioned into the pivotal part of the study evaluating th
Read more →PTCTRG7916 Increased SMN Protein Production in SUNFISH Clinical Trial in Patients with Type 2/3 Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from Part 1 of the SUNFISH trial of RG7916 in Type 2/3 spinal muscular atrophy (SMA)...
SOUTH PLAINFIELD, N.J. , Oct. 3, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced data from Part 1 of the SUNFISH trial of RG7916 in Type 2/3 spinal muscular atrophy (SMA) patients. RG7916 is part of PTC's joint development program in SMA with Roche and
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 18, 2017 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Sept. 21, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on September 18, 2017 it approved non-statutory stock options to purchase an aggregate of 32,500 shares of its common stock to thirteen new employees. The awards we
Read more →PTCTPTC Therapeutics Announces Winners of Global Duchenne Muscular Dystrophy Patient Group STRIVE Awards in Recognition of World Duchenne Awareness Day PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2017 global STRIVE Awards (Strategies to Realize...
SOUTH PLAINFIELD, N.J. , Sept. 7, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is pleased to announce the recipients of the Company's 2017 global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organiz
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on August 7, 2017 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Aug. 10, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on August 7 , 2017 it approved non-statutory stock options to purchase an aggregate of 31,000 shares of its common stock to ten new employees. The awards were made p
Read more →PTCTPTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update - Translarna second quarter sales of $45.8 M representing 197% growth over 2Q2016 - - Over 1,200 patients on EMFLAZA 12 weeks i
PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update - Translarna second quarter sales of $45.8 M representing 197% growth over 2Q2016 - - Over 1,200 patients on EMFLAZA 12 weeks into launch - - ~400% dose-dependent increase in full len
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Second Quarter Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter financial...
SOUTH PLAINFIELD, N.J. , July 25, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its second quarter financial results and provide an update on the company's business and outlook on Tuesday
Read more →PTCTPTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to Senior Vice President and Head of Clinical Development PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Joseph McIntosh, M.D. to Senior Vice President and Head of Clinical...
SOUTH PLAINFIELD, N.J. , July 24, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the promotion of Joseph McIntosh , M.D. to Senior Vice President and Head of Clinical Development. Dr. McIntosh will be responsible for all aspects of Clinical Developmen
Read more →PTCTPTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of the results of the ACT DMD trial study ataluren, the only treatment for the...
SOUTH PLAINFIELD, N.J. , July 18, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the publication of the results of the ACT DMD trial study ataluren, the only treatment for the underlying cause of nonsense mutation Duchene muscular dystrophy (nmDMD), i
Read more →PTCTPreliminary Phase 2 Data from Spinal Muscular Atrophy Program Presented at CureSMA Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of preliminary clinical data from the company's joint development program with ...
SOUTH PLAINFIELD, N.J. , July 1, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the presentation of preliminary clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) at the Cure S
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 27, 2017 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , June 30, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on June 27 , 2017 it approved non-statutory stock options to purchase an aggregate of 74,750 shares of its common stock to seven new employees. The awards were made
Read more →PTCTppmdpresentation Accessing EMFLAZA (deflazacort) for Duchenne muscular Dystrophy PPMD 2017 Connect Conference
Accessing EMFLAZA (deflazacort) for Duchenne muscular Dystrophy PPMD 2017 Connect Conference June 29, 2017; 4:00pm Stuart Peltz, PhD PTC Therapeutics, South Plainfield, NJ Forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 All s
Read more →PTCTNew Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of new analyses utilizing alternative methods to understand the progression of ...
SOUTH PLAINFIELD, N.J. , June 22, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the presentation of new analyses utilizing alternative methods to understand the progression of Duchenne muscular dystrophy and the benefits of Translarna in nonsense mut
Read more →PTCTPTC Therapeutics Announces FDA Advisory Committee Meeting for Ataluren for the Treatment of Nonsense Mutation Dystrophinopathy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has notified the company of the tentative...
SOUTH PLAINFIELD, N.J. , June 6, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the U.S. Food and Drug Administration (FDA) has notified the company of the tentative scheduling of a Peripheral and Central Nervous Systems Drugs Advisory Committee
Read more →PTCTPTC Therapeutics Announces Executive Promotions
PTC Therapeutics Announces Executive Promotions SOUTH PLAINFIELD, N.J., June 5, 2017 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointments of Marcio Souza to Chief Operating Officer and Christine Utter to Principal Financial Officer and Treasurer. "I am extre
Read more →PTCTPTC Therapeutics Announces Executive Promotions PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointments of Marcio Souza to Chief Operating Officer and Christine Utter to Principal...
SOUTH PLAINFIELD, N.J. , June 5, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the appointments of Marcio Souza to Chief Operating Officer and Christine Utter to Principal Financial Officer and Treasurer. "I am extremely pleased to announce these pr
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 30, 2017 it approved non-statutory stock options to purchase an aggregate of 46,000 ...
SOUTH PLAINFIELD, N.J. , June 2, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on May 30, 2017 it approved non-statutory stock options to purchase an aggregate of 46,000 shares of its common stock to seven new employees. The awards were made pur
Read more →PTCTNew Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of new post-hoc analyses from the placebo arm of its ACT DMD Phase 3 trial...
SOUTH PLAINFIELD, N.J. , May 23, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the presentation of new post-hoc analyses from the placebo arm of its ACT DMD Phase 3 trial with respect to the effect of corticosteroids on multiple measures of disease p
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 17, 2017 it approved non-statutory stock options to purchase 46,500 shares of its...
SOUTH PLAINFIELD, N.J. , May 19, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on May 17, 2017 it approved non-statutory stock options to purchase 46,500 shares of its common stock to ten new employees. The awards were made pursuant to the NASDA
Read more →PTCTPTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2017....
SOUTH PLAINFIELD, N.J. , May 8, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the first quarter ending March 31, 2017 . "We are thrilled to bring EMFLAZA to Duchenne muscular dystrophy patients i
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss First Quarter Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter financial...
SOUTH PLAINFIELD, N.J. , April 24, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its first quarter financial results and provide an update on the company's business and outlook on Monday,
Read more →PTCTPTC Therapeutics Completes Acquisition of Emflaza™ for the Treatment of Duchenne Muscular Dystrophy in the U.S. PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has completed its acquisition of all rights to Emflaza™ (deflazacort) for the treatment of...
SOUTH PLAINFIELD, N.J. , April 20, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced it has completed its acquisition of all rights to Emflaza™ (deflazacort) for the treatment of Duchenne muscular dystrophy (DMD) in the U.S. Execution of the asset purcha
Read more →PTCTPTC Therapeutics Completes Acquisition of Emflaza for the Treatment of Duchenne Muscular Dystrophy in the U.S.
PTC Therapeutics Completes Acquisition of Emflaza for the Treatment of Duchenne Muscular Dystrophy in the U.S. SOUTH PLAINFIELD, N.J., April 20, 2017 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has completed its acquisition of all rights to Emflaza (deflazacort) f
Read more →PTCTPTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs
PTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs SOUTH PLAINFIELD, N.J., April 10, 2016 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Shane Kovacs, Chief Financial Officer, will be leaving the company in mid-May 2017 to return to the f
Read more →PTCTPTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending...
SOUTH PLAINFIELD, N.J. , March 16, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2016 . "For nearly 20 years, PTC has been committed to delive
Read more →PTCTPTC Therapeutics Announces Agreement to Acquire Emflaza™ for the Treatment of Duchenne Muscular Dystrophy in U.S. PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has entered into an asset purchase agreement with Marathon Pharmaceuticals, LLC to acquire...
SOUTH PLAINFIELD, N.J. , March 16, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced it has entered into an asset purchase agreement with Marathon Pharmaceuticals, LLC to acquire all rights to Emflaza™ (deflazacort). Emflaza is the first treatment approv
Read more →PTCTPTC Therapeutics Announces Agreement to Acquire Emflaza for the Treatment of Duchenne Muscular Dystrophy in U.S.
PTC Therapeutics Announces Agreement to Acquire Emflaza for the Treatment of Duchenne Muscular Dystrophy in U.S. SOUTH PLAINFIELD, N.J., March 16, 2017 - PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced it has entered into an asset purchase agreement with Marathon Pharmaceut
Read more →PTCTPTC Therapeutics Announces Timing Change for Fourth Quarter and Year End 2016 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end...
SOUTH PLAINFIELD, N.J. , March 13, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2016 financial results and provide an update on the company's business and
Read more →PTCTPTC Therapeutics Announces FDA Acknowledgment of New Drug Application Filing for Translarna™ for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy SOUTH PLAINFIELD, N.J., March 6, 2017 /PRNewswire/-- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration ...
SOUTH PLAINFIELD, N.J. , March 6, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the filing over protest of PTC's New Drug Application (NDA) for Translarna™ (ataluren), an oral, first-i
Read more →PTCTPTC Therapeutics Announces Results from Pivotal Phase 3 Clinical Trial of Ataluren in Patients Living with Nonsense Mutation Cystic Fibrosis - ACT CF trial missed primary and secondary endpoints - - Company to host confe
PTC Therapeutics Announces Results from Pivotal Phase 3 Clinical Trial of Ataluren in Patients Living with Nonsense Mutation Cystic Fibrosis - ACT CF trial missed primary and secondary endpoints - - Company to host conference call today, March 2nd at 9:00 am ET - SOUTH PLAINFI
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2016 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end...
SOUTH PLAINFIELD, N.J. , Feb. 28, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2016 financial results and provide an update on the company's business and
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 20, 2017 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Feb. 21, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on February 20, 2017 it approved non-statutory stock options to purchase an aggregate of 55,900 shares of its common stock to 14 new employees. The awards were made
Read more →PTCTPTC Therapeutics Announces Third Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the third annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award...
SOUTH PLAINFIELD, N.J. , Feb. 8, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the third annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne muscular dystrophy (DMD). STRIVE provides funds to pati
Read more →PTCTPTC Therapeutics Provides Corporate Update and Outlines 2017 Strategic Priorities
PTC Therapeutics Provides Corporate Update and Outlines 2017 Strategic Priorities to Maximize the Global Value of Translarna and Advance its Innovative Pipeline - Preliminary 2016 Translarna unaudited net sales of approximately $81M, a 140% increase vs. 2015 - - Strategic upda
Read more →PTCTPTC Therapeutics Provides Corporate Update and Outlines 2017 Strategic Priorities to Maximize the Global Value of Translarna™ and Advance its Innovative Pipeline PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a corporate update, which will be detailed as part of the company presentation at the 35th...
SOUTH PLAINFIELD, N.J. , Jan. 9, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today provided a corporate update, which will be detailed as part of the company presentation at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th at 7:30 am PT
Read more →PTCTEuropean Commission Ratifies Positive CHMP Opinion for the Renewal of Translarna™ Marketing Authorization for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it received notification today from the European Commission (EC) of its adoption of a positive...
"As we continue towards our goal of providing Translarna to all who may benefit, we are pleased by the EC ratification of the recent CHMP positive opinion," said Stuart W. Peltz , Ph.D., Chief Executive Officer, PTC Therapeutics. "This important regulatory milestone supports the
Read more →PTCTRG7916 Granted Orphan Drug Designation in the U.S. for the Treatment of Spinal Muscular Atrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to...
SOUTH PLAINFIELD, N.J. , Jan. 6, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to RG7916 for the treatment of patients with Spinal Muscular Atrophy (SMA). RG79
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 3, 2017 it approved non-statutory stock options to purchase 4,000 shares of its ...
SOUTH PLAINFIELD, N.J. , Jan. 5, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on January 3, 2017 it approved non-statutory stock options to purchase 4,000 shares of its common stock to one new employee. The award was made pursuant to the NASDAQ
Read more →PTCTPTC Therapeutics Announces Initiation of FIREFISH Study in Infant (Type I) SMA Patients PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA...
SOUTH PLAINFIELD, N.J. , Jan. 5, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) initiated a clinical study in infants with Type I SMA. The stu
Read more →PTCTPTC Therapeutics to Present 2017 Corporate Update at the 35th Annual J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a corporate update at the upcoming 35th Annual J.P. Morgan...
SOUTH PLAINFIELD, N.J. , Jan. 3, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will present a corporate update at the upcoming 35 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 7:30 am PT . The present
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 14, 2016 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Dec. 16, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on December 14, 2016 it approved non-statutory stock options to purchase an aggregate of 5,600 shares of its common stock to two new employees. The awards were made
Read more →PTCTPTC Therapeutics Receives France's 2016 Prix Galien for Translarna™ SOUTH PLAINFIELD, N.J., Dec. 8, 2016 /PRNewswire/-- PTC Therapeutics Inc. (NASDAQ: PTCT), today announced that the company received France's 2016...
SOUTH PLAINFIELD, N.J. , Dec. 8, 2016 /PRNewswire/ -- PTC Therapeutics Inc. (NASDAQ: PTCT ), today announced that the company received France's 2016 Prix Galien for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in the Medicines
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 17, 2016 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Nov. 18, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on November 17, 2016 it approved non-statutory stock options to purchase an aggregate of 33,600 shares of its common stock to eight new employees. The awards were ma
Read more →PTCTCHMP Recommends Renewal of Translarna's™ Marketing Authorization for Nonsense Mutation Duchenne Muscular Dystrophy Based on Continued Positive Benefit-Risk Assessment PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
SOUTH PLAINFIELD, N.J. , Nov. 11, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the renewal of the conditional marketing authorizati
Read more →PTCTPTC Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30,...
SOUTH PLAINFIELD, N.J. , Nov. 2, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the third quarter ending September 30, 2016 . "For the past 18 years, we have focused significant effort towards dev
Read more →PTCTSpinal Muscular Atrophy Program Advances into Phase 2 Clinical Studies in SMA Patients with RG7916 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche (SIX: RO, ROG;...
SOUTH PLAINFIELD, N.J. , Oct. 20, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche (SIX: RO, ROG; OTCQX: RHHBY ) and the SMA Foundation (SMAF) initiated a Phase 2 study in pe
Read more →PTCTPTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) for Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a regulatory update on Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne...
SOUTH PLAINFIELD, N.J. , Oct. 17, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today provided a regulatory update on Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). U.S. regulatory update PTC Therapeutics announc
Read more →PTCTPTC Therapeutics Announces New Analyses that Support the Potential Benefit of Ataluren in Preserving Lung Function in Non-Ambulatory Nonsense Mutation Duchenne Muscular Dystrophy Patients PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced new data supporting the potential benefit of ataluren in preserving lung function in...
SOUTH PLAINFIELD, N.J. , Oct. 6, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced new data supporting the potential benefit of ataluren in preserving lung function in non-ambulatory nonsense mutation Duchenne muscular dystrophy patients (nmDMD). The res
Read more →PTCTNew Research Validates Translarna's™ (ataluren) Mechanism of Action to Promote Readthrough of Nonsense Mutations and Produce Full-length Functional Protein PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Proceedings of the National Academy of Sciences (PNAS) has published new results...
SOUTH PLAINFIELD, N.J. , Oct. 4, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Proceedings of the National Academy of Sciences (PNAS) has published new results further validating Translarna's™ (ataluren) mechanism of action to promote readth
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 8, 2016 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Sept. 12, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on September 8, 2016 it approved non-statutory stock options to purchase an aggregate of 22,900 shares of its common stock to eleven new employees. The awards were
Read more →PTCTPTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2016 global STRIVE Awards (Strategies to Realize...
SOUTH PLAINFIELD, N.J. , Sept. 7, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is pleased to announce the recipients of the Company's 2016 global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organiz
Read more →PTCTPTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced global regulatory updates on Translarna™ (ataluren) for the treatment of nonsense mutation...
SOUTH PLAINFIELD, N.J. , July 25, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced global regulatory updates on Translarna ™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) and nonsense mutation cystic fibrosis (nmC
Read more →PTCTNHS England Enables Access to Translarna™ ▼ (ataluren) For Patients with Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company and NHS England have successfully negotiated a Managed Access Agreement (MAA)...
Primarily affecting males, Duchenne muscular dystrophy (DMD) is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of skeletal, diaphragm, and heart muscles. Patients with DMD lose the ability to w
Read more →PTCTPTC Therapeutics Appoints Dawn Svoronos to Board of Directors PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Dawn Svoronos to the company's Board of Directors. Ms. Svoronos most...
SOUTH PLAINFIELD, N.J. , June 13, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the appointment of Dawn Svoronos to the company's Board of Directors. Ms. Svoronos most recently served as President of Merck's Europe / Canada region from 2009 to 2011 a
Read more →PTCTNew Analyses from Phase 3 Study 009 of Translarna™ (ataluren) in Patients with Cystic Fibrosis Presented at 39th European Cystic Fibrosis Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that new analyses from the company's previous Phase 3, double-blind, placebo-controlled,...
SOUTH PLAINFIELD, N.J. , June 10, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that new analyses from the company's previous Phase 3, double-blind, placebo-controlled, 48-week 009 trial of Translarna™ (ataluren) for the treatment of nonsense mutatio
Read more →PTCTPTC Therapeutics Announces Winners of the Global Cystic Fibrosis Patient Group Awards PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's global STRIVE Awards (Strategies to Realize Innovation,...
SOUTH PLAINFIELD, N.J. , May 16, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is pleased to announce the recipients of the Company's global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organizations
Read more →PTCTPTC Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2016....
SOUTH PLAINFIELD, N.J. , May 5, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the first quarter ending March 31, 2016 . "We are working hard to make Translarna available to all Duchene muscular d
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 22, 2016 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , April 22, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on April 22, 2016 it approved non-statutory stock options to purchase an aggregate of 26,000 shares of its common stock to 4 new employees. The awards were made pur
Read more →PTCTNICE Recommends Translarna™ (ataluren) for the Treatment of Patients with Nonsense Mutation Duchenne Muscular Dystrophy in England PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the National Institute for Health and Care Excellence (NICE) has recommended Translarna ∇ ...
SOUTH PLAINFIELD, N.J. , April 15, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced that the National Institute for Health and Care Excellence (NICE) has recommended Translarna ∇ (ataluren) for ambulatory patients aged five years and older with nonsens
Read more →PTCTPTC Therapeutics Announces Workforce Reduction as Part of Operating Expense Management Plan PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company is reducing its workforce by approximately 18%, which will primarily affect...
SOUTH PLAINFIELD, N.J. , March 23, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company is reducing its workforce by approximately 18%, which will primarily affect employees and contractors in the U.S. This reduction is part of PTC's progra
Read more →PTCTPTC Therapeutics Provides Update on Health Canada Review of Translarna™ (ataluren) for the Treatment of Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company intends to submit the results of the recently completed Phase 3 ACT DMD study...
SOUTH PLAINFIELD, N.J. , March 14, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company intends to submit the results of the recently completed Phase 3 ACT DMD study for review by Health Canada as part of the New Drug Submission (NDS) for T
Read more →PTCTPTC Therapeutics Announces Presentation of Results from Phase 3 ACT DMD Clinical Trial of Translarna™ (ataluren) in Patients with Duchenne Muscular Dystrophy at 5th International Congress of Myology PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that data from the Phase 3, double-blind, placebo-controlled, 48-week ACT DMD trial of...
SOUTH PLAINFIELD, N.J. , March 14, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that data from the Phase 3, double-blind, placebo-controlled, 48-week ACT DMD trial of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dy
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 25, 2016 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , March 2, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on February 25, 2016 it approved non-statutory stock options to purchase an aggregate of 29,500 shares of its common stock to 12 new employees. The awards were made
Read more →PTCTPTC Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending...
SOUTH PLAINFIELD, N.J. , Feb. 29, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2015 . "We are shocked and disappointed to have received a Ref
Read more →PTCTPTC Therapeutics Provides Update on German pricing and Reimbursement Process for Translarna™ (ataluren) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has had multiple discussions with the German Federal Association of the...
SOUTH PLAINFIELD, N.J. , Feb. 26, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company has had multiple discussions with the German Federal Association of the Statutory Health Insurances (GKV-SV) over the last several months to come to agre
Read more →PTCTPTC Receives Refuse to File Letter from FDA for Translarna™ (ataluren) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it received yesterday evening a Refuse to File letter from the United States Food and Drug ...
SOUTH PLAINFIELD, N.J. , Feb. 23, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that it received yesterday evening a Refuse to File letter from the United States Food and Drug Administration (FDA) regarding PTC's New Drug Application (NDA) for Transl
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2015 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end...
SOUTH PLAINFIELD, N.J. , Feb. 15, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2015 financial results and provide an update on the company's business and
Read more →PTCTPTC Therapeutics Announces Second Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the second annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award ...
SOUTH PLAINFIELD, N.J. , Feb. 12, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the second annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne muscular dystrophy (DMD). STRIVE provides funds to pa
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Leerink Partners'...
SOUTH PLAINFIELD, N.J. , Jan. 28, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the following conferences: The presentations will be webcast live on the Events and Presentations page under the investo
Read more →PTCTPTC Therapeutics Outlines Business Priorities for the Development and Commercialization of Translarna™ and Progress of the Company Pipeline PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a corporate update, which will be detailed at the company's presentation at the 34th Annual J.P. ...
SOUTH PLAINFIELD, N.J. , Jan. 11, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today provided a corporate update, which will be detailed at the company's presentation at the 34 th Annual J.P. Morgan Healthcare Conference. Stuart W. Peltz , Ph.D., Chief Executive Of
Read more →PTCTPTC Completes Rolling NDA Submission to FDA and Submits Phase 3 ACT DMD Clinical Trial Results to EMA for Translarna™ (ataluren) for Treatment of Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the completion of its rolling submission of a New Drug Application (NDA) to the United States...
SOUTH PLAINFIELD, N.J. , Jan. 8, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the completion of its rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ (ataluren), an oral, first
Read more →PTCTSpinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that RG7916, an additional SMN2 splicing modifier from the company's joint development program...
SOUTH PLAINFIELD, N.J. , Jan. 7, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) today announced that RG7916, an additional SMN2 splicing modifier from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA), has ente
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 4, 2016 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Jan. 6, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on January 4, 2016 it approved non-statutory stock options to purchase an aggregate of 41,600 shares of its common stock to 18 new employees. The awards were made pur
Read more →PTCTPTC Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 34th Annual J.P. Morgan...
SOUTH PLAINFIELD, N.J. , Dec. 23, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will present a company overview at the upcoming 34 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2016 at 9:30 am PT . The presen
Read more →PTCTPTC Therapeutics and Massachusetts General Hospital Collaborate on Rare Disease Research PTC Therapeutics, Inc. (Nasdaq: PTCT) has entered into a research collaboration with Massachusetts General Hospital (MGH, a Partners Healthcare...
SOUTH PLAINFIELD, N.J. , Dec. 9, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) has entered into a research collaboration with Massachusetts General Hospital (MGH, a Partners Healthcare hospital) for the treatment of rare genetic disorders resulting from pre-mRNA spl
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 3, 2015 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Dec. 4, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on December 3, 2015 it approved non-statutory stock options to purchase an aggregate of 57,200 shares of its common stock to 26 new employees. The awards were made pu
Read more →PTCTPTC Completes Enrollment of Phase 3 Clinical Trial of Translarna™ for Patients with Cystic Fibrosis PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has completed enrollment of ACT CF, the company's second Phase 3 clinical trial of...
SOUTH PLAINFIELD, N.J. , Nov. 19 , 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that it has completed enrollment of ACT CF, the company's second Phase 3 clinical trial of Translarna™ (ataluren) for patients with nonsense mutation cystic fibrosis (nm
Read more →PTCTPTC Therapeutics Reports Third Quarter 2015 Financial Results, Provides Corporate Update and Reviews Key Findings from ACT DMD PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30,...
SOUTH PLAINFIELD, N.J. , Nov. 9, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the third quarter ending September 30, 2015 . "We recently reported results from our Phase 3 ACT DMD clinical trial
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Credit Suisse 24th...
SOUTH PLAINFIELD, N.J. , Nov. 3, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the following conferences: The presentations will be webcast live on the Events and Presentations page under the investor
Read more →PTCTPTC Therapeutics Announces Launch of STRIVE Grant Award Program for Cystic Fibrosis PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its Strategies to Realize Innovation, Vision and Empowerment (STRIVE) Awards...
SOUTH PLAINFIELD, N.J. , Oct. 29, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the expansion of its Strategies to Realize Innovation, Vision and Empowerment (STRIVE) Awards program to provide funding to nonprofit organizations serving the cystic fib
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2015 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2015 financial ...
SOUTH PLAINFIELD, N.J. , Oct. 27, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its third quarter 2015 financial results and provide an update on the Company's business, outlook and clini
Read more →PTCTPTC Announces Results from Phase 3 ACT DMD Clinical Trial of Translarna™ (ataluren) in Patients with Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from the Phase 3, double-blind, placebo-controlled, 48-week ACT DMD trial of...
SOUTH PLAINFIELD, N.J. , Oct. 15, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced results from the Phase 3, double-blind, placebo-controlled, 48-week ACT DMD trial of Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the
Read more →PTCTPhase 2 Data from Spinal Muscular Atrophy Program to be Presented at the 20th International Annual Congress of the World Muscle Society PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that clinical data from the company's joint development program with Roche and the SMA...
BRIGHTON, United Kingdom , Oct. 4, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced that clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) were presented at the 20 th Internati
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 2, 2015 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Oct. 2, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on October 2, 2015 it approved non-statutory stock options to purchase an aggregate of 58,300 shares of its common stock to 13 new employees. The awards were made pur
Read more →PTCTPTC Therapeutics Submits European Application For Translarna™ for Cystic Fibrosis PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) has validated the submission of a variation for a new ...
SOUTH PLAINFIELD, N.J. , Sept. 30, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced that the European Medicines Agency (EMA) has validated the submission of a variation for a new indication for Translarna™ (ataluren) for the treatment of nonsense mutat
Read more →PTCTPTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce five recipients of its first-ever global awards program, the STRIVE Awards (Strategies...
SOUTH PLAINFIELD, N.J. , Sept. 4, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is pleased to announce five recipients of its first-ever global awards program, the STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment), designed to aid nonprofit or
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on August 20, 2015 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Aug. 21, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on August 20, 2015 it approved non-statutory stock options to purchase an aggregate of 166,200 shares of its common stock to 35 new employees. The awards were made p
Read more →PTCTPTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2015....
SOUTH PLAINFIELD, N.J. , July 30, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the second quarter ending June 30, 2015 . "PTC is progressing on many fronts across the organization. We are excite
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2015 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2015...
SOUTH PLAINFIELD, N.J. , July 16, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its second quarter 2015 financial results and provide an update on the company's business and outlook on Th
Read more →PTCTPTC Therapeutics' CEO Stuart W. Peltz, Ph.D. Finalist For The 2015 NJBiz Innovation Hero Award PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its co-founder and Chief Executive Officer, Stuart W. Peltz, Ph.D., is a finalist for ...
Please replace the press release from June 23rd , 10:30 am ET with the following corrected version. The corrected version reads: PTC Therapeutics' CEO Stuart W. Peltz, Ph.D. Finalist For The 2015 NJBiz Innovation Hero Award SOUTH PLAINFIELD, N.J. , June 23, 2015 /PRNewswire/ --
Read more →PTCTPTC Therapeutics Appoints Glenn D. Steele Jr., M.D., Ph.D. to Board of Directors PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Glenn D. Steele Jr., M.D., Ph.D. to the company's Board of Directors. Dr....
SOUTH PLAINFIELD, N.J. , June 15, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the appointment of Glenn D. Steele Jr. , M.D., Ph.D. to the company's Board of Directors. Dr. Steele served as President and Chief Executive Officer of Geisinger Health f
Read more →PTCTPTC Therapeutics and BioMarin Pharmaceutical to Host DMD Industry Symposium PTC Therapeutics, Inc. (NASDAQ: PTCT) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that they will host an Industry Update...
SOUTH PLAINFIELD, N.J. and SAN RAFAEL, Calif. , June 12, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that they will host an Industry Update Symposium on Advances in Duchenne Muscular Dystrophy (DMD)
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 9, 2015 it approved non-statutory stock options to purchase an aggregate of 55,200 ...
SOUTH PLAINFIELD, N.J. , June 12, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on June 9, 2015 it approved non-statutory stock options to purchase an aggregate of 55,200 shares of its common stock to 8 new employees. The awards were made pursua
Read more →PTCTGerman Federal Joint Committee Issues Positive Medical Benefit Rating for Translarna™ in Patients with Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the Benefit Assessment by Germany's Federal Joint Committee (G-BA) indicated that...
"We are pleased by the positive assessment we received from the G-BA for Translarna. It reflects the medical benefit provided for nonsense mutation DMD patients where there are no other approved therapies," said Stuart W. Peltz , Ph.D., Chief Executive Officer, PTC Therapeutics,
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 15, 2015 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , May 15, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on May 15, 2015 it approved non-statutory stock options to purchase an aggregate of 112,150 shares of its common stock to 14 new employees. The awards were made pursu
Read more →PTCTPTC Therapeutics Launches STRIVE Grant Award Program PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has launched STRIVE (Strategies to Realize Innovation, Vision and Empowerment), an awards...
SOUTH PLAINFIELD, N.J. , May 11, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced it has launched STRIVE (Strategies to Realize Innovation, Vision and Empowerment), an awards program aimed at providing funds to patient advocacy organizations to develop
Read more →PTCTPTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2015....
SOUTH PLAINFIELD, N.J. , May 4, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the first quarter ending March 31, 2015 . "We are off to a strong start this year. In our first full quarter since th
Read more →PTCTPTC Therapeutics' Cancer Stem Cell Program Targeting BMI1 Enters Phase 1 PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that its oncology program targeting BMI1, a protein linked to drug-resistant cancers, has...
SOUTH PLAINFIELD, N.J. , April 28, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced that its oncology program targeting BMI1, a protein linked to drug-resistant cancers, has entered a Phase 1 study in patients with advanced solid tumors. The open-label
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Deutsche Bank 40th...
SOUTH PLAINFIELD, N.J. , April 23, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the following conferences: The presentation will be webcast live on the Events and Presentations page under the investo
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss First Quarter 2015 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2015 financial ...
SOUTH PLAINFIELD, N.J. , April 20, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its first quarter 2015 financial results on Monday, May 4, 2015 at 4:30 p.m. (ET) after the closing of the
Read more →PTCTPhase 1 Data from Spinal Muscular Atrophy Program to be Presented at the 2015 American Academy of Neurology Annual Meeting PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Phase 1 clinical data from the company's joint development program with Roche and the SMA...
WASHINGTON , April 20, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Phase 1 clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) will be presented at the 2015 American Aca
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 7, 2015 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , April 10, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on April 7, 2015 it approved non-statutory stock options to purchase an aggregate of 264,200 shares of its common stock to 25 new employees. The awards were made pu
Read more →PTCTPTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the appointment of Eric Pauwels as Senior Vice President and General Manager Commercial...
SOUTH PLAINFIELD, N.J. , April 8, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced the appointment of Eric Pauwels as Senior Vice President and General Manager Commercial Operations, Americas. Eric will be responsible for the commercial strategy, organ
Read more →PTCTPTC Therapeutics and University of Pennsylvania Collaborate on Orphan Disease Research PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced a collaboration with the Orphan Disease Center at the Perelman School of Medicine at the...
SOUTH PLAINFIELD, N.J. , March 19, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) today announced a collaboration with the Orphan Disease Center at the Perelman School of Medicine at the University of Pennsylvania focused on translational research for discovering and
Read more →PTCTPTC Announces Translarna™ Access Program In Duchenne Muscular Dystrophy for Siblings of Patients Participating in PTC Clinical Trials PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that it will make Translarna available for siblings of patients in certain open label PTC...
"For families with more than one child suffering from nonsense mutation Duchenne muscular dystrophy, having only one child enrolled in our clinical trials with access to Translarna, can cause great distress for parents," said Stuart W. Peltz , Ph.D., Chief Executive Officer, PTC
Read more →PTCTPTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ended...
SOUTH PLAINFIELD, N.J. , Feb. 27, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2014 . "2014 was a transformative year for PTC. We are now a gr
Read more →PTCTPTC Therapeutics to Participate at Upcoming March Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company...
SOUTH PLAINFIELD, N.J. , Feb. 16, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the following conferences: The company updates will be webcast live on the Events and Presentations page under the inves
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2014 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to discuss fourth quarter and year end...
SOUTH PLAINFIELD, N.J. , Feb. 13, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to discuss fourth quarter and year end 2014 financial results and provide an update on the company's business and out
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 6, 2015 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Feb. 6, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on February 6, 2015 it approved non-statutory stock options to purchase an aggregate of 66,750 shares of its common stock to 13 new employees. The awards were made pu
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: 2015 Leerink Global ...
SOUTH PLAINFIELD, N.J. , Feb 5, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the following conferences: The company updates will be webcast live on the Events and Presentations page under the investo
Read more →PTCTPTC Therapeutics to Present at the 33rd Annual J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 33rd Annual J.P. Morgan Healthcare...
SOUTH PLAINFIELD, N.J. , Jan. 7, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the 33 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15 th at 11:00 am PT at the Westin St. Francis in
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 2, 2015 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Jan. 2, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on January 2, 2015 it approved non-statutory stock options to purchase an aggregate of 26,600 shares of its common stock to 11 new employees. The awards were made pur
Read more →PTCTPTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States ...
SOUTH PLAINFIELD, N.J. , Dec. 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ for the treatment of no
Read more →PTCTTranslarna Granted Orphan Drug Designation in the U.S. and Europe for the Treatment of Mucopolysaccharidosis I PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)...
SOUTH PLAINFIELD, N.J. , Dec. 19, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT ) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan-drug designation (ODD) to Translarna™ (ataluren) for the
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2014 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Dec. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on December 15, 2014 it approved non-statutory stock options to purchase an aggregate of 46,750 shares of its common stock to ten new employees. The awards were made
Read more →PTCTPTC Therapeutics Announces Launch of Translarna™ (ataluren) in Germany PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) is now commercially available to patients in Germany, the first...
SOUTH PLAINFIELD, N.J. , Dec. 3, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Translarna™ (ataluren) is now commercially available to patients in Germany , the first country to launch in the European Union (EU), with first shipments expected to
Read more →PTCTPTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that the 2014 Legend of Technology Award for Vision, Innovation, and Leadership has been...
SOUTH PLAINFIELD, N.J. , Nov. 21, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is proud to announce that the 2014 Legend of Technology Award for Vision, Innovation, and Leadership has been awarded to Stuart W. Peltz , Ph.D., Chief Executive Officer. This award reco
Read more →PTCTSpinal Muscular Atrophy Program Enters Phase 1b/2a Trial in Patients with SMA PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA...
SOUTH PLAINFIELD, N.J. , Nov. 19, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced today that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a Phase 1b/2a study in adult and pediatric patien
Read more →PTCTPTC Therapeutics Appoints Dr. Tuyen Ong SVP, Head of Clinical Development and Translational Research PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Tuyen Ong, M.D., MRCOphth, MBA, as Senior Vice President, Head of Clinical...
SOUTH PLAINFIELD, N.J. , Nov. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the appointment of Tuyen Ong , M.D., MRCOphth, MBA, as Senior Vice President, Head of Clinical Development and Translational Research. Dr. Ong will be responsible for Cli
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 14, 2014 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Nov. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on November 14, 2014 it approved non-statutory stock options to purchase an aggregate of 92,000 shares of its common stock to fifteen new employees. The awards were
Read more →PTCTPTC Therapeutics Recognized for Outstanding Innovation at the 2014 Rare & Orphan Advocacy and Research (ROAR) Awards PTC Therapeutics, Inc. (NASDAQ: PTCT) received the Outstanding Innovation Award at The 2014 Rare & Orphan Advocacy & Research Awards for Translarna™, ...
SOUTH PLAINFIELD, N.J. , Nov. 14, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) received the Outstanding Innovation Award at The 2014 Rare & Orphan Advocacy & Research Awards for Translarna ™ , the first treatment approved in the European Union for Duchenne muscular
Read more →PTCTPTC Therapeutics to Webcast Upcoming Science Day and Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it will hold its 2nd Annual Science Day on Monday, November 24, 2014 from 8:00 a.m. to...
SOUTH PLAINFIELD, N.J. , Nov. 13, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced today that it will hold its 2 nd Annual Science Day on Monday, November 24, 2014 from 8:00 a.m. to 12:00 p.m. ET at the Le Parker Meridien in New York City . Members of PTC's s
Read more →PTCTPTC Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ended September 30,...
SOUTH PLAINFIELD, N.J. , Nov. 6, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the third quarter ended September 30, 2014 . "During the quarter we continued to make significant progress during th
Read more →PTCTPTC Therapeutics Expands Access For Translarna™ (Ataluren) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been approved to be included in the list of drugs reimbursable...
AIFA's Technical and Scientific Committee gave a positive opinion for the inclusion of Translarna to be available and reimbursed to patients at its recent October meeting. The approval is based on the request of specialist physicians and Parent Project Onlus to gain access to Tra
Read more →PTCTPTC Therapeutics to Present at the Credit Suisse 23rd Annual Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Credit Suisse 23rd Annual Healthcare...
SOUTH PLAINFIELD, N.J. , Oct. 29, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the Credit Suisse 23 rd Annual Healthcare Conference on Tuesday, November 11 th at 4:30 pm MT at the Arizona Biltmore in
Read more →PTCTTranslarna™ Phase 2b Data Published in Muscle & Nerve PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of data and related analysis which provide strong support for concluding that...
SOUTH PLAINFIELD, N.J. , Oct. 27, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the publication of data and related analysis which provide strong support for concluding that Translarna™ (ataluren) was active and showed clinically meaningful improveme
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2014 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2014 financial ...
SOUTH PLAINFIELD, N.J. , Oct. 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its third quarter 2014 financial results and provide an update on the company's business and outlook on Thu
Read more →PTCTPTC Therapeutics Announces Pricing of Public Offering of Common Stock PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the pricing of an underwritten public offering of 3,000,000 shares of its common stock pursuant ...
SOUTH PLAINFIELD, N.J. , Oct. 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced today the pricing of an underwritten public offering of 3,000,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was previou
Read more →PTCTPTC Therapeutics Announces Proposed Public Offering of Common Stock PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it is commencing an underwritten public offering of 3,000,000 shares of its common stock...
SOUTH PLAINFIELD, N.J. , Oct. 8, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced today that it is commencing an underwritten public offering of 3,000,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was
Read more →PTCTPTC Therapeutics to Present at the Leerink Partners Rare Disease Roundtable PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Leerink Partners Rare Disease Roundtable...
SOUTH PLAINFIELD, N.J. , Sept. 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the Leerink Partners Rare Disease Roundtable on Wednesday, October 1st at 8:25 am ET at Le Parker Meridien in New York C
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 23, 2014 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Sept. 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on September 23, 2014 it approved non-statutory stock options to purchase an aggregate of 208,300 shares of its common stock to eighteen new employees. The awards w
Read more →PTCTPTC Therapeutics Expands Global Presence in Support of Translarna™ Launch in Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its global presence with the addition of key executives to leadership...
SOUTH PLAINFIELD, N.J. , Sept. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the expansion of its global presence with the addition of key executives to leadership positions in PTC's global commercial team and the establishment of its internation
Read more →PTCTPTC Therapeutics Completes Enrollment of Landmark Trial in Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has completed enrollment of ACT DMD, the Phase 3 confirmatory trial of Translarna™...
SOUTH PLAINFIELD, N.J. , Sept. 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that it has completed enrollment of ACT DMD, the Phase 3 confirmatory trial of Translarna™ (ataluren) for patients with nonsense mutation Duchenne muscular dystrophy (nmD
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will participate at two upcoming investor conferences: - FBR 1st Annual Healthcare...
SOUTH PLAINFIELD, N.J. , Aug. 20, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that it will participate at two upcoming investor conferences: - FBR 1 st Annual Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 3 rd -
Read more →PTCTPTC Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ended June 30, 2014....
SOUTH PLAINFIELD, N.J. , Aug. 7, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the second quarter ended June 30, 2014. "This has been an exciting quarter for PTC. In May we received a positive op
Read more →PTCTOrally Delivered Compounds, Which Selectively Modify RNA Splicing Prevent Deficits In Mouse Models Of Spinal Muscular Atrophy Today the journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the...
SOUTH PLAINFIELD, N.J. , Aug. 7, 2014 /PRNewswire/ -- Today the journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in mouse models of
Read more →PTCTPTC Therapeutics Receives Conditional Approval in the European Union for Translarna™ For the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the European Commission has granted conditional marketing authorization for Translarna™...
SOUTH PLAINFIELD, N.J. , Aug. 4, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the European Commission has granted conditional marketing authorization for Translarna™ (ataluren), in the European Union (EU) for the treatment of nonsense mutation
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on July 31, 2014 it approved non-statutory stock options to purchase an aggregate of...
SOUTH PLAINFIELD, N.J. , Aug. 1, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on July 31, 2014 it approved non-statutory stock options to purchase an aggregate of 67,700 shares of its common stock to seven new employees. The awards were made pu
Read more →PTCTPTC Therapeutics to Present at the Wedbush Life Sciences Management Access Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Wedbush Life Sciences Management Access...
SOUTH PLAINFIELD, N.J. , July 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company update at the Wedbush Life Sciences Management Access Conference on Tuesday, August 12th at 4:15 pm ET at the Le Parker Meridien in
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2014...
SOUTH PLAINFIELD, N.J. , July 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its second quarter 2014 financial results and provide an update on the company's business and outlook on Th
Read more →PTCTPTC Therapeutics Announces Expanded Access Program For Translarna™ (ataluren) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to...
SOUTH PLAINFIELD, N.J. , July 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna™ (ataluren) available to patients before commercial availabi
Read more →PTCTPTC Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will present a company overview at the 9th Annual JMP Securities Healthcare...
SOUTH PLAINFIELD, N.J. , June 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that they will present a company overview at the 9 th Annual JMP Securities Healthcare Conference on Wednesday, June 25 th at the Westin New York Grand Central in New Yor
Read more →PTCTShane Kovacs Receives the 2014 New Jersey Technology Council CFO - Deal of the Year Award PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Shane Kovacs, Chief Financial Officer, has received the 2014 Deal of the Year Award from...
SOUTH PLAINFIELD, N.J. , June 13, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Shane Kovacs , Chief Financial Officer, has received the 2014 Deal of the Year Award from the New Jersey Technology Council (NJTC). The Deal of the Year Award is par
Read more →PTCTPTC Therapeutics Appoints Ronald C. Renaud, Jr. to Board of Directors PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Ronald C. Renaud, Jr. to the company's Board of Directors. Mr. Renaud has...
SOUTH PLAINFIELD, N.J. , June 11, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the appointment of Ronald C. Renaud, Jr. to the company's Board of Directors. Mr. Renaud has served as the President and Chief Executive Officer of Idenix Pharmaceuticals
Read more →PTCTPTC Therapeutics Receives Positive Opinion from CHMP for Translarna™ (ataluren) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for re-examination, the Committee for Medicinal Products for Human...
SOUTH PLAINFIELD, N.J. , May 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opin
Read more →PTCTPTC Therapeutics Provides EMA Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will provide an update on the re-examination of its marketing authorization...
SOUTH PLAINFIELD, N.J. , May 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will provide an update on the re-examination of its marketing authorization application to the European Medicines Agency (EMA) for conditional marketing a
Read more →PTCTPTC Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will present a company overview at the Jefferies 2014 Global Healthcare Conference on ...
SOUTH PLAINFIELD, N.J. , May 21, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that they will present a company overview at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4 th at 2:00 pm ET at the Grand Hyatt in New York City . T
Read more →PTCTAtaluren Phase 3 Trial Results in Nonsense Mutation Cystic Fibrosis Published in The Lancet Respiratory Medicine PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation cystic...
SOUTH PLAINFIELD, N.J. , May 16, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) were published in Lancet Respiratory Medicine . The results demon
Read more →PTCTPTC Therapeutics to Present at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will present a company overview at two upcoming investor conferences: Deutsche Bank...
SOUTH PLAINFIELD, N.J. , April 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that they will present a company overview at two upcoming investor conferences: The presentation will be webcast live on the Events and Presentations page under the inv
Read more →PTCTPTC Therapeutics to Host Conference Call to Discuss First Quarter 2014 Financial Results PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2014 financial ...
SOUTH PLAINFIELD, N.J. , April 22, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Company will host a webcast conference call to report its first quarter 2014 financial results on Tuesday, May 6, 2014 at 4:30 p.m. (ET) after the closing of th
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 17, 2014 it granted non-statutory stock options to purchase an aggregate of 9,800 ...
SOUTH PLAINFIELD, N.J. , April 21, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on April 17, 2014 it granted non-statutory stock options to purchase an aggregate of 9,800 shares of its common stock to four new employees. The grant was made purs
Read more →PTCTPTC Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported its financial results for the fourth quarter and full-year...
SOUTH PLAINFIELD, N.J. , March 6, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013. "2013 was a landmark year for PTC with significant ac
Read more →PTCTPTC Therapeutics To Present At The Cowen & Company 34th Annual Health Care Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will present a company overview at the Cowen & Company 34th Annual Health Care...
SOUTH PLAINFIELD, N.J. , Feb. 28, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that they will present a company overview at the Cowen & Company 34th Annual Health Care Conference on Wednesday, March 5 th at 9:20 am ET at the Marriott Copley Plaza Ho
Read more →PTCTPTC Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it granted a non-statutory stock option to purchase 150,000 shares of its common stock to...
SOUTH PLAINFIELD, N.J. , Feb. 27, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that it granted a non-statutory stock option to purchase 150,000 shares of its common stock to Robert Spiegel , M.D., PTC's newly appointed Chief Medical Officer. The gra
Read more →PTCTPTC Therapeutics to Host Fourth Quarter and Year End 2013 Financial Results Conference Call PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that will host a webcast conference call to discuss financial results for the fourth quarter...
SOUTH PLAINFIELD, N.J. , Feb. 27, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that will host a webcast conference call to discuss financial results for the fourth quarter and year end 2013 on Thursday, March 6, 2014 at 4:30 p.m. (ET) after the clos
Read more →PTCTPTC Therapeutics Expands International Commercial Team PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Guido Schopen, M.D. to General Manager and Head of Medical Affairs for...
SOUTH PLAINFIELD, N.J. , Feb. 25, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the appointment of Guido Schopen , M.D. to General Manager and Head of Medical Affairs for Europe . Dr. Schopen will be responsible for European commercial operations, re
Read more →PTCTPTC Therapeutics to Present at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in two upcoming investor conferences: (Logo:...
SOUTH PLAINFIELD, N.J. , Feb. 20, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that they will participate in two upcoming investor conferences: (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) - Management will participate in a panel en
Read more →PTCTPTC Therapeutics Announces Closing of Registered Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the closing of its previously announced registered public offering of 5,163,265 shares of its...
SOUTH PLAINFIELD, N.J. , Feb. 19, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced today the closing of its previously announced registered public offering of 5,163,265 shares of its common stock, including 673,469 shares sold by PTC as a result of the full e
Read more →PTCTPTC Therapeutics Announces Pricing of Public Offering of Common Stock PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the pricing of an underwritten public offering of 4,489,796 million shares of common stock at a ...
SOUTH PLAINFIELD, N.J. , Feb. 12, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the pricing of an underwritten public offering of 4,489,796 million shares of common stock at a public offering price of $24.50 per share, before underwriting discounts.
Read more →PTCTPTC Therapeutics Announces Proposed Public Offering of Common Stock PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has commenced an underwritten public offering of approximately $75 million of shares of ...
SOUTH PLAINFIELD, N.J. , Feb. 10, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced today that it has commenced an underwritten public offering of approximately $75 million of shares of its common stock. The number of shares to be offered and the price for the
Read more →PTCTPTC Therapeutics Announces that Stuart W. Peltz, Ph.D., CEO is the Recipient of the 2014 Dr. Sol J. Barer Award for Vision, Innovation and Leadership PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its founder and Chief Executive Officer, Stuart W. Peltz, Ph.D. has been awarded the...
SOUTH PLAINFIELD, N.J. , Jan. 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is proud to announce that its founder and Chief Executive Officer, Stuart W. Peltz , Ph.D. has been awarded the 2014 Dr. Sol J. Barer Award for Vision, Innovation, and Leadership. Named
Read more →PTCTPTC Therapeutics Provides Update on CHMP Opinion for Conditional Approval of Ataluren for Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (NASDAQ: PTCT) (PTC) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
SOUTH PLAINFIELD, N.J. , Jan. 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) (PTC) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Company's marketing auth
Read more →PTCTPTC Therapeutics Expands Management Team PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced an expansion of its senior management team with the appointment of Robert J. Spiegel M.D., FACP ...
SOUTH PLAINFIELD, N.J. , Jan. 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced an expansion of its senior management team with the appointment of Robert J. Spiegel M.D ., FACP to Chief Medical Officer and Murad Husain to Vice President, Global Regul
Read more →PTCTGemeinsames Programm zu spinaler Muskelatrophie geht in erste Stufe der klinischen Entwicklung PTC Therapeutics, Inc. (NASDAQ: PTCT), die SMA Foundation und Roche (SIX: RO, ROG; OTCQX: RHHBY) haben heute bekannt gegeben, dass ihr gemeinsames...
SOUTH PLAINFIELD, New Jersey , 22. Januar 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), die SMA Foundation und Roche (SIX: RO, ROG; OTCQX: RHHBY ) haben heute bekannt gegeben, dass ihr gemeinsames Forschungsprogram zu spinaler Muskelatrophie (SMA) in die erste Stuf
Read more →PTCTUn programme conjoint dans le domaine de l'atrophie musculaire spinale entre en première phase du développement clinique PTC Therapeutics, Inc. (NASDAQ : PTCT), la SMA Foundation, et Roche (SIX : RO, ROG ; OTCQX : RHHBY), ont annoncé aujourd'hui que leur programme de...
SOUTH PLAINFIELD, New Jersey , 22 janvier 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ : PTCT ), la SMA Foundation, et Roche (SIX : RO, ROG; OTCQX : RHHBY ), ont annoncé aujourd'hui que leur programme de recherche conjoint dans le domaine de l'atrophie musculaire spinale (
Read more →PTCTJoint Program in Spinal Muscular Atrophy Enters First Stage of Clinical Development PTC Therapeutics, Inc. (NASDAQ: PTCT), the SMA Foundation, and Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that their joint research program...
SOUTH PLAINFIELD, N.J. , Jan. 22, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), the SMA Foundation, and Roche (SIX: RO, ROG; OTCQX: RHHBY ), announced today that their joint research program in Spinal Muscular Atrophy (SMA) has entered the first stage of clinical d
Read more →PTCTPTC Therapeutics To Present At The J.P. Morgan Healthcare Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 2014 J.P. Morgan Healthcare Conference...
SOUTH PLAINFIELD, N.J. , Jan. 6, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will present a company overview at the 2014 J.P. Morgan Healthcare Conference on Monday, January 13 at 3:00 pm PT . (Logo: http://photos.prnewswire.com/p
Read more →PTCTPTC Therapeutics Added to NASDAQ Biotechnology Index PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI),...
SOUTH PLAINFIELD, N.J. , Dec. 23, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI ), effective prior to the market open today. (Logo: http://photos.prnewswire.com/p
Read more →PTCTAtaluren Clinical Data Demonstrate an Increase in Dystrophin Expression in Duchenne Muscular Dystrophy Patients PTC Therapeutics, Inc.,(NASDAQ: PTCT) today announced the publication of data in PLOS ONE demonstrating that nonsense mutation Duchenne muscular...
SOUTH PLAINFIELD, N.J. , Dec. 12, 2013 /PRNewswire/ -- PTC Therapeutics, Inc.,(NASDAQ: PTCT ) today announced the publication of data in PLOS ONE demonstrating that nonsense mutation Duchenne muscular dystrophy (nmDMD) patients treated with ataluren, an investigational new drug,
Read more →PTCTPTC Therapeutics Reports Third Quarter 2013 Financial and Corporate Results PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small ...
SOUTH PLAINFIELD, N.J. , Nov. 14, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes, today a
Read more →PTCTPTC Therapeutics to Host Third Quarter 2013 Financial Results Conference Call and Webcast PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that PTC management will host a webcast conference call to discuss financial results for the...
SOUTH PLAINFIELD, N.J. , Nov. 7, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that PTC management will host a webcast conference call to discuss financial results for the third quarter ended September 30, 2013 and provide a corporate update on Thurs
Read more →PTCTPTC Therapeutics to Present at Credit Suisse Annual Health Care Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2013 Credit Suisse Annual...
SOUTH PLAINFIELD, N.J. , Nov. 5, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will present a company overview at the upcoming 2013 Credit Suisse Annual Health Care Conference on Tuesday, November 12 at 4:30 pm ET . (Logo: http://ph
Read more →PTCTPTC Therapeutics to Showcase Breadth of Pipeline at Upcoming R&D Day PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it will hold its first R&D Day on Friday, October 25, 2013 from 8:30 a.m. to 12:00 p.m. ET ...
SOUTH PLAINFIELD, N.J. , Oct. 18, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced today that it will hold its first R&D Day on Friday, October 25, 2013 from 8:30 a.m. to 12:00 p.m. ET at the Four Seasons Hotel in New York City . Members of PTC's senior manag
Read more →PTCTPTC Therapeutics to Present at the North American Cystic Fibrosis Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that the following two posters will be presented at the 27th Annual North American Cystic Fibrosis...
SOUTH PLAINFIELD, N.J. , Oct. 10, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced that the following two posters will be presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah , on October 17-19 : (Logo: http://photos
Read more →PTCTPTC Therapeutics Expands Management Team PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Mr. Martin Rexroad as Senior Vice President, Human Resources and Mr. R.A....
SOUTH PLAINFIELD, N.J. , Oct. 1, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the appointment of Mr. Martin Rexroad as Senior Vice President, Human Resources and Mr. R.A. Session II as Vice President, Corporate Development, both reporting to Ms. Cla
Read more →PTCTPTC Therapeutics to Present at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in two upcoming investor conferences. Management will participate in ...
SOUTH PLAINFIELD, N.J. , Sept. 27, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that they will participate in two upcoming investor conferences. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) The Leerink presentation will be webcast l
Read more →PTCTPTC Therapeutics to Present at World Muscle Society Congress PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that four posters will be presented at the 18th International World Muscle Society Congress (WMS) in...
SOUTH PLAINFIELD, N.J. , Sept. 25, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced that four posters will be presented at the 18 th International World Muscle Society Congress (WMS) in Asilomar, California , on October 1-5 . The following posters will be pre
Read more →PTCTPTC Therapeutics to Present at European Pediatric Neurology Society Congress PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that two abstracts have been accepted for the 10th European Pediatric Neurology Society Congress...
SOUTH PLAINFIELD, N.J. , Sept. 18, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced that two abstracts have been accepted for the 10 th European Pediatric Neurology Society Congress (EPNS) in Brussels, Belgium , on September 25-28 . (Logo: http://photos.prne
Read more →PTCTPTC Therapeutics to Present at Upcoming Investor Conferences PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in following conferences in September: Stuart W. Peltz, Ph.D., Chief ...
SOUTH PLAINFIELD, N.J. , Aug. 29, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that they will participate in following conferences in September: The presentations will be webcast live on the Events and Presentations page under the investor relation
Read more →PTCTNew Evidence Published in Muscle and Nerve on Measuring 6-Minute Walk Distance in Duchenne Muscular Dystrophy Data published in the medical journal Muscle & Nerve demonstrate the clinical meaningfulness of the 6-minute walk test (6MWT) as a primary endpoint...
SOUTH PLAINFIELD, N.J. , Aug. 26, 2013 /PRNewswire/ -- Data published in the medical journal Muscle & Nerve demonstrate the clinical meaningfulness of the 6-minute walk test (6MWT) as a primary endpoint to measure disease progression and walking ability in ambulatory Duchenne mus
Read more →PTCTPTC Therapeutics Reports Second Quarter 2013 Financial and Corporate Results PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary...
SOUTH PLAINFIELD, N.J. , Aug. 12, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, today a
Read more →PTCTPTC Therapeutics Announces Achievement Of Major Milestone In SMA Collaboration PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the selection of a development candidate in its spinal muscular atrophy (SMA) collaboration...
SOUTH PLAINFIELD, N.J. , Aug. 8, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the selection of a development candidate in its spinal muscular atrophy (SMA) collaboration with Roche and the SMA Foundation. The achievement of the milestone triggers a
Read more →PTCTPTC Therapeutics to Present at Wedbush Conference PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Shane Kovacs, Chief Financial Officer of PTC Therapeutics will present a company overview...
SOUTH PLAINFIELD, N.J. , Aug. 6, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that Shane Kovacs , Chief Financial Officer of PTC Therapeutics will present a company overview at the Wedbush Securities Life Sciences Management Access Conference in New
Read more →PTCTPTC Therapeutics To Host Second Quarter 2013 Financial Results Conference Call And Webcast PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will report financial results for the second quarter ended June 30, 2013...
SOUTH PLAINFIELD, N.J. , Aug. 5, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the company will report financial results for the second quarter ended June 30, 2013 following the close of market on Monday, August 12, 2013 . PTC management will ho
Read more →PTCTPTC Therapeutics Closes Initial Public Offering PTC Therapeutics, Inc. (PTC) (Nasdaq: PTCT) today announced the closing of its initial public offering of 9,627,800 shares of common stock at a...
SOUTH PLAINFIELD, N.J. , June 25, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) (Nasdaq: PTCT ) today announced the closing of its initial public offering of 9,627,800 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts, includ
Read more →PTCTPTC Therapeutics Prices Initial Public Offering PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering...
SOUTH PLAINFIELD, N.J. , June 20, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in t
Read more →PTCTPTC Therapeutics Appoints Shane Kovacs as Chief Financial Officer PTC Therapeutics, Inc. (PTC) today announced the appointment of Shane Kovacs as Chief Financial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of...
SOUTH PLAINFIELD, N.J. , June 3, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Shane Kovacs as Chief Financial Officer, reporting to Stuart W. Peltz , Ph.D., CEO of PTC Therapeutics. Mr. Kovacs will be responsible for all finance-related act
Read more →PTCTPTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering PTC Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission...
SOUTH PLAINFIELD, N.J. , May 16, 2013 /PRNewswire/ -- PTC Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock. The
Read more →PTCTPTC Therapeutics Closes $60 Million Private Financing PTC Therapeutics, Inc. (PTC) today announced the successful completion of a $60 million financing led by Brookside Capital Partners Fund, L.P....
SOUTH PLAINFIELD, N.J. , March 7, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the successful completion of a $60 million financing led by Brookside Capital Partners Fund, L.P. Joining Brookside as new investors in this financing are Adage Capital Management,
Read more →PTCTPTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (PTC) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA)...
SOUTH PLAINFIELD, N.J. , Dec. 6, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) seeking conditional approval for ataluren, an investigational new drug for the tre
Read more →PTCTPTC Therapeutics Appoints Geoffrey McDonough, M.D., To Board of Directors PTC Therapeutics, Inc. (PTC) today announced the appointment of Geoffrey McDonough, M.D., to the company's Board of Directors. Dr. McDonough is the...
SOUTH PLAINFIELD, N.J. , Nov. 6, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Geoffrey McDonough , M.D., to the company's Board of Directors. Dr. McDonough is the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi),
Read more →PTCTPTC Therapeutics Receives $1 Million Grant Award from the National Institutes of Health (NIH) to Support Research for a Treatment for Dengue Fever PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million grant award from the National Institute of Allergy and Infectious Diseases...
SOUTH PLAINFIELD, N.J. , Oct. 22, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to discover antiviral agen
Read more →PTCTPTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors PTC Therapeutics, Inc. (PTC) today announced the appointment of Jerome B. Zeldis, M.D., Ph.D., to the company's Board of Directors. Dr. Zeldis is the ...
SOUTH PLAINFIELD, N.J. , Sept. 28, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Jerome B. Zeldis , M.D., Ph.D., to the company's Board of Directors. Dr. Zeldis is the Chief Executive Officer of Celgene Global Health and the Chief Medical Of
Read more →PTCTPTC Therapeutics Closes $30 Million Financing PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as...
SOUTH PLAINFIELD, N.J. , July 23, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures,
Read more →PTCTPTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration PTC Therapeutics, Inc. (PTC) today announced that it has selected an experimental drug candidate to advance in its BMI1 program for aggressive and...
SOUTH PLAINFIELD, N.J. , July 11, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has selected an experimental drug candidate to advance in its BMI1 program for aggressive and drug-resistant tumors. The milestone triggers drawdown of the next $2.3 millio
Read more →PTCTPTC Therapeutics Initiates Open-Label Study for Ataluren in Patients with Nonsense Mutation Duchenne/Becker Muscular Dystrophy PTC Therapeutics, Inc. (PTC) today announced the initiation of an open-label study in the European Union, Israel, Australia and Canada for patients...
SOUTH PLAINFIELD, N.J. , June 27, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the initiation of an open-label study in the European Union, Israel , Australia and Canada for patients with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who recei
Read more →PTCTTop-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results PTC Therapeutics, Inc. today announced the results from a Phase 3 study of ataluren, an investigational new drug, in patients with nonsense mutation...
SOUTH PLAINFIELD, N.J. , June 8, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. today announced the results from a Phase 3 study of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). The results demonstrated positive trends in lung func
Read more →PTCTPTC Therapeutics Announces Executive Promotions PTC Therapeutics, Inc. (PTC) today announced the promotions of Claudia Hirawat to President and Mark Boulding to Executive Vice President and Chief...
SOUTH PLAINFIELD, N.J. , April 2, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the promotions of Claudia Hirawat to President and Mark Boulding to Executive Vice President and Chief Legal Officer. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO )
Read more →PTCTPTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5 million Seeding Drug Discovery (SDD) Award from the Wellcome Trust to support the...
SOUTH PLAINFIELD, N.J. , Dec. 22, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5 million Seeding Drug Discovery (SDD) Award from the Wellcome Trust to support the development of small-molecule drugs that target life-threatening infections ca
Read more →PTCTRoche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA) Roche (SIX: RO, ROG; OTCQX: RHHBY), PTC Therapeutics, Inc. (PTC) and the SMA Foundation, announced today a licensing agreement for PTC's Spinal...
BASEL, Switzerland , SOUTH PLAINFIELD, N.J., and NEW YORK , Nov. 29, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY ), PTC Therapeutics, Inc. (PTC) and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme. SMA is a ge
Read more →PTCTPTC Therapeutics Receives Grand Challenges Explorations Funding PTC Therapeutics, Inc. announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill &...
SOUTH PLAINFIELD, N.J. , Nov. 7, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox idea
Read more →PTCTPTC Therapeutics and Genzyme Announce Restructuring of Collaboration PTC Therapeutics, Inc. and Genzyme, a Sanofi company, announced today the restructuring of their collaboration. Under the original agreement, PTC...
SOUTH PLAINFIELD, N.J. and CAMBRIDGE, Mass. , Sept. 2, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. and Genzyme, a Sanofi company, announced today the restructuring of their collaboration. Under the original agreement, PTC held commercial rights for the U.S. and Canada and Genzyme
Read more →PTCTAtaluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with...
SOUTH PLAINFIELD, N.J. , July 1, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal .
Read more →PTCTPTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer PTC Therapeutics, Inc. (PTC) today announced the appointment of Robert J. Spiegel M.D., FACP as Chief Medical Officer. Dr. Spiegel served previously...
SOUTH PLAINFIELD, N.J. , March 30, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Robert J. Spiegel M.D ., FACP as Chief Medical Officer. Dr. Spiegel served previously as Chief Medical Officer of Schering-Plough. PTC also announced today the
Read more →PTCTPTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients PTC Therapeutics, Inc. (PTC) and Parent Project Muscular Dystrophy (PPMD) today announced an expansion of their collaboration to discover new...
SOUTH PLAINFIELD, N.J. and HACKENSACK, N.J. , Feb. 1, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) and Parent Project Muscular Dystrophy (PPMD) today announced an expansion of their collaboration to discover new treatments for patients with Duchenne/Becker muscular dystrophy
Read more →PTCTPTC Therapeutics' President and CEO Elected AAAS Fellow Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the Advancement...
SOUTH PLAINFIELD, N.J. , Jan. 19, 2011 /PRNewswire/ -- Stuart W. Peltz , Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and publi
Read more →PTCTPTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in...
SOUTH PLAINFIELD, N.J. , Dec. 21, 2010 /PRNewswire/ -- PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). (Logo: http://photos.pr
Read more →PTCTObservational Data From One-Year Follow-up Study Validate Six-Minute Walk Distance as an Outcome Measure in Duchenne and Becker Muscular Dystrophy Data published in the December issue of the medical journal Muscle and Nerve confirm the utility of six-minute walk distance (6MWD) as a clinically...
SOUTH PLAINFIELD, N.J. , Dec. 1, 2010 /PRNewswire/ -- Data published in the December issue of the medical journal Muscle and Nerve confirm the utility of six-minute walk distance (6MWD) as a clinically meaningful endpoint in dystrophinopathy, a disease continuum comprising Duchen
Read more →PTCTPTC Publishes Results from Phase 2 Study of Ataluren in Children with Cystic Fibrosis PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic...
SOUTH PLAINFIELD, N.J. , Nov. 15, 2010 /PRNewswire/ -- PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medi
Read more →PTCTPTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren in Patients With Methylmalonic Acidemia PTC Therapeutics, Inc. today announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a Phase...
SOUTH PLAINFIELD, N.J. , Oct. 26 /PRNewswire/ -- PTC Therapeutics, Inc. today announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a Phase 2 clinical trial in nonsense mutation methylmalonic acidemia (nmMMA). MMA is a rar
Read more →PTCTPivotal Data Presented at the World Muscle Society Congress Suggest Ataluren Slows the Loss of Walking Ability in Patients with Nonsense Mutation Duchenne/Becker Muscular Dystrophy PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of ...
SOUTH PLAINFIELD, N.J. , Oct. 15 /PRNewswire/ -- PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease co
Read more →PTCTPTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of...
SOUTH PLAINFIELD, N.J. , Sept. 21 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren
Read more →Competitive Position
How PTCT ranks across every disease it competes inCompetitive Position is a premium feature
See how PTCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial